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RESUMEN/ABSTRACT  
		
	
		
	
RESUMEN 
  
 El acortamiento telomérico como un factor causal del riesgo a desarrollar cáncer, es un 
tema complejo, que parece depender de varios factores. En un trabajo anterior publicado por 
nuestro grupo, encontramos que los pacientes portadores de mutaciones en los genes BRCA1 y 
BRCA2 presentaban un acortamiento telomérico acelerado que se asociaba con un fenómeno de 
anticipación trans-generacional en la aparición del cáncer, lo que sugería que en el contexto de 
cáncer de mama hereditario, las mutaciones en BRCA1 y BRCA2 modificaban el riesgo al 
desarrollo de la enfermedad a través de su efecto modificador en la biología del mantenimiento 
telomérico. Posteriormente, dos trabajos independientes con un tamaño muestral superior 
encontraron resultados muy dispares en relación a los publicados inicialmente por nuestro grupo; 
sin embargo, los tres trabajos eran estudios retrospectivos y no tuvieron en cuenta la existencia 
de posibles modificadores de la longitud telomérica como factores de confusión. 
 De esta manera el objetivo principal de esta Tesis ha estado enfocado en la identificación 
de factores genéticos y exógenos modificadores de la longitud telomérica, principalmente dentro 
del contexto de cáncer de mama y ovario hereditario. Para ello hemos planteado un estudio 
prospectivo con familias portadoras o no, de mutación en los genes BRCA1 y BRCA2 a los que se 
ha citado en consulta para la extracción de muestras biológicas y para completar un cuestionario 
sobre su tratamiento y evolución de la enfermedad. 
En relación a los factores exógenos, en un primer estudio pudimos confirmar que la 
quimioterapia acortaba los telómeros en los pacientes que estaban en siendo tratados; aunque este 
efecto era de carácter transitorio. Así, al corregir los resultados de longitud telomérica por el 
estado de tratamiento, tanto los resultados como las conclusiones eran diferentes en relación al 
efecto modificador de la longitud telomérica de los genes BRCA1 y BRCA2 como factor causal 
en riesgo al desarrollo de cáncer.  Lo que nos lleva a pensar que la quimioterapia es un factor de 
confusión en este tipo de estudios. 
 Continuamos estudiando factores genéticos como potenciales modificadores de la 
longitud telomérica. Así pues, se evaluaron 2 polimorfismos modificadores del riesgo a 
desarrollar cáncer de mama y ovario para portadores de mutaciones en los genes BRCA1 y 
BRCA2. Estos polimorfismos, se encuentran en regiones reguladoras de la transcripción de las 
glucosilasas OGG1 y NEIL2, las cuales están involucradas en la vía de reparación del ADN por 
escisión de base (BER), muy activa en la reparación del daño oxidativo a nivel telomérico. De 
esta forma, nos planteamos estudiar las bases moleculares responsables de esta asociación y su 
relación con la biología del mantenimiento de la longitud telomérica. Para ello, se evaluó el papel 
de estos polimorfismos en relación a la regulación transcripcional de OGG1 y NEIL2, su 
contribución en la inestabilidad genómica y/o telomérica, así como su relación con el estrés 
oxidativo. De esta manera, identificamos que estos polimorfismos tienen un efecto funcional a 
nivel transcripcional y pueden afectar a la eficiencia de la reparación del daño oxidativo en el 
telómero. Además, parecen tener un papel importante en la regulación de la longitud telomérica 
en portadores de mutaciones en BRCA1 y BRCA2.  
Basándonos en la posibilidad de una posible relación de letalidad sintética entre OGG1 
(BER) y BRCA1 de la vía de reparación del ADN de recombinación homóloga (HR), hemos 
probado la inhibición farmacológica de la enzima OGG1, utilizando un panel de inhibidores de 
OGG1, en un conjunto de líneas celulares de cáncer deficientes de BRCA1 y BRCA2.Hemos 
identificado que en las células con el mismo fondo genético, la inactivación de BRCA1 hace 
células muy sensibles a estos inhibidores, lo que podría abrir un nuevo marco para el tratamiento 
del cáncer de mama hereditario. 
Complementariamente, en la presente Tesis doctoral se muestran dos ejemplos de 
enfermedades hereditarias, angiosarcoma cardiaco hereditario y anemia aplásica, en las que el 
factor desencadenante de la enfermedad es la desregulación de la longitud telomérica, causada 
por mutaciones en los genes asociados a las shelterinas, y a la telomerasa respectivamente. Lo 
que pone de manifiesto la relación existente entre la biología del telomero en relación al cáncer 
y/o a otras enfermedades.  
 
		
	
 
 
 
 
 
 
  
		
	
ABSTRACT 
  
 The role of telomere shortening on cancer risk is a complex issue, and likely depending 
on several factors. In a previous study published by our group, we showed that patients harboring 
mutations in the BRCA1 and/or BRCA2 genes presented an accelerated telomeric shortening and 
an anticipation in the onset of cancer across successive generations in families affected. This 
suggested, that in the context of hereditary breast and ovarian cancer, mutations in BRCA1 and 
BRCA2 modified the risk of developing cancer through an accelerated telomere shortening. 
Subsequently, two independent studies using a larger number of families found very 
different results, compared to those reported by our group; however, the three studies were 
retrospective, and did not consider the possible existence of telomere length modifiers as 
confounding factors. In this way, the main objective of this Thesis has been focused on the 
identification of genetic and environmental factors modifying the telomere length, mainly in the 
context of hereditary breast and ovary cancer. To this end, we proposed a prospective study 
involving families affected by hereditary breast and ovarian cancer, with or without mutation in 
the BRCA1 and BRCA2 genes. Participants, have been cited in medical consultancy for the 
extraction of biological samples and to complete a questionnaire about their treatment and 
evolution of the disease. 
Regarding the exogenous factors, in a first study we could confirm that the chemotherapy 
shortened the telomeres in the patients who were being treated, although this effect was transitory. 
After correction for the treatment status, both the results and the conclusions were different in 
relation to the effect of the BRCA1 and BRCA2 mutations on telomere shortening as a causal risk 
factor for developing of cancer. Suggesting that chemotherapy was indeed a confounding factor 
for this type of studies.  
We continued studying genetic factors as potential telomere length modifiers: In this case, 
two “cancer risk polymorphisms”, which modify breast and ovarian cancer risk susceptibility, for 
BRCA1 and BRCA2 mutation carriers. 
These polymorphisms were found in transcriptional regulatory regions of OGG1 and 
NEIL2 genes. Both genes, encoding for DNA glycosylases which are key enzymes, involved in 
the base excision repair pathway (BER) which has an important role on repairing oxidative DNA 
damage at telomeres. Hence, we wanted to study molecular bases responsible for this association 
and its role on the telomere biology. 
Hence, we evaluated the role of these SNPs in relation to OGG1 and NEIL2 
transcriptional regulation, its contribution on genomic and / or telomere instability, as well as its 
possible relation with systemic oxidative stress. Thus, we identified that these SNPs have a 
functional effect at the transcriptional level and can affect the enzyme efficiency of repairing 
oxidative DNA damage at the telomere, as well as telomere length for BRCA1 and BRCA2 
mutations carriers. 
Based on a possible synthetic lethality relationship between OGG1 (BER) and BRCA1 
(HR) DNA repair pathways, we tested the antiproliferative properties of inhibiting 
pharmacologically OGG1 enzyme using a panel of OGG1 inhibitors, in a set of BRCA1 and 
BRCA2 deficient cancer cell lines. We have identified that in cells with the same genetic 
background, inactivation of BRCA1 make cells very sensitive to OGG1 inhibitors. This may open 
a new framework for the treatment of hereditary breast cancer. 
 In addition, we present two examples of hereditary diseases, hereditary cardiac 
angiosarcoma and aplastic anemia, in which the molecular mechanism of the disease initiation is 
telomere dysregulation, caused by mutations in genes associated with the shelterin complex and 
the telomerase respectively. This examples illustrate the complexity of telomere biology in 
relation to cancer and / or other diseases. 
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1. GENERAL ASPECTS OF TELOMERE BIOLOGY 
 
DNA replication at the end of the chromosome is a challenging task for eukaryotes (De 
Lange 2009). There are two main problems that are solved by a unique structure: first, DNA 
polymerases require a primer because they can only proceed in the 5´ to 3´ direction. Hence, after 
each round of replication, sequences of DNA would be lost at the end of the chromosome. This 
is known as the DNA “end-replication problem”. In eukaryotes, this sequence length equilibrium 
is solved by telomeres, which contain an array of tandemly repeated nucleotide sequences 
localized at the end of the chromosome that act as a “buffer” to withstand the erosion of DNA. 
Hence, in the absence of special telomere maintenance mechanisms, linear chromosomes shorten 
progressively with every round of DNA replication, eventually leading to cellular senescence or 
apoptosis (Lingner et al. 1995).  
However, a cellular reverse transcriptase called telomerase counteracts telomere 
shortening in many organisms, including humans (Gilson & Géli 2007). Telomerase is required 
for unlimited proliferation of immortal human tumor cells, as well as for the extended 
proliferation in germinal, embryonic and certain stem cells where it contributes to the 
maintenance of telomere length (TL), but it is absent in most somatic cells (Gilson & Géli 2007). 
The other biological problem that was referred to above is called the “end-protection 
problem”. In eukaryotes, the ends of chromosomes could be mistaken for damaged or broken 
DNA. In this scenario, cells might attempt to “repair” the chromosome ends recognized as double-
stranded breaks (DSBs). In mammals, telomeres solve the end-protection problem through a 
multiprotein structure called the “shelterin complex” that includes TRF1, TRF2, RAP1, TIN2, 
POT1, and TPP1 gene products. This multiprotein complex coats the repeating sequences of the 
telomeres (De Lange 2005). Telomere regions are frequently compromised by DNA damage that 
accumulates during aging (Cesare et al. 2009), likely through oxidation-mediated base 
modifications and associated strand breaks (Hewitt et al. 2012). In addition, compaction of the 
telomere by the shelterin complex may render telomere DNA damage more resistant to DNA 
repair (Fumagalli et al. 2012). If not repaired efficiently, damaged telomeres will suffer 
accelerated erosion and restrict the proliferative lifespan of cells. Currently, how the telomeric 
structure and the shelterin proteins protect telomeres against DNA damage are urgent questions 
for understanding the role of telomeres during oncogenesis. 
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2. TELOMERE STRUCTURE 
	
2.1. Telomere DNA  
 
TL is highly variable between species, within species, within an organism, and even 
between chromosomes. In humans, TL ranges from 10-15 kb of the repetitive G-rich sequence 
5´-T2AG3-3´, plus 75-600 nucleotides of a 3´ single-stranded overhang (McElligott & Wellinger 
1997; Canela et al. 2007) (Figure 1A). In humans, DNA shortens by around 30-150 bp per 
replication cycle in cells without telomere maintenance mechanisms (Harley et al. 1990; Takubo 
et al. 2002). 
The 3´ single-stranded overhang of a telomere can invade the double-stranded telomeric 
tracts and thus form two internal loops, the d-loop and the T-loop (Griffith et al. 1999; Greider 
1999) (Figure 1B). In addition to T-loops, G-strand telomeric DNA from most organisms forms 
G-quadruplex (G4) structures, stable secondary DNA structures that are held together by multiple 
guanine–guanine base pairs (Webb et al. 2013). 
 
 
 
 
Figure 1. Structure of mammalian telomeres. (A) Chromosomes in mammalian cells end in long arrays 
of [TTAGGG] repeats. The strand containing the 3´ terminus, termed the G-strand, is rich in guanine and 
is many nucleotides longer than its complementary C-strand. This G overhang varies in length between 
different organisms. (B) Schematic representation of a telomere in a T-loop configuration. The G-strand 
is shown in red, the C-strand in green. This figure was modified from (Lazzerini 2009). 
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Presumably, the T-loop acts like a protective cap at the end of the chromosomes by 
preventing recognition by the DNA damage repair machinery as DNA double-strand breaks and 
subsequent inappropriate activation of DNA damage checkpoints (De Lange 2005). However, 
cell division will inevitably lead to telomere shortening and thus to destabilization of the 
telomeres, due to the inability to recruit the proteins of the shelterin complex. Consequently, the 
T-loop will no longer form properly, the chromosome ends will be left uncapped, and the cells 
will either trigger senescence or apoptosis.  
 
2.2. Telomere lengthening: Telomerase 
 
Telomere shortening can be counteracted by two known lengthening mechanisms. Most 
cancer cells, as well as germline and stem cells, activate the ribonucleoprotein enzyme telomerase 
to compensate for telomere loss (Kim et al. 1994; Wright et al. 1996). In contrast, in 
approximately 10% to 15% of cancers, telomeres are maintained by homologous recombination 
(HR) dependent alternative lengthening of telomeres (ALT) rather than by telomerase activation 
(Dilley et al. 2016).  
Telomerase reverse transcriptase (TERT) is a unique cellular enzyme that is a component 
of the ribonucleoprotein telomerase: via reverse transcription of its own RNA template (TERC), 
telomerase synthesizes the tandem 5′-TTAGGG-3′ exonucleotide repeats of telomeric DNA, 
which prevents chromosome attrition resulting from incomplete semiconservative DNA 
replication at chromosomal ends (Bryan & Cech 1999). By using TERC, TERT can add a six-
nucleotide repeating sequence, 5´-TTAGGG (in vertebrates, the sequence differs in other 
organisms) to the 3´ strand of chromosomes. These TTAGGG repeats (with their various protein 
binding partners) are called telomeres. The template region of TERC is 3´-CAAUCCCAAUC-5´ 
(Gavory et al. 2002) (Figure 2). 
Telomerase is not active in most human somatic cells because transcription by TERT, the 
catalytic subunit, is repressed by several tumor suppressor pathways (Lin & Elledge 2003). For 
instance, the WNT signaling pathway, which is important for stem cell identity, affects TERT 
gene expression. β-catenin, a central player in WNT signaling, acts directly to activate TERT 
transcription in embryonic and adult stem cells as well as in human cancer cells (Hoffmeyer et al. 
2012). The c-MYC oncogene also positively regulates TERT transcription (Wu et al. 1999). 
Hence, activation of oncogenes during carcinogenesis correlates with unlimited telomerase 
activation. 
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2.3. Telomere protection: shelterin complex 
 
The tandemly repeated telomere sequence TTAGGG associates with the six-protein 
shelterin complex, which enables cells to distinguish their natural chromosome ends from DNA 
breaks, represses DNA repair reactions, and regulates telomerase-based telomere maintenance 
(Palm & De Lange 2008) (Figure 3). During the non-mitotic phase of the cell cycle, both the 
double and single-stranded telomeric DNA is protected by the telomeric repeat-binding factor 1 
(TRF1), TRF2, RAP1, TERF1-interacting nuclear factor 2 (TIN2), TPP1 and POT1 (De Lange 
2005). Deletion of any of these genes leads to disruption of TL regulation and end protection. 
The telomeric repeat binding factors TRF1 and TRF2 bind to double-stranded telomeric DNA 
and have a role in telomere stabilization and TL regulation (Van Steensel & De Lange 1997; Van 
Steensel et al. 1998). Both proteins are extremely abundant and ubiquitously expressed during 
the cell cycle (Crabbe et al. 2004).  
RAP1 is an essential but poorly characterized constitutive binding partner of TRF2 (Li et 
al. 2000). RAP1 forms a complex with TRF2 (Matsutani et al. 2001) and is dependent on TRF2 
for its telomeric localization and stability; most of it is lost upon TRF2 gene deletion (Celli & De 
Figure 2. Mechanism of telomere extension by telomerase. Human telomerase ribonucleoprotein 
consisting of telomerase reverse transcriptase (TERT) and telomerase RNA (TR) is illustrated. The 
processive cycle of telomere binding to the telomerase RNA template (blue), extension through addition 
of dNTPs (red), and translocation adds GGTTAG repeats to the 3´ telomeric terminus. The process is 
interrupted when the extended telomere dissociates from telomerase (dotted red line). This figure was 
adapted from (Harley 2002). 
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Lange 2005). Additionally, RAP1 is recruited to telomeres via TRF2 and it is known to negatively 
regulate TL (De Lange 2005). 
Other proteins from the shelterin complex do not directly interact with telomeric DNA. 
TIN2 associates with TRF1, TRF2 and TPP1, and forms a heterodimer with POT1 (Houghtaling 
et al. 2004; Kim et al. 2004; Kim et al. 1999; Ye et al. 2004). TPP1 connects POT1 with TIN2. 
These interactions are necessary for proper telomere association of POT1 and are essential for TL 
regulation (Sexton et al. 2014). Finally, POT1 is a protein that in humans is encoded by the POT1 
gene; it contains two N-terminal oligonucleotide/oligosaccharide-binding (OB) folds, which 
allows its binding to the telomeric G-strand overhang (Lei et al. 2004; Baumann & Cech 2001; 
Loayza & De Lange 2003). POT1 regulates TL by preventing telomerase access to telomeres by 
sequestering the DNA terminus (Loayza & De Lange 2003; Chen et al. 2007). 
Shelterin represses two main DNA-damage signaling pathways: the ATR kinase pathway, 
blocked by POT1, and the ATM kinase pathway, blocked by TRF2 (De Lange 2010). 
 
 
 
	
	
Figure 3. The shelterin complex. (A) The six proteins that constitute the shelterin complex (see text 
for details). (B) Schematic model of shelterin complex bound to a telomere in a T-loop configuration. 
TRF1 and TRF2 bind double-stranded TTAGGG repeats and TIN2 independently, thus different 
subcomplexes can exist at telomeres and are depicted in this scheme. This figure was modified from 
(Lazzerini et al 2009). 
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3. REACTIVE OXYGEN SPECIES AFFECT TELOMERE BIOLOGY, AGING 
AND CANCER 
 
In normal human somatic cells, telomeres gradually shorten after each cell division. Once 
telomeres become too short, cells enter senescence. Therefore, telomeres limit the number of cell 
divisions. Even though progressive shortening of telomeres occurs after each cell division, the 
speed at which telomeres shorten depends on many factors (Passos et al. 2007; Hewitt et al. 2012). 
Cellular environment is crucial for regulating TL and telomerase activity. In particular, oxidative 
stress is one of the main contributors to the shortening of telomeres. When mitochondrial 
dysfunction occurs concomitant with increased reactive oxygen species (ROS) generation, the 
susceptibility of telomeres to oxidative damage leads to accelerated telomere shortening, 
increased probability of uncapping, activation of a DNA damage response, and irreversible cell 
cycle arrest (Martens et al. 2000; Borodkina et al. 2014). In addition, it has been documented that 
oxidative stress also interferes with telomere maintenance via its effect on telomerase activity 
(Finkel et al. 2000; Fouquerel et al. 2016).  
Free radicals and other ROS are produced in a wide range of physiological processes. 
Mitochondrial respiration is a major endogenous source of ROS. The electron transport chain or 
oxidative phosphorylation system is located in the inner mitochondrial membrane and is 
responsible for the production of ATP, generation of ROS, and regulation of programmed cell 
death.  
Chronic elevation of the levels of ROS causes damage to the electron transport system, 
which in turn produces ROS at an even higher rate. Reactive oxygen species can also cause 
mutations in DNA that lead to cancer (Mena et al. 2009; Audeh et al. 2010). Thus oxidative stress 
plays an important role in cell death, which can lead to accelerated aging and various pathologies 
including neoplastic, cardiovascular, inflammatory, and degenerative diseases (Benz & Yau 
2008; Stephens et al. 2009).  
 
3.1. Oxidative DNA damage and Base Excision Repair 
  
The chemical instability of the DNA molecule can result in hydrolytic loss of DNA bases, 
base oxidations, non-enzymatic methylations and other chemical alterations. DNA damage can 
also occur because of reactions with exogenous (environmental) and endogenous (intracellular) 
DNA-reactive species (Lindahl 1993; Friedberg 2003). 
A nucleic acid can be oxidized by ROS through a Fenton reaction (Wardman & Candeias 
1996). To date, around 20 oxidative lesions have been discovered in DNA (Cooke et al. 2003). 
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The most frequently oxidized bases found at the telomere region are oxidation products of 
guanine, 8-oxoG and FapyG lesions (Figure 4).  
 
 
The Base Excision Repair (BER) pathway is an essential repair pathway that corrects 
multiple DNA alterations that frequently occur in DNA. BER deficiency affects genome stability 
and it is involved in different pathological conditions, including premature aging (Lombard et al. 
2005), neurodegeneration (Caldecott 2008) and cancer (Bartkova et al. 2006). 
The major players involved in BER have been known for a long time (Lindahl 1990), and 
the entire BER process has been reconstituted with purified enzymes (Kubota et al. 1996; Dianov 
& Lindahl 1994) (Figure 5). BER is initiated by a damage-specific DNA glycosylase (Lindahl 
1979). Currently, 11 human DNA glycosylases that recognize and excise a wide range of DNA 
base damages are described to act at the first step of the pathway (Table 1).  
 
 
 
 
Figure 4. ROS and Reactive Nitrogen Species are constantly produced during aerobic 
metabolism. ROS generate several dozen oxidized base lesions and single-strand breaks (SSBs) in the 
genome. SSBs are also generated as intermediates during the processing of oxidized bases via Base 
Excision Repair (BER). ROS-induced SSBs contain diverse termini, like 3´-phosphoglycolate, 3´-
phosphate, 5´-OH and 5´-deoxyribose phosphate (5´dRP) (Mitra et al. 2014). 
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Table 1. Summary of the properties of known glycosylases in humans 
GLYCOSYLASE TYPE* SUBSTRATES 
MPG monofunctional 3-meA, hypoxanthine 
UNG monofunctional uracil 
OGG1 bifunctional 8-oxoG, FapyG 
NTH1 bifunctional Tg, hoU, hoC, urea, FapyG 
NEIL1-NEIL3 bifunctional Tg, hoU, hoC, urea, FapyG, FapyA 
MYH monofunctional A:8-oxoG 
SMUG1 monofunctional U, hoU, hmU, fU 
TDG monofunctional T:G mispair 
MBD4 monofunctional T:G mispair 
*monofunctional glycosylases have only glycosylase activity, whereas bifunctional glycosylases also 
possess AP lyase activity. 
 
Following the removal of the damaged base, APE1 (apurinic/apyrimidinic endonuclease 
1) cuts the DNA backbone at abasic sites, leaving a single nucleotide gap and a deoxyribose 
fragment. The gap is then repaired by short-patch or long-patch repair depending on the cell cycle 
phase and nature of the deoxyribose fragment (Figure 5). In short-patch repair, the repair gap is 
only one nucleotide, while in long-patch repair replicative polymerases insert 2-8 nucleotides, 
displacing the pre-existing bases 3´ to the original lesion. In the long patch pathway, the 
overhanging single-strand flap is removed by flap endonuclease 1 (FEN1). In short patch repair 
DNA polymerase β (Polβ) inserts a single nucleotide and removes the dRP-fragment through its 
associated dRPase activity, and the single-strand break is sealed in a ligation step completed either 
by the DNA repair enzyme DNA ligase III in association with XRCC1 for the short patch pathway 
or by the replicative DNA ligase I in the long patch pathway (reviewed in (Wallace 2014)).                                                    
Pathogenic defects in BER have only been identified for the initiating DNA glycosylases 
(UNG-Hyper-IgM syndrome and MUTYH associated polyposis (Kavli et al. 2005; Oliver et al. 
2003) possibly because repair defects at BER intermediate steps are poorly tolerated. Attempts at 
generation knockout mice for APE1, FEN1, Polβ, XRCC1 or Ligase III results in embryonic 
lethality at an early stage of embryogenesis (Tebbs et al. 1999; Gu et al. 1994; Puebla-Osorio et 
al. 2006; Kucherlapati et al. 2006; Kucherlapati et al. 2002; Xanthoudakis et al. 1999). 
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3.2. BER in telomere maintenance 
 
The long arrays of TTAGGG repeats make telomeres particularly susceptible to oxidative 
lesions. Oxidative damage is thought to be a primary cause of telomere shortening, based on 
observations that telomere attrition rate is significantly decreased when cells are grown under 
hypoxic conditions or in the presence of antioxidants (Von Zglinicki 2002; Richter & Zglinicki 
2007). In addition, both uracil residues and oxidized guanine derivatives are commonly present 
at telomeres (Vallabhaneni et al. 2015; Oikawa & Kawanishi 1999). Mounting evidence from 
both in vivo and in vitro studies suggests that BER is actively promoted at telomeres (Vorlícková 
3´-OH
5´-dRP
3´-OH 5´-P
Base Damage
DNA Glycosylase
AP-Endonuclease
5´-dRP lyase
DNA Polymerase
DNA Ligase
DNA Polymerase
Flap-Endonuclease
DNA Ligase
SHORT PATCH BER LONG PATCH BER
Figure 5. Steps involved in Short Patch and Long Patch Base Excision Repair pathway. 
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et al. 2012; Rhee et al. 2011; Wang et al. 2010; Chakraborty et al. 2015; Zhou et al. 2015), 
although the exact mechanism of BER at telomeres is still unknown. 
In relation with this, DNA glycosylases like OGG1 and NEIL1-3 have an important role 
in oxidative damage repair at telomeres (Dziaman et al. 2014; Wang et al. 2010; Zhou et al. 2015; 
Osorio et al. 2014). Accumulation of oxidative DNA damage at the telomere region by incorrect 
functioning of BER can affect TL and cause different abnormalities like telomere sister chromatid 
exchanges, increased telomere single- and double-strand breaks, and telomere G-strand losses. 
The accumulation of 8-oxo-G at telomeres can disrupt TRF1 and TRF2 binding to the telomere, 
leading to uncapped telomeres (Opresko et al. 2005) and subsequent telomere instability. In 
addition, it was recently described that 8-oxoG regulates telomere elongation by telomerase in 
humans (Fouquerel et al. 2016). 
 
 
4. TELOMERES IN CANCER  
	
Telomere erosion can promote genome instability when combined with other cellular and 
genomic alterations, potentially leading to tumorigenesis. Conversely, it can also act as a powerful 
tumor suppressor by activation of the replicative senescence process (Shay & Wright 2002; 
Counter et al. 1992; Ma et al. 2011). 
In humans, the distribution of TL among different chromosome arms is heterogeneous, 
with some chromosomes having longer telomeres than others (Zou et al. 2004). Importantly, this 
telomere signature is partially a heritable trait that is determined at fertilization and maintained 
throughout life (Broer et al. 2013; Slagboom et al. 1994). The time point at which chromosome 
arms will become uncapped depends on the specific telomere shortening rate occurring in each 
cell type or tissue. When TL reaches a very short threshold (perhaps when T-loops cannot be 
maintained) an uncapping signal is generated, resulting in cellular senescence (Figure 6). 
However, rare cells (∼1:106–107), after having acquired sufficient genome / telomere instability, 
progress to the activation of a telomere maintenance mechanism (telomerase or ALT) that leads 
to immortalization and malignancy. Emerging evidence indicates that telomerase promoter 
mutations are highly prevalent in multiple cancer types (Heidenreich et al. 2014). 
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5. LEUKOCYTE TELOMERE LENGTH AND DISEASE 
	
Measurement of leukocyte telomere length (LTL) in large epidemiologic studies has 
become popular since 2002, when a qPCR method to measure LTL was first reported (Cawthon 
2002). The qPCR approach is advantageous in such studies, because it is amenable to high-
throughput platforms and requires very small amounts of DNA. There is also an adequate 
correlation between qPCR and terminal restriction fragment length, the previous method used to 
quantify TL (Cawthon 2009). Its implementation led to early association studies of LTL and 
cancer, which suggested that shorter LTL was associated with increased risk for certain cancers 
(Wu et al. 2003). Indeed, early  meta-analyses were conducted to determine whether “short 
telomeres are associated with cancer risk” and found an increased overall risk for cancer (Ma et 
al. 2011; Wentzensen et al. 2011). Because telomere shortening is observed in the aging process, 
several studies also addressed a likely connection between LTL and mortality. Initial studies 
suggested that telomere shortening in human beings contributes to mortality in many age-related 
Figure 6. Diagram of factors affecting telomere length in primary somatic cells from human 
tissues. This figure was obtained from (Aubert & Lansdorp 2008). 
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diseases (Cawthon et al. 2003). Hence, during the initial period of TL association studies, there 
was agreement that telomere shortening was associated with cancer risk and mortality. 
Further studies revealed a large complexity in TL association studies (Weischer et al. 
2013; Rode et al. 2015). These studies were significantly improved by population-based designs 
to minimize selection bias, large sample size, long follow-up, and by prospective study designs 
that conferred them accuracy and minimized reverse causality. The conclusions of these studies 
suggested that there was no association between cancer risk and short TL, although reduced 
survival was associated with short LTL after cancer (Weischer et al. 2013) and high mortality 
(Rode et al. 2015).  
Because genotype-phenotype associations are not vulnerable to biases caused by reverse 
causation or environmental confounding, the latest TL association studies tried to avoid this 
problem by implementing Mendelian randomization in TL association studies. This is an 
epidemiologic technique wherein genetic variants known to be associated with long or short  LTL 
are used as surrogate markers to investigate the effect of those genetic variants on cancer/disease 
(Smith & Ebrahim 2003). This approach has been established as the technically most consistent 
method to estimate the relationships between TL and cancer risk in the past few years (Zhang et 
al. 2015; Codd et al. 2013; Iles et al. 2014). Recently, TL-associated genotype studies conducted 
in 95,568 individuals from the general population concluded that genetic determinants of long 
telomeres are associated with increased cancer risk, particularly melanoma and lung cancer (Rode 
et al. 2015). However, this latter study lacked ethnic diversity, since all samples were from the 
Danish population. This may result to be a limitation if these results are extrapolated.  
 
 
6. TELOMEROPATHIES 
	
Defects in genes involved in telomere maintenance (shelterin complex or telomerase) 
result in a wide spectrum of overlapping symptoms (Kirwan & Dokal 2008) which converge in 
disease manifestation. 
The symptoms of these disorders are extensive; the age of onset is highly variable and 
genetic anticipation is involved. However, these disorders share a similar underlying molecular 
mechanism, premature telomere shortening, that leads to a spectrum of diseases (Holohan et al. 
2014) (Table 2). 
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Table 2. List of genes/complexes that cause telomere disorders when defective (Opresko & 
Shay 2016) 
GENE DISEASES 
TIN2 Dyskeratosis congenita/ Hoyeraal Hreidarsson syndrome/ Revesz syndrome 
RTEL 1 Dyskeratosis congenita/ Hoyeraal Hreidarsson syndrome 
CTC1 Coats Plus 
Apollo 
(SNM1B) 
Hoyeraal Hreidarsson syndrome 
TERT, TERC, 
Dyskerin, 
NHP2, NOP10 
Dyskeratosis congenita, idiophatic pulmonary fibrosis, aplastic anemia 
TCAB1 Diskeratosis congenita 
                                     
 
6.1. Telomere biology in Hereditary Breast and Ovarian Cancer (FBOC)  
 
Inherited predisposition to breast and ovarian cancer accounts for approximately 5% of 
all breast and ovarian cancer cases and is characterized by an autosomal dominant pattern of 
inheritance, young age of onset and bilateral breast and ovarian cancer. FBOC is associated with 
inherited mutations mainly in two genes, BRCA1 and BRCA2, which are tumor suppressor genes 
responsible for maintaining genome stability through their involvement in homologous 
recombination (HR) double-stranded break (DSB) DNA repair (Roy et al. 2012). Carrying an 
inherited mutation in the BRCA1 or BRCA2 genes increases a woman's lifetime risk of developing 
breast and ovarian cancer, although there are considerable differences in disease manifestation. 
At the age of 70, cumulative cancer risk for BRCA1 and BRCA2 mutation carriers ranges from 
43% to 88% for breast cancer development, and from 11% to 59% for ovarian cancer (Antoniou 
et al. 2003; Milne et al. 2008).  
This high variability is the consequence of other genetic modifiers and/or environmental 
factors. For example, we recently described that two single nucleotide polymorphisms (SNPs) 
located in the OGG1 and NEIL2 genes (Table 1), were cancer risk modifiers for BRCA1 and 
BRCA2 mutation carriers, respectively (Osorio et al. 2014). 
Genetic anticipation, is a phenomenon whereby as a genetic disorder is passed on to the 
next generation, the symptoms of the genetic disorder become apparent at an earlier age with each 
generation. Genetic anticipation, has previously been described in several hereditary cancer 
syndromes (Table 1)  and also in FBOC (Dagan & Gershoni-Baruch 2001; Peixoto et al. 2006).  
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Telomere shortening was more recently described as a mechanism of cancer anticipation. 
Importantly, there is evidence that BRCA1 protein is localized at telomeres and may regulate TL 
and stability (Blasco 2005; Badie et al. 2015; Badie et al. 2010; Cabuy et al. 2009; Uziel et al. 
2016). In addition, BRCA2 gene has been described to be involved in telomere replication (Badie 
et al. 2010). 
Based on the above evidence, our group hypothesized that telomere shortening may be 
associated with age anticipation in hereditary breast cancer. In an initial study, we showed that 
cancer cases harboring mutations in the BRCA1 and BRCA2 genes presented significantly shorter 
LTL compared to sporadic cancer cases. In addition, progressive telomere shortening in those 
cases  was associated with earlier onset of breast cancer in successive generations of affected 
families (Martinez-Delgado et al. 2011). These results provided evidence that telomere shortening 
could be the causal explanation for earlier age of cancer onset in successive generations among 
breast cancer families, and suggested that it might be a mechanism of genetic anticipation in 
hereditary breast cancer (Martinez-Delgado et al. 2011), as observed previously in other genetic 
disorders such as Dyskeratosis Congenita. 
After this initial study, 2 consecutive studies including a larger sample size of BRCA1 and 
BRCA2 mutation carriers found contradictory associations between BRCA mutations and TL. The 
first study reported that TL was normal in BRCA1 and BRCA2 mutation carriers (Killick et al. 
2014), and the second study showed that LTL was long in BRCA1 and BRCA2 mutation carriers, 
although it was not associated with an increased cancer risk (Killick et al. 2014). These results 
led to a contradiction in the literature regarding the association between TL and cancer or other 
diseases, and point to differences in the strategies used to perform these studies (prospective or 
retrospective), technical issues, and/or the existence of TL modifiers as the possible source of 
variability (Aviv et al. 2011; Raschenberger et al. 2016). 
 
 
7. TELOMERE LENGTH VARIATION IN HUMANS 
	
7.1. Genetic basis of TL 
	
Intra-uterine variables including genetic and other factors during pregnancy determine 
TL of individuals at birth (Benetos et al. 2014). Genetic determinants of TL have been widely 
investigated. Twin studies indicate that heritable factors may contribute up to 80% of the inter-
individual variation in TL (Graakjaer et al. 2004; Slagboom et al. 1994). Quantitative trait linkage 
studies have mapped several loci for TL (Mangino et al. 2008; Vasa-Nicotera et al. 2005; Andrew 
et al. 2006). Recently, genetic variants at ACYP2, TERC, TERT, NAF1, OBFC1, ZNF208 and 
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RTEL1 have been identified to be associated with TL in three genome-wide association studies 
(GWAS) in people of European descent (Codd et al. 2010; Codd et al. 2013; Levy et al. 2010; 
Bojesen et al. 2013) and in a Chinese population (Du et al. 2015), although each of the LTL-
associated variants explains only a small proportion of the total variance in TL across individuals 
(Codd et al. 2013). It is therefore possible that other as yet undiscovered genetic variants can 
explain TL variability in the general population or in the context of FBOC. 
After birth, internal and external environmental factors accelerate or slow down the 
attrition of telomeres (Kimura et al. 2008).	Some of these factors are described below. 
 
7.2. Inflammation, oxidative stress and telomere length 
 
Oxidative stress has been shown to exert a major influence on the rate of telomere 
shortening (Houben et al. 2009) because oxidative damage is repaired less well in telomeric DNA 
than elsewhere in the chromosome (Von Zglinicki 2002). The inflammatory process induces 
oxidative stress and reduces cellular antioxidant capacity. Many chronic conditions in humans are 
associated with chronic inflammation, immune system impairment and accelerated aging. In 
addition, abnormalities in the telomere/telomerase system of these patients have been reported in 
many of these disorders.  
There is a long list of autoimmune diseases like rheumatoid arthritis, systemic lupus 
erythematosus, multiple sclerosis, etc. that are characterized by immune system dysfunction, and 
thus inflammatory cascades seem to play a major part in disease onset and progression (Kordinas 
et al. 2016). Telomere shortening and deregulation of telomerase activity have been reported in 
association with autoimmune diseases (Dehbi et al. 2013; Wu et al. 2007; Guan et al. 2015).  
A common disease like periodontitis, a chronic infection with a prevalence between 10-
30% in the general adult population, is associated with chronic inflammation, oxidative stress and 
telomere shortening (Masi et al. 2011). Diabetes is a spectrum of diseases with the most important 
ones being type 1 diabetes and type 2 diabetes, and it has a prevalence of around 8.5%. Diabetes 
is associated with inflammation and oxidative stress and some studies have identified a connection 
between telomere/telomerase dysfunction and diabetes  (Liew et al. 2009). 
Psychiatric disorders such as depression, schizophrenia, anxiety disorder, bipolar disorder 
and post-traumatic stress disorder pose serious and emerging global health threats and have in 
recent years been associated with accelerated aging, chronic inflammation and immune system 
deregulation (Lindqvist et al. 2015). For example, depression affects 350 million people 
worldwide and is associated with higher levels of IL-1β, IL-6, IFN-γ and TNF-α (Hughes et al. 
2016). In addition, there are studies connecting psychiatric disorders with telomeres and 
telomerase. Leucocyte telomere length has been studied in many psychiatric disorders. Shorter 
telomeres have been observed in depressed patients compared to healthy controls, and in addition 
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shorter telomeres where associated with the severity and duration of the disease (Lindqvist et al. 
2015). 
 
7.3. Environmental factors that affect telomere length in humans 
 
Some environmental stresses disrupt TL homeostasis (Romano et al. 2013). In humans, 
stresses like alcohol or tobacco intake shorten telomeres (Pavanello et al. 2011; Salihu et al. 
2014). Postnatal exposure to different kinds of environmental stressors such as environmental 
pollution (Meillère et al. 2015), social and psychological stress (Boonekamp et al. 2014; Price et 
al. 2013) and nutritional deficiencies (Noguera et al. 2015) can accelerate the rate of telomere 
loss, possibly related to the fact that telomere shortening is greater after increased exposure to 
stress hormones (Haussmann et al. 2012; Herborn et al. 2014). Cortisol is a hormone associated 
with chronic stress, and is related with telomere shortening and lower levels of telomerase activity 
(Shaffer et al. 2012). In addition, other factors related with lifestyle are known to modify TL in 
the general population: dietary patterns (Rafie et al. 2016) and common pathological conditions 
like obesity or depression have been associated with telomere shortening (Shaffer et al. 2012; 
Chen et al. 2014). Interestingly, poor sleep quality and short sleep duration are associated with 
shorter LTL in men (Jackowska et al. 2012). 
 
7.4. Cancer therapies that affect telomere length 
 
In cancer patients, additional factors such as exposure to chemotherapeutic agents or 
radiotherapy can modify TL (Li et al. 2012). Telomere dysfunction induced by chemotherapeutic 
agents is drug-specific. The alkylating agent cyclophosphomide was shown to induce in 
spermatogonial cells a significant increase in DNA damage, which was localized preferentially at 
telomeres. This telomere DNA damage was accompanied by telomere shortening and a significant 
reduction in both telomerase mRNA levels and telomerase activity (Marcon et al. 2011; Liu et al. 
2015). In addition, it is known that mitotic inhibitors such as Taxol, which are normally included 
in conventional breast cancer chemotherapy schedules, can cause telomere uncapping and trigger 
telomere dysfunction in cancer cells (Lu et al. 2013). In contrast, telomere elongation has been 
detected after treatment with the hypomethylating agent 5-aza-2'-deoxycytidine (5-aza-CdR) and/ 
or the histone deacetylase inhibitors trichostatin A (TSA). 
In summary, TL exhibits considerable inter-individual variability, and it is likely that all 
sources of variability mentioned above should be considered in TL association studies in order to 
obtain reliable results and clarify the utility of LTL as a biomarker to predict cancer/disease 
susceptibility. 
	23 
	
HYPOTHESIS 
 
 
 
 
OBJECTIVES 
In the present study, we tried to confirm the above hypothesis by analyzing exogenous 
(chemotherapy) and endogenous (genetic variants in OGG1 and NEIL2) factors that can act as 
modifiers of TL. To this end, we worked prospectively with a series of families with a history of 
breast and ovarian cancer screened for BRCA1 and BRCA2 mutations. The families included 
affected and unaffected BRCA1 and BRCA2 mutation carriers, BRCAX cancer cases and non-
carrier controls. We followed these families for three years and took blood samples every 12 
months in order to: 
1. Evaluate the effect of chemotherapy as a possible telomere length modifier; 
2. Evaluate the role of rs2304277 in OGG1, a DNA glycosylase involved in BER pathway, 
as a modifier of cancer risk;  
3. Evaluate the role of rs804271 in NEIL2, another DNA glycosylase involved in BER 
pathway, as a modifiers of cancer risk;  
4. Evaluate the possible synthetic lethal/sickness interaction between homologous 
recombination and BER DNA repair pathways, and its implication for the treatment of 
BRCA1 and BRCA2 cancer cases. 
 
 
	  
Cells from peripheral blood are exposed to internal and external agents that can alter DNA repair 
capacity, oxidative stress or cell cycle speed. Most of them are related directly or indirectly with 
TL. Therefore, retrospective studies or studies that do not take these factors into consideration 
can lead to misleading results regarding TL in association with disease susceptibility. 
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The impact of chemotherapy on telomere length (TL) have been already addressed in 
vitro (cultured cell lines and normal human leucocytes) and in vivo (in different tumors). We have 
tried to evaluate whether chemotherapy could be a confounding factor for TL association studies 
evaluating telomere shortening as a causal explanation for cancer risk susceptibility in hereditary 
breast cancer. In relation to this topic, previous finding and conclusions have led to a confusing 
scenario in the literature  
To summarize, our study has focused on the effect of cancer treatment on TL in both 
familial and sporadic breast cancer cases. We have found that chemotherapy exerts a transient 
telomere shortening effect on human leukocytes, and that after the treatment a normal TL can be 
recovered. In the context of familiar breast cancer patients, we cannot rule out that BRCA1 and 
BRCA2 might be minor modifiers of TL, but it appears that treatment is the true cause of TL 
modifications. The rates of telomere shortening and recovery may vary depending on the type of 
treatment. 
We performed a cross-sectional study measuring leukocyte TL of 266 sporadic breasts 
cancer patients treated with first-line chemotherapy, with a median follow up of 240 days. 
Additionally, we performed both cross-sectional and longitudinal studies in a series of 236 
familial breast cancer patients that included affected and non-affected BRCA1/2 mutation carriers. 
We have measured in leukocytes from peripheral blood: The telomere-length, percentage of short 
telomeres (<3Kb), telomerase activity levels and the annual telomere shortening speed. 
These results stress the need to perform prospective and retrospective studies, considering 
the variability found as a consequence of the treatment status (untreated, during treatment and 
post treatment) of the patients, to obtain conclusive results about the relationship between 
telomere-length and disease.    
 Impact factor (IF) = 4.085  
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Abstract
Purpose—Recently, we observed that telomeres of BRCA1/2 mutation carriers were shorter than 
those of controls or sporadic breast cancer patients, suggesting that mutations in these genes might 
be responsible for this event. Given the contradictory results reported in the literature, we tested 
whether other parameters, such as chemotherapy, could be modifying telomere-length.
Methods—We performed a cross-sectional study measuring leukocyte telomere-length of 266 
sporadic breasts cancer patients treated with first-line chemotherapy, with a median follow up of 
240 days.
Additionally, we performed both cross-sectional and longitudinal studies in a series of 236 familial 
breast cancer patients that included affected and non-affected BRCA1/2 mutation carriers. We 
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have measured in leukocytes from peripheral blood: The telomere-length, percentage of short 
telomeres (<3Kb), telomerase activity levels and the annual telomere shortening speed.
Results—In sporadic cases we found that chemotherapy exerts a transient telomere shortening 
effect (around 2 years) that varies depending on the drug combination.
In familial cases, only patients receiving treatment were associated with telomere shortening but 
they recovered normal telomere-length after a period of two years.
Conclusion—Chemotherapy affects telomere-length and should be considered in the studies that 
correlate telomere-length with disease susceptibility.
Keywords
Chemotherapy; Sporadic Breast Cancer; Familial Breast and Ovarian Cancer; telomere-length; 
Telomerase
INTRODUCTION
Telomeres are nucleoprotein structures that cap and protect the ends of chromosomes against 
chromosomal fusion, recombination and terminal DNA degradation 1. In humans, the 
average telomere-length typically ranges from 10 to 15 kb 2, but telomere DNA shortens 
with each cell replication. This leads to a progressive telomere shortening during life that 
ranges from 24.7 to 45.5 bp/year 3. This shortening continues until the telomere reaches a 
critical length 4, which triggers cell-cycle arrest leading to senescence or apoptotic cell 
death.
Germ cells and stem cells can counteract telomere shortening through the action of an 
enzyme called telomerase, which can synthesize telomeric DNA de novo 5. However, cancer 
cells present altered DNA damage response mechanisms and are able to divide even when 
they present critically short telomeres by up regulating telomerase activity or activating the 
‘alternative lengthening of telomeres’ mechanism 5.
There are several retrospective case-control and longitudinal studies suggesting that short 
telomeres found in DNA from surrogate tissues may predispose to different diseases 
including cancer 6-11. However, the largest prospective study in the general population to 
date (47,102 subjects with a 20-year follow-up) has recently suggested only a weak 
relationship between short telomeres and breast cancer risk among a large group of cancer 
types 12.
These results led to a contradiction in the literature regarding the association between 
telomere-length and cancer or other diseases, and point to differences in the strategies used 
to perform these studies (prospective or retrospective), technical issues, and/or the existence 
of telomere-length modifiers as sources of variability 13-16.
In a previous study we found that patients with hereditary breast cancer (BRCA1/2 and non-
BRCA1/2 carriers) presented shorter telomeres than sporadic breast cancer patients and the 
control population, suggesting a modifier effect of the BRCA1 and BRCA2 genes on 
telomere-length17. Because our study was retrospective, like two other recent studies that 
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presented contradictory results 18, 19, we decided to investigate the possible cause of these 
discrepancies.
We have focused our attention on the possible impact of chemotherapeutic cancer treatment, 
because some publications have already suggested a telomere shortening effect after the 
administration of chemotherapy in vivo (in different tumors) and in vitro (in normal human 
leukocytes and a mouse spermatogonial cell line) 20, 21.
We have explored this hypothesis in sporadic and familial breast cancer, and we have found 
that chemotherapy has a telomere shortening effect that is reversible after a period of time 
once the treatment is finished.
SAMPLES AND METHODS
Samples
Two different series of patients and two different strategies were used. We took a cross-
sectional approach in a set of sporadic breast cancer cases and both a cross-sectional and a 
longitudinal approach in a series of familial breast cancer cases.
The first series comprised 253 sporadic breast cancer patients (age range: 30-81years) who 
were undergoing or had already received chemotherapy and 13 patients recently diagnosed 
that had not received chemotherapy (age range: 28-68y). They were included in a clinical 
trial that involved chemotherapy based on taxane derivatives and were followed for a median 
of 240 days (range 5-1855 days). We established two main categories based on their status: 
“During treatment” and “Post treatment”. In addition, patients were classified according to 
the taxane combination they received (Table1). Details regarding doses, number of cycles, 
duration and patient follow-up after treatment are summarized in Table S1.
The second series consisted of 236 familial breast cancer patients belonging to 104 families 
(23 harboring deleterious mutations in BRCA1, 28 in BRCA2, and 53 not associated to any 
of the known genes (BRCAX)). Most of the families were selected from the registry of the 
Familial Cancer Consultation of the CNIO and had been attended between 2011 and 2013. 
Individuals from these families met high risk criteria and 22 had been previously screened 
for mutations in BRCA1 and BRCA2 by a combination of denaturing high-performance 
liquid chromatography (DHPLC) and direct sequencing as previously reported 23. Due to the 
lack of a complete knowledge concerning the specific chemotherapy treatment regimens and 
the follow up of the patients after finishing the treatment, we established two general groups 
of patients. Only patients that were known to have been treated with any kind of 
chemotherapy were included in this analysis. Those, whose sample was extracted less than 
two years after diagnosis were considered as “During treatment”; while those whose sample 
was extracted more than two years after diagnosis were considered as “Post treatment”.
We measured leukocyte telomere-length by quantitative PCR, in the DNA of all individuals 
from this series, and whenever possible we measured the telomere-length and the percentage 
of short telomeres by High Throughput QFISH, and the telomerase activity levels in 
peripheral blood. In the FBOC series, we had the opportunity to compare 2 telomere-length 
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measurements that corresponded to samples obtained at two different time points, with an 
average of 6 years between both extraction points. Using the 2 measurements we were able 
to calculate the telomere shortening rate per year.
A summary of all pertinent information (sample size, median age, age range and the 
experiments performed) of both cohorts of patients is shown in Table 2.
A set of 330 healthy Spanish women previously described 24, without personal or familial 
antecedents of cancer (age range 19-77y) was used as a control population (Table2-
controls1) in order to adjust the telomere-length of both sporadic and familial breast cancer 
cases according to age.
The study was performed in accordance with the principles of the Declaration of Helsinki. 
Written informed consent was obtained from all patients prior to sample collection, and the 
study was approved by the Ethics Committee of Clinical Investigation from Centro Integral 
Oncologico Clara Campal, Madrid.
Telomere-length quantification
DNA from peripheral blood was extracted using MagNA Pure LC 2.0 System (Roche 
Diagnostics, Indianapolis, Indiana). Telomere-length was measured using quantitative PCR-
based technique. This technique calculates the telomere-length as a ratio of telomere amount 
(t) relative to 36B4 reference gene amount (s)25.The measurement unit used in this 
technology is the t/s value. Primers used to perform the quantitative PCR have been 
described previously17. DNA samples were amplified in a total reaction volume of 10 μl 
containing 1× Gotaq quantitative PCR Master Mix (Promega, Madison, Wisconsin), 500 nM 
of primer Tel1, 1000 nM of primer Tel2, 10-30 ng of DNA and a common thermal cycling 
profile for both “t” and “s” determination. For 36B4 reactions, the concentrations of primers 
were 500 nM of 36B4u and 500 nM of 36B4d. All samples were analyzed in triplicate using 
an ABI 7900HT thermal cycler, in 384-well format. Telomere-length was calculated as 
previously described 17.
Measurement of telomere-length and short telomere content by High Throughput Q-FISH
For telomere-length by High Throughput Q-FISH measurement, peripheral blood 
mononuclear cells were hybridized with a PNA-tel Cy3-labeled probe. Telomere-length was 
determined as previously described 26 .
DAPI and Cy3 signals were acquired simultaneously in separate channels using a Leica 
TCS-SP5 confocal microscope (Wechsler, Germany). and maximum intensity projections 
from image stacks were generated for image quantification. In all cases, background noise 
was subtracted from the image prior to quantification. The “average telomere fluorescence” 
values represent the average Cy3 pixel intensity for the total nuclear area. Percentage of cells 
with short telomeres was calculated as those with intensity values within the first quartile.
Telomerase Assay
Protein extracts were obtained from peripheral blood mononuclear cells cultured in RPMI 
supplemented with 20 % fetal bovine serum and phytohemagglutinin during 4-5 days, 
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according to the recommendations of the manufacturer of the TRAPeze telomerase detection 
kit (Merck Millipore, Darmstadt, Germany). The average telomerase activity was 
determined in each sample using 0.5, 0.25 and 0.125 μg of protein extract and normalized 
with the internal control included in the assay.
Telomere Shortening Rate
When possible, we calculated the difference in t/s values between blood samples extracted in 
two different time points (average of six years). The result was divided by the number of 
years that separated both samples. A positive result indicated shortening, while a negative 
value indicated elongation of the telomere.
Statistical analysis
Telomere-length measurements were adjusted for age using the line of best fit for controls. 
Thus, the difference between the actual and the predicted value was calculated for each 
sample. Following this method we adjusted t/s values obtained by quantitative PCR (y=
−0.0174*X+1.96), the Kb obtained by High Throughput Q-FISH (−0.0587*X+12.007) and 
the percentage of short telomeres (0.1501*X+11.331).
The Kolmogorov-Smirnov test was used to evaluate whether telomere-length measurements 
obtained from healthy controls, familial breast cancer and sporadic cancer cases followed a 
normal distribution. As a normal distribution could not be assumed for healthy controls, a 
Mann-Whitney U test was applied (Table S2, figure 3a and figure 3b) Unpaired Student t-
test for normal distributions was applied in the comparative analysis of telomerase activity, 
telomere shortening rate (Table S3 and Table S4) and percentage of short telomeres among 
the familial breast cancer groups (Figure 4).
Spearman correlation test was used to establish whether correlation between variables were 
statistically significant (Figure 1).
Statistical calculations were performed using SPSS version 18 (SPSS Inc, Chicago, Illinois) 
and Graph pad Prism 5.03(San Diego, California). Nominal two-sided p-values less than 
0.05 were considered statistically significant. Graphics were performed using Graph pad 
Prism 5.03 and Microsoft Office Excel 2007.
RESULTS
Controls
We evaluated the telomere-length distribution in 330 healthy women as a function of age in 
order to obtain a regression line to adjust the t/s values from both the familial breast cancer 
and the sporadic series. As expected, we found a decrease in telomere-length with age. 
(Figure S1).
Sporadic cases
We tested whether chemotherapy itself has an effect on telomere shortening. To address this 
hypothesis we evaluated the telomere-length distribution of patients included in the “During 
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treatment” category. We observed a strong correlation between telomere shortening and 
treatment duration (r=−0.43; p=3.71E-05) (Figure 1a). We did the same evaluation in the 
“Post treatment” category, and we observed that the distribution had the opposite shape, with 
a significant positive correlation between telomere-length and time after treatment (r=0.17; 
p=0.02) (Figure 1b).
We next did a comparative analysis of telomere-length during different periods of the 
treatment time line, (Figure 2). We compared the median telomere-length of each group, 
with the median telomere-length of the control group. The telomere-length (t/s values 
adjusted by age) in patients before treatment did not differ compared to controls (Figure 2, 
black line). From the beginning of the treatment, we observed a shortening effect that 
became statistically significant in patients treated for more than 90 days and remained 
significantly shortened until 360 days after the treatment. Patients whose samples were 
extracted later than 360 days after the end of the treatment tended to recover normal 
telomere-length values, and did not show significant differences when compared to controls. 
The results of this analysis are summarized in Table S2.
In patients treated with therapy based in taxane derivatives (Table 1), we observed a more 
significant telomere shortening effect in those treated with FEC+T/T+FEC (red line) 
compared to those treated with AC+T/T+AC (green line) however, the latter seemed to 
recover their telomere-length faster (Figure 2).
Familial Breast Cancer Cases
Cross-sectional study—We performed this analysis to explore both, the role of 
BRCA1/2 mutations as telomere-length modifiers and the possible correlation between 
telomere shortening and cancer treatment. Healthy BRCA1/2 mutation carriers (n=54) did 
not present shorter telomeres when compared to controls (n=330), while significantly shorter 
telomeres were found in affected BRCA1/2 mutation carriers (n=50; p=0.044) and BRCAX 
patients (n=63; p=0.048) (Figure 3a).
In view of the behavior of telomeres in sporadic breast cancer cases according to the 
treatment status, we decided to reanalyze the data from the familial breast cancer series. We 
established two categories consisting of cancer patients from whom samples were extracted 
within two years from the beginning of the treatment, called “During treatment 
BRCA1/2/X”, and a second group composed of patients whose samples were taken more 
than two years after the beginning of treatment, called “Post treatment-BRCA1/2/X”. We 
used two years as a cut-off, because in the sporadic series we observed that the recovery 
phase starts approximately two years since diagnosis.
No significant differences were found between “Post treatment-BRCA1/2/X” patients and 
controls (Table2-controls1). However, the “During treatment-BRCA1/2/X” group presented 
significant shortened telomere t/s values compared with the controls (p=0.0005) and the 
“Post treatment-BRCA1/2/X” groups (p=0.007) (Figure 3b).
We also evaluated the leukocyte telomerase activity in this cohort of patients (Figure 3c). We 
found that healthy BRCA1/2 mutation carriers presented similar telomerase activities to the 
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healthy controls (Table 2-controls2). Interestingly, all cancer patients, independently of the 
mutation type and the treatment time, presented significantly lower levels of telomerase 
activity, being patients “During treatment” the ones showing the lowest values (p=0.0009) 
(Table S3).
In parallel, we used High Throughput Q-FISH technology in order to validate our results 
using an alternative technology. We found the same results regarding telomere-length for the 
“During treatment-BRCA1/2/X” group (Figure 4a), confirming the presence of a 
significantly higher percentage of short telomeres (<3Kb) for this group of patients (p=0.01) 
compared to the control population (Table 2-controls2) (Figure 4b).
Longitudinal study—We performed a longitudinal retrospective study in order to analyze 
telomere shortening rate in a set of 31 BRCA1/BRCA2 mutation carriers with two 
independent blood samples taken separately by an average period of 6 years: 15 were 
healthy carriers, 9 affected carriers with the two samples obtained once the chemotherapy 
had finished, and 7 affected carriers in which the first sample was obtained “During 
treatment” and the second extraction point in the “Post treatment”. Additionally we analyzed 
the telomere shortening rate in a set of 25 controls from which we also had samples taken at 
two time point (Table 2-controls3).
Healthy BRCA1/2 carriers presented a faster telomere shortening rate compared to the 
control group, although the differences were not significant; while “Post treatment-
BRCA1/2” patients presented a telomere shortening rate very similar to the control group. 
By contrast, “During treatment-BRCA1/2” patients presented a different pattern, going from 
short telomeres at the first measurement, to normal telomeres 7 years later (Figure 5). In this 
case the elongation speed was very pronounced, and statistically different from the normal 
shortening of the control population (p=0.011). The results of this analysis are summarized 
in Table S4.
DISCUSSION
We previously reported that BRCA1/2 might be telomere-length modifiers, because 
mutation carrier patients presented shorter telomeres than the control population and 
sporadic breast cancer cases 17. However, two recent reports did not find any relationship 
between the presence of BRCA1/2 mutations and telomere shortening, nor between 
telomere-length and an increased cancer risk 18, 19. The three studies were done in a 
retrospective manner, and in none of them treatment status, which might constitute a 
confounding factor, was evaluated independently as a possible modifier of telomere-length. 
We tried to overcome this possible bias by working with two independent cohorts of women 
with breast cancer (sporadic and familial) and two different approaches (cross-sectional and 
longitudinal).
According to the results obtained in the sporadic set of patients treated with different 
chemotherapy schedules and followed for a maximum period of 1855 days, telomere 
shortening starts at 91-180 days after the beginning of treatment and reaches its maximum 
effect between 91-180 days after finishing treatment. Then a recovery phase starts, and it 
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lasts for a maximum of 1855 days after which the original telomere-length is recovered 
(Table S2). Similar results were observed in the familial breast cancer series in both, cross-
sectional and longitudinal studies.
There are some reports suggesting a possible deleterious effect of chemotherapy on 
telomere-length and/or telomerase activity, although some of these seem to be contradictory.
The first authors, who addressed this question, reported significant telomere shortening 
accompanied by a significant reduction in telomerase activity in the blood cells of pediatric 
leukemia patients after the administration of cancer treatment 27. Another early longitudinal 
study in breast cancer patients undergoing chemotherapy, reported a clear negative effect on 
different hematological parameters, including telomere shortening, after high doses of FEC
+T 28. On the other hand, in a recent longitudinal study performed in a set of 33 breast 
cancer patients undergoing AC+T/T+AC chemotherapy no changes were detected in 
telomere-length, at three and twelve months after the end treatment 29 .
It is probable that in this case patients were already at the “recovery phase” proposed in this 
study. Surprisingly, increased expression of the senescence markers p16 and ARF was 
detected, which have been correlated with telomere damage in primary cells 30.
Engelhard et al. were the first to raise the question of whether telomere shortening is 
permanent or telomeres regain their initial length after discontinuation of chemotherapy 27.
In this regard, our results confirm there is a telomere recovery after treatment, although we 
have observed that the shortening effect and the time to reach the “recovery phase” varies 
depending on the treatment type, with a shortening effect more severe at the initial phase of 
the treatment for patients under the AC+T/T+AC regimen, while those treated with FEC
+T/T+FEC present a more delayed “recovery phase”. It seems that telomere stability is 
affected by conventional chemotherapies in different manner depending on the specific drug 
mechanism of action (Alkylating agents, anti-replicative molecules, spindle poisons, anti-
topoisomerase I and II) being the effects on the telomere heterogeneous.
Some authors have evaluated the role of several chemotherapy drugs in vitro and in cancer 
patients at a more mechanistic level 21, 31, 32. For instance, the alkylating agent 
cyclophosphamide, was shown to induce in spermatogonial cells a significant increase in 
DNA damage, which was localized preferentially at telomeres. This telomere DNA damage 
was accompanied by telomere shortening and a significant reduction in both telomerase 
mRNA levels and significantly diminished telomerase activity 21. These negative effects 
may be explained due to the high guanine content of the telomere sequence and the TERC 
gene, which may increase the risk of DNA-DNA crosslink damage by cyclophosphamide 21.
In another longitudinal study using 6 cycles of CHOP (cyclophosphamide, doxorrubicine, 
vincristine and Prednisone) in a cohort of 14 Non-Hodgkin lymphoma patients, significant 
telomere shortening was maintained up to 2 years, after the treatment ends. The same study 
evaluated the anti-metabolite drug 5-fluoracil alone in a set of 10 colon cancer cases. TL was 
measured 2 and 12 months after the end of the treatment showing an initial telomere attrition 
that was recovered after one year 31. The authors propose a possible mechanism based on 
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whether these drugs are able to target hematopoietic stem cells, or only mature progenitors, 
to explain a long or a short-term effect in telomere shortening 31. In addition, it is also 
known that mitotic inhibitors such as taxol, which are normally included in conventional 
breast cancer chemotherapy schedules, can causes telomere uncapping, triggering telomere 
dysfunction in cancer cells 32.
Taking all this evidences together we can assume some variation in the telomere dynamics 
during and after the treatment, depending which type of anticancer chemotherapy drugs are 
included in the patients treatment.
In the familial breast cancer model we followed both cross-sectional and longitudinal 
approaches in order to test whether the BRCA genes and chemotherapy are modifiers of 
telomere-length and/or telomerase activity.
In the cross-sectional approach we found similar results as in our previous study 17, familial 
cases presented shorter telomeres than controls; however, a substantial proportion of the 
samples had been taken during or after a short time of chemotherapy administration. When 
we corrected for treatment status we were not able to detect any effect of the BRCA1/2 
mutations on telomere shortening, neither in healthy carriers nor in post treated-BRCA1/2 
patients, suggesting that the treatment is the real telomere-length modifier (Figure 3b). These 
results could explain partially, the discrepancies reported in the literature regarding the role 
of the BRCA1/2 genes as modifiers of telomere-length17. In a recent report by Pooley et al, 
BRCA1/2 mutation carriers showed longer telomeres than controls, and the authors suggests 
that an increase in telomerase levels could be associated with this event 18. However, in the 
present study we have not found higher levels of telomerase activity in healthy BRCA1/2 
patients, while treated patients (independently of their mutational status), presented both 
shorter telomeres and significant lower telomerase activity levels.
Regarding the longitudinal study, BRCA1/2 affected carriers with two telomere-length 
measurements covering the “Post treatment” period, did not present significant differences in 
the shortening rate compared to healthy BRCA1/2 carriers and/or controls. However, 
BRCA1/2 patients, with the first sample taken during treatment and the second sample taken 
7 years later (during the post treatment period) presented a recovery of telomere-length after 
chemotherapy, confirming our observations in the sporadic series (Fig 5).
To summarize, our study has focused on the effect of treatment on telomere-length in both 
familial and sporadic breast cancer cases. We cannot rule out that BRCA1 and BRCA2 
might be minor modifiers of telomere-length, but it appears that treatment is the true cause 
of telomere shortening. The rates of telomere shortening and recovery may vary depending 
on the treatment. These results stress the need to perform prospective and retrospective 
studies, considering the variability found as a consequence of the treatment status (untreated, 
during treatment and post treatment) of the patients, to obtain conclusive results about the 
relationship between telomere-length and disease.
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Figure 1. 
a) Correlation between telomere-length (t/s) and treatment time (r=−0.43; p=3.71E-05). b) 
Correlation between telomere-length (t/s) and time after treatment (r=0.17; p=0.02).
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Figure 2. 
Telomere-length evolution during treatment and after treatment. Mann Whitney test was 
used to determine significant differences between controls and the different subgroups. The 
discontinuous lines represent significantly shortened telomeres compared to controls for all 
the patients together (black line) and for the two major drug schedules (red and green lines).
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Figure 3. 
a) Distribution of telomere-length (t/s) values adjusted for age for the familial breast cancer 
groups according to mutational status. The Mann Whitney test was used to test for 
significant differences in telomere-length between controls and the different subgroups. b) 
Distribution of telomere-length (t/s) values adjusted for age for the familial breast cancer 
groups according to treatment status (Mann Whitney test). c) Comparative analysis of 
telomerase activity levels in the familial breast cancer series; Student’s unpaired t-test was 
used to determine significant differences among groups.
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Figure 4. 
a) Comparative analysis regarding telomere-length (adjusted Kb) in the familial breast 
cancer series (Unpaired Student t-test). b) Comparative analysis regarding content of short 
telomeres (<3Kb) in the familial breast cancer series (Unpaired Student t-test).
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Figure 5. 
Theoretical telomere-length (TL) evolution based on two telomere-length measurements 
along the time (average 6 years). We observed a similar behavior for controls, Healthy 
BRCA1/2 carriers and Post treatment affected patients carrying BRCA1/2 mutations 
regarding telomere shortening rate, ranging from 0.028 to 0.033 t/s per year. Strikingly 
patients with control samples during treatment and post treatment presented an opposite 
elongation pattern, of −0.086 t/s year.
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Table 1
Details regarding the two main Taxane subgroup schedules
During treatment After treatment
Drug/Combination n Me-days treatment Range/days * n Me-Days post treatment Range/days #
AC+T/T+AC 24 88 0-204 42 166.5 14-1855
FEC+T/T+FEC 63 85.5 0-161 124 281 1-1219
Me-days treatment: Median number of treatment days; Me-days post treatment: Median post treatment follows up in days; A: Doxorubicin; C: 
Cyclophosphamide; F: 5-Fluorouracil; E: Epirubicin; T: Paclitaxel
*
Days counted from the first day of treatment.
#
Days counted from last day of treatment.
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Figure S1 
 
Figure S1: Telomere Length distribution in peripheral blood leukocytes as a function of age for 
the control women population (n = 330), measured by q-PCR. The regression line for control is 
drawn (y=-0.0174*X+1.96) (r =0, 2633). 
 
 
 
 
 
 
 
 
 
 
 
Table S1 Characteristics of Taxane-based schedules . 
 
Taxol 
schedule 
Treatment 
strategy 
n Taxanes 
(mg/m2) 
Days of 
treatment 
Other drugs 
(mg/m2) 
Days of 
treatment 
AC+T Adjuvant 51 80 60-80 (60/600) 80-100 
T+AC Neoadjuvant 15 80 60-80 (60/600) 80-100 
FEC90+T Adjuvant 134 100 60-80 (600/90/600) 80-100 
T+FEC90 Neoadjuvant 53 80 60-80 (600/90/600) 80-100 
 
A: Doxorubicin; C: Cyclophosphamide; F: 5-Fluorouracil; E: Epirubicin; T: Paclitaxel 
 
Table S2 Comparative analysis between controls and sporadic breast cancer cases: before, 
during and after finishing chemotherapy.  
 n t/s adjusted for age p-value  
Controls 330 -0.077 ns 
Pre-treatment 13 0.012 ns 
During treatment 0-90d* 44 0.0715 ns 
During treatment 91-180d 42 -0.273 0.0038 
Post-treatment 0-91d# 33 -0.22 0.0007 
Post-treatment  91-180d  35 -0.389 0.0001 
Post-treatment  181-360d  38 -0.306 0.0093 
Post-treatment  361-520d  24 -0.135 ns 
Post-treatment  >520d  37 -0.008 ns 
 
p-value: Mann Whitney test  was used to test for significant differences among the groups with 
controls (ns) Non significant differences. 
* Days counted from the first day of treatment. 
# Days counted from last day of treatment. 
 
 
 
 
 
Table S3 Comparative analysis of the telomerase activity among the familial breast cancer 
groups. 
 
n Telomerase p-value* 
Controls 69 93.1             - 
Healthy-BRCA1/2 32 88.8 ns 
Affected-BRCA1 12 61.1 0.04 
Affected-BRCA2 11 54.5 0.01 
Affected-BRCAX 23 62.3 0.002 
During treatment-BRCA1/2/X 19 51.8 0.0009 
p-value*: Unpaired Student's t-test was used to establish the significance of the differences 
between the control group and the other groups 
 
Table S4 Telomere shortening rate per year among the familial breast cancer groups. 
 n 
Gap 
(years) 
Median 
age 
Age 
range 
Telomere 
Shortening
Rate p-value* 
Controls  25 5 35 22-55y 0.028 - 
Healthy-BRCA1/2  15 6 29 35-61y 0.033 ns 
Post treatment-BRCA1/2  9 6 47 35-58y 0.03 ns 
During treatment-BRCA1/2  7 7 46 29-61y -0.086 0.01 
 
p-value*: Unpaired Student's t-test was used to establish the significance of the differences 
between the control group and the other groups 
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 In a recent study published by our group, we identified a polymorphism (rs2304277) 
in the 3´UTR region of the OGG1 gene that modify the risk of developing ovarian cancer for 
BRCA1 mutation carriers  
In order to explain at a molecular level this association, we studied the possible implication of 
this polymorphism on OGG1 transcriptional regulation and its contribution on genome and 
telomere instability.   
 We have worked with two independent sample sets: A series of hereditary breast and 
ovarian cancer patients with a heterogeneous BRCA mutational status, and with panel of 
lymphoblastoid cell lines derived from patients with BRCA1 mutations or non-carriers controls.      
We found similar results in both cases: The presence of the polymorphisms as associated to a 
decrease of the transcriptional levels of OGG1. In addition, we also found a synergistic effect 
between the mutation and the polymorphism that was associated with higher levels of genome 
and telomere instability. Those individuals or cell lines that had both genetic events (mutation in 
BRCA1 / BRCA2 and the polymorphism rs2304277) had accelerated telomeric shortening 
associated with a short TL phenotype. In addition, the presence of the polymorphism was 
associated with a higher γH2AX signal intensity, especially for those cells carrying the BRCA1 
mutation. 
 These results suggest that this variant could be associated to a higher cancer risk in 
BRCA1 mutation carriers, due to an OGG1 transcriptional down regulation and its effect on 
genome /telomere instability. And points to a possible synthetic lethality relationship between 
BRCA1 and OGG1. 
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ABSTRACT
We have recently shown that rs2304277 variant in the OGG1 glycosidase gene of 
the Base Excision Repair pathway can increase ovarian cancer risk in BRCA1 mutation 
carriers. In the present study, we aimed to explore the role of this genetic variant 
on different genome instability hallmarks to explain its association with cancer risk.
We have evaluated the effect of this polymorphism on OGG1 transcriptional 
regulation and its contribution to telomere shortening and DNA damage accumulation. 
For that, we have used a series of 89 BRCA1 and BRCA2 mutation carriers, 74 BRCAX 
cases, 60 non-carrier controls and 23 lymphoblastoid cell lines (LCL) derived from 
BRCA1 mutation carriers and non-carriers.
We have identified that this SNP is associated to a significant OGG1 transcriptional 
down regulation independently of the BRCA mutational status and that the variant 
may exert a synergistic effect together with BRCA1 or BRCA2 mutations on DNA 
damage and telomere shortening.
These results suggest that this variant, could be associated to a higher cancer 
risk in BRCA1 mutation carriers, due to an OGG1 transcriptional down regulation and 
its effect on genome instability.
INTRODUCTION
Carrying an inherited mutation in the BRCA1 
or BRCA2 genes increases a woman's lifetime risk of 
developing breast and ovarian cancers although there are 
considerable differences in disease manifestation. At the 
age of 70, cumulative cancer risk for BRCA1 and BRCA2 
mutation carriers ranges from 43% to 88% for breast 
cancer development, and from 11% to 59% for ovarian 
cancer [1, 2].
In the context of BRCA1 and BRCA2 mutation 
carriers, it has been shown that other factors such as 
single nucleotide polymorphisms (SNPs) in genes from 
other DNA repair pathways could cause a higher genomic 
instability, hence increasing the cancer risk predisposition 
[3–6]. In this regard, a well-known synthetic lethal 
interaction is described between the BRCA1 and BRCA2 
genes and the poly ADP ribose polymerase (PARP1), 
involved in the Base Excision Repair (BER) pathway [7]. 
BER corrects oxidative lesions in the DNA bases, which 
represent the major portion of endogenous DNA damage 
due to chemical reactions during cellular metabolism 
[8]. These lesions cause different types of DNA damage 
including DNA single-strand breaks (SSBs) or DNA 
double-strand breaks (DSBs) which are the principal 
source of genomic instability [9, 10]. In the presence 
of a defective BRCA1 or BRCA2 background, this 
accumulation of double-strand DNA breaks can persist 
and lead to cell cycle arrest or cell death; making BRCA-
deficient cells extremely sensitive to PARP inhibitors 
(PARPi).
In addition, telomere instability/shortening 
occurring during oxidative and inflammatory stress can be 
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explained by the strong tropism for guanine (G) oxidation 
at the telomere sequence (TTAGGG) [11]. For this reason, 
BER pathway is essential to maintain telomere integrity 
in mammals [12]. In fact, cellular changes due to BER 
defects have been implicated in a multitude of diseases, 
ranging from cardiovascular diseases, arthritis, cancer, as 
well as aging and age-related disorders [13, 14].
SNPs in genes involved in the BER pathway have 
been reported to modify ovarian and breast cancer risk in 
BRCA1 and BRCA2 mutation carriers. In particular, one 
of the most recent examples was described by our group 
for a SNP (rs2304277) in the OGG1 (8-guanine DNA 
glycosylase) gene that was associated with increased 
ovarian cancer risk in BRCA1 mutation carriers [5].  The 
OGG1 gene encodes for a key enzyme involved in the 
first steps of BER that removes a highly mutagenic base, 
8-oxodeoxyguanosine, generated by oxidative stress [15].
In this study, by using two independent sample sets 
with different BRCA status, we have explored the role of 
this polymorphism on OGG1 transcriptional regulation 
and its possible implication on genome instability. With 
this, we would like to explain the cancer risk modifier 
effect that this gene exerts in carriers of BRCA1 and 
BRCA2 mutations.
RESULTS
SNP frequency in FBOC and LCL
We genotyped the SNP rs2304277 in both, FBOC 
and LCLs sample sets, to perform genotype/phenotype 
studies (role of the SNP on: OGG1 mRNA expression, 
telomere studies, and DNA damage). In the FBOC 
samples, we identified 36% of the samples (81/223) 
carrying the variant. The same frequency was reported in 
our previous study analyzing more than 23000 cases and 
controls [5].
The different group of cases and controls presented 
similar frequencies that are summarized in Supplementary 
Table S1. No significant differences were found among 
groups.
From a total of 23 cell lines, 9 harbored the SNP 
(39%). From 16 of the LCL with BRCA1 mutation 
7 LCL harbored the SNP (43%) and from the 7 non-
carrier controls, 2 had the variant (33%) (Supplementary 
Table S2).
Expression of OGG1 in FBOC, Gtex server and 
LCLs
In order to know if the SNP could affect gene 
expression, we first analyzed in the FBOC series the 
OGG1 mRNA expression levels considering both, the 
BRCA mutational status and the presence or absence of 
the OGG1 variant to stratify and compare expression 
values among groups (Figure 1a).
First, we did an independent lineal regression 
analysis in BRCA1/2 mutation carriers to test whether 
cancer status (individuals with or without cancer 
antecedents) could affect OGG1 mRNA levels; because it 
did not affect, we decided to include healthy and affected 
BRCA1/2 mutation carriers in the same group (BRCA1/2) 
for expression  studies, Supplementary Table S3.
In the comparative analysis, we detected an OGG1 
mRNA down regulation in individuals harboring the 
variant. This down regulation was statistically significant 
when we stratified all the FBOC individuals by the presence 
of the variant (with/without) regardless the BRCA status 
(BRCA1/2, BRCAX and non-carrier controls), p=0.011. 
Although. we were not able to detect significant differences 
within each mutational group (non carrier controls, 
BRCA1/2 and BRCAX) probably due to the reduced 
sample size (Figure 1a); a complementary lineal regression 
analysis confirmed a significant down regulation associated 
to the SNP in the non carrier controls (β=-0.63);p=0.049), 
in BRCA1/2 (β=-0.57;p=0.027) and a trend in the BRCAX 
group(β=-0.34;p=0.123), suggesting that the variant 
could be associated per se to lower OGG1 mRNA levels 
independently of the BRCA mutational group.
In parallel, we tested in silico the SNP effect on 
transcriptional regulation in different tissues using the 
Gtex eQTL web server (http://www.gtexportal.org). 
Interestingly, we observed down regulation for whole 
blood, uterus, vagina and ovary, but only the last one 
presented a significant OGG1 transcriptional down 
regulation (p=0.023), Supplementary Table S4. Ovary is 
the tissue where this variant was originally found to be 
associated to an increased cancer risk [5].
Finally, we measured OGG1 mRNA basal levels 
among the 23 LCL considering the BRCA status, and 
presence or absence of the SNP. Only when we group all 
LCL together considering the presence of the SNP we are 
able to detect significant down regulation (p=0.04) Figure 
1b, probably because the sample size was too small to 
detect significant association p-values of OGG1 mRNA 
down regulation within groups (BRCA1 non carriers LCLs 
and BRCA1 LCLs).
Telomere length studies in FBOC
We explored the role of this variant on TL 
maintenance. Hence we measured TL and percentage of 
short telomeres by HT QFISH in the blood cells from 
FBOC patients and non-carrier controls to establish 
genotype/phenotype associations.
We first evaluated the TL distribution in 60 healthy 
women as a function of age to obtain a regression line to 
adjust the TL from FBOC samples. As expected, we found 
a decrease in TL with age, Supplementary Figure S1.
Because mean TL is strongly heritable [16] and 
our series contains related individuals, we used a single 
member (genotype) from each family for both, BRCA 
status and presence or absence of the SNP for the analysis. 
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Whenever possible, we used the index-case of the family 
and if this sample was not available, we used the latest 
genotype included in the family as common criteria of the 
study.
Chemotherapy status, another possible confounding 
factor that alters TL was corrected to perform this analysis 
[17]. We eliminated those cancer patients who were 
undertaking chemotherapy or those within a window of 
2 years since the last cycle of chemotherapy. In total, 13 
BRCA1/2 cases and 26 BRCAX cases were excluded.
Hence, we used a total of 44 controls (19 harboring 
the SNP), 21 BRCA1 carriers (10 harboring the SNP), 28 
BRCA2 carriers (9 harboring the SNP), 1 patient harboring 
mutation in both genes and 38 BRCAX (15 harboring the 
SNP).
First, we did an independent lineal regression 
analysis in BRCA1/2 mutation carriers to test whether 
cancer status (individuals with or without cancer 
antecedents) could affect TL and percentage of short 
telomeres; because it did not affect these 2 factors 
(Supplementary Table S3), we decided to include healthy 
and affected BRCA1/2 mutation carriers in the same group 
(BRCA1/2) for telomere  studies.
In the comparative analysis, Mann Whitney U test 
revealed no significant differences neither in adjusted TL 
nor in percentage of short telomeres between controls 
harboring and not harboring the variant (Figure 2a & 
Figure 2b). However, we observed significant shorter TL 
among BRCA1/2 carriers harboring the variant compared 
to those BRCA1/2 carriers not harboring the SNP 
(p=0.003) or controls (p=0.009), Figure 2a. Additionally, 
increased percentage of short telomeres were detected in 
BRCA1/2 mutation carriers harboring the SNP compared 
to the control group (p=0.018), Figure 2b. In the group of 
BRCAX cases we did not detect any effect of the SNP on 
TL although we found a significant increased percentage 
of short telomeres (p=0,009) compared to controls, Figure 
2a and Figure 2b.
Then, we analyzed all FBOC patients together 
considering the presence/absence of the variant to test the 
effect of the SNP alone, regardless the BRCA mutational 
status. We were not able to observe significant differences 
on TL but we detected a significant increased percentage 
of short telomeres in the group harboring the SNP 
(p=0.016), Figure 2a and Figure 2b.
Linear regression analysis revealed that TL was 
significantly modified by the presence of the SNP in 
the group of patients harboring mutations in BRCA1 or 
BRCA2 genes (BRCA1/2) (β= -1.438; C.I (-2.554 – 
(-0.323); p=0.013), Supplementary Table S3; but not in the 
non-carrier controls or BRCAX groups (data not shown).
Hence, we stratified BRCA1/2 patients according 
to the SNP and we compared the linear model between 
each of the groups (BRCA1/2 with/without the SNP 
and controls). Significant differences were detected in 
BRCA1/2 carriers harboring the SNP when compared 
to those not harboring the SNP (p=0.010) or controls 
(p=0.034), Figure 2c. In fact, we observed a faster 
Figure 1: a. Comparative analysis relative to the OGG1 mRNA expression levels between FBOC groups (BRCA1 & BRCA2, 
BRCAX) and controls according the presence of the OGG1 SNP. Control group harbouring the variant showed a statistical trend of 
lower OGG1 mRNA levels (p=0.07); while we didn’t detect significant differences in OGG1 transcriptional levels within BRCA1 and 
BRCA2 group due to the presence of the SNP (p=0.11). When all FBOC samples, were stratified according to the presence of the SNP, we 
observed significant lower OGG1 mRNA expression levels in the individuals harbouring the variant (p=0.011). Line at mean with standard 
error mean (SEM) b. Transcriptional mRNA basal levels of OGG1 in Lymphoblastoid cell lines (LCLs). Each dot at the graph, represent 
the mean OGG1 mRNA values from two independent measurements (two clones of each sample) for most LCL analyzed (20/23), for 3 
samples we could measure only once. We found that LCL harbouring the SNP presented significant lower OGG1 mRNA levels when 
compared to those who did not harbour the SNP (p=0.04). Line at mean with standard error mean (SEM).
a b
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telomere shortening (slope) in the group of patients 
harboring both, the BRCA1/2 mutation together with the 
SNP, compared to those who did not harbor the SNP, or 
the control group, Figure 2c (legend).
Telomere length study in LCLs
We compared telomere shortening during normal 
replication among the BRCA1 LCLs  to confirm 
experimentally the faster telomere shortening (slopes) 
observed in the FBOC patients who harbored the 
BRCA1/2 mutation together with the variant. Additionally, 
we measured and compared the accumulation of short 
telomeres along the cell culture.
Due to technical issues and the differences in 
growth rate, we could only use a set of 8 out of the 16 
LCLs harboring mutation in BRCA1 gene to follow the 
Figure 2: a. Distribution of the TL (Kb) values adjusted for age according to mutational status. We did not detect significant 
differences in TL for the control group due to the presence of the SNP; while TL was significantly shorter in BRCA1/2 mutation carriers 
harbouring the variant when compared to non carriers of the SNP (p=0.003) or controls(0.009). We were not able to find any difference in 
TL among the BRCAX group of patients. Additionally we stratify all the FBOC samples according to the presence of the variant and we did 
not detect any significant difference in TL between carriers and non carriers. Line at mean with standard error mean (SEM) b. Comparative 
analysis among FBOC genotypes regarding the percentage of short telomeres (<3Kb). We did not detect significant differences in 
the percentage of short telomeres neither in the control nor in the BRCA1/2 groups when the variant was present; however BRCA1/2 or 
BRCAX harbouring the variant presented significant higher % of short telomeres compared to controls(all)(p=0.018; p=0.009). Additionally 
we stratify all the FBOC samples according to the presence of the variant, and we could detect a significant higher % of short telomeres in 
those samples harbouring the SNP (p=0.016) Line at mean with standard error mean (SEM) c. Telomere shortening lines in BRCA1 or 
BRCA2 mutations carriers group (BRCA1/2) with and without the variant, and the non-carriers controls. TL (Kb) is represented in 
this graph according to age (years). Regression line is draw in green colour for controls (y=-0.080*age+13.367), blue colour for BRCA1/2 
patients (y=-0.537*age+12.188) and red colour for BRCA1/2 with the variant (y=-0.0918*age+12.705). F-test: BRCA1/2 vs BRCA1/2 
rs2304277 (p=0.010); Controls vs BRCA1/2 rs2304277 (p=0.034).
a b
c
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telomere shortening during 55 passages. From the 8 LCL 
with mutation in BRCA1 gene 3 presented also the SNP.
Our results revealed significant faster telomere 
shortening after 55 cell culture passages, in the group of 
samples harboring BRCA1  mutation together with the 
SNP (p=0.033). This result is similar from the previous 
obtained in patients suggesting that this event is taking 
place only when BRCA1 mutation and the variant are 
together, Figure 3a. We could also confirm a significant 
accumulation of short telomeres in the LCL harboring 
the BRCA1 mutation together with the variant after 55 
passages of cell culture (p=0.03), Figure 3b.
DNA damage
To test the possible contribution of the SNP to a 
higher DNA damage we measured the mean γH2AX 
intensity signal in the cell nucleus at basal conditions (first 
passage and no irradiation).
We plotted all the γH2AX values from the LCL in 
a cumulative frequency histogram to establish a damage 
threshold above which we observed an exponentially 
increase in the γH2AX intensity values, which indicates 
the cells with a clear nuclear DNA damage. We established 
the threshold in 95 arbitrary units of γH2AX of nuclear 
intensity (Figure 4a).
Then, we calculated the frequency of damaged cells 
among LCLs with different genotypes and the intensity 
of the nuclear γH2AX signal in these cells to evaluate the 
possible impact of the OGG1 SNP on DNA damage. We 
found minimum differences in the percentage of damaged 
cells associated to the presence of the SNP (5.8% and 
6.3% in LCLs with and without the SNP, respectively). 
However, the intensity of the damage was significantly 
higher in LCLs harboring the SNP (p=0.010) compared to 
those not harboring the variant, Figure 4b.
DISCUSSION
We have previously found that the OGG1 SNP 
rs2304277may be a modifier of cancer risk in BRCA1 
mutation carriers [5]. OGG1 belongs to the BER pathway 
that plays an important role correcting DNA lesions 
originated by oxidative stress. These lesions are the 
principal source of genomic instability and can drive to 
cancer development. In this study we have shown how this 
variant can contribute to increase cancer risk in BRCA1 
carriers, by reducing the mRNA OGG1 expression levels, 
increasing the DNA damage as a consequence of genomic 
instability generated, and shortening the telomeres in a 
synergic way with the BRCA1 mutation.
Because rs2304277 is located 1.8Kb downstream 
of 3’UTR region of the OGG1 and post transcriptional 
modifications, like potential illegitimate microRNA target 
site [18, 19], could be altering normal OGG1 mRNA 
regulation, we decided to explore the role of this SNP on 
transcriptional regulation using two set of samples. The first 
set consisted in 223 blood samples from controls and FBOC 
patients with a heterogeneous BRCA mutational status 
(BRCA1, BRCA2 and BRCAX) and the second was a panel 
of 23 LCLs derived from BRCA1 mutation carriers and 
non-carrier controls. The percentage of heterozygotes for 
Figure 3: We measured TL differences between passage nº1 and passage nº55 for each LCL, to calculate telomere 
shortening/ lengthening in Kb and the gain or lose of critical short telomeres(<3Kb) a. Telomere length lose or gain after 
55 passages of culture among BRCA1 mutated LCLs. Significant telomere shortening in LCL harbouring BRCA1 mutation together with 
the SNP was detected after 55 passages compared to those not harbouring the variant (p=0.033). Line at mean with standard error means 
(SEM) b. Percentage of critical short telomeres gain or lose after 55 passages of culture among among BRCA1 mutated  LCLs. 
Significant increased amount of short telomeres was found in the LCL harbouring BRCA1 mutation together with the SNP after 55 passages 
compared to those not harbouring the variant (p=0.03). Line at mean with standard error means (SEM).
a b
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the SNP in the FBOC and LCL set of samples was 36% and 
39%, respectively, which was the expected frequency [5].
We confirmed in both sample sets (FBOC series 
and LCL) significant lower expression of OGG1 mRNA 
transcript associated to the SNP, independently of BRCA 
mutational status, (Figure 1a & Figure 1b). We extended 
the analysis using Gtex eQTL dB (http://www.gtexportal.
org) looking for the SNP effect over OGG1 mRNA 
levels in different tissues and we found significant down 
regulation in ovary (p=0.023) tissue where this SNP was 
initially found to be associated to a higher cancer risk, 
Supplementary Table S4.
These results suggest that this cancer risk variant is 
likely associated with mRNA OGG1 transcriptional down 
regulation which can potentially lead to higher genome 
instability due to a defective 8-oxoG repair capacity. 
In this way, the aberrant accumulation of 8-oxoG was 
previously associated with faster development of lung 
adenocarcinoma in OGG1 knock-out mice models [20] 
while in transgenic mice it was demonstrated that over 
expression of OGG1 attenuated breast cancer progression 
and metastasis through a reduction in the oxidative damage 
[21]. All these data suggest a critical role of this gene in 
cancer development and progression which, together with 
BRCA mutations could result in higher genome instability 
and increased cancer risk.
Given the role of the BER pathway and in particular 
the OGG1 enzyme on telomere repair [11, 22], we 
explored the impact of this SNP on some features related 
to telomere biology considered as hallmarks of genome 
instability, such as telomere shortening or the percentage 
of critically short telomeres. We found in the linear 
regression analysis, that the SNP may be a TL modifier 
for BRCA1 and BRCA2 mutations carriers (p=0.013). 
Carriers of BRCA1/2 mutations and OGG1 SNP presented 
a significant shorter TL compared to controls (p=0.009) 
and mutation carriers not harboring the SNP (p=0.003) 
(Figure 2a), likely due to an accelerated telomere 
shortening during life-time (Figure 2c). We also found an 
increase of short telomeres in those individuals harboring 
the SNP, regardless the BRCA mutational status (p=0.016) 
(Figure 2b).
These results were experimentally validated in our 
LCL set by measuring TL after 55 passages. We could 
confirm a significant faster telomere shortening in the 
group of samples harboring a BRCA1 mutation together 
the SNP (p=0.033) (Figure  3a), which correlated with a 
significant accumulation of short telomeres after a total 
of 55 cell culture passages (p=0.03) (Figure 3b). Our 
results point to a synergistic effect of the SNP and the 
BRCA1 mutation on telomere shortening. This telomere 
instability may be due to the cell tropism for the 
accumulation of oxidative lesions at the telomeric region 
[23, 24] in the context of defective BER performance 
[22] triggered by the SNP effect on OGG1 down 
regulation. In this sense other authors have reported that 
SNPs located in the 3’UTR region of OGG1 could be 
associated with a lower 8-oxoG repair activity being 
particularly sensitive to the cellular redox status. [25, 26]
The region represented by the SNP has been 
previously spotted by other authors who also found 
associations with different cancer types [27–29]. Then, 
Figure 4: a. Threshold of γH2AX nuclear intensity damage. We selected the intensity value of 95(arbitrary units) as a cut of to establish 
the damaging signal intensity because this was the value in where the distribution change shape exponentially, indicating which are the 
normal and the abnormal (damaging)values. b. Comparative analysis regarding the signal intensity of γH2AX at the nucleus among 
the LCL genotypes. The effect of the variant is not significant in the control group (p>0.05) while in the group of cells carrying mutation 
in BRCA1, we found higher γH2AX signal intensity when the variant was present (p = 0.09). We stratified all the 23 LCL according the 
presence of the variant and we detected significant higher γH2AX intensity in the carriers of the variant (p =0.010). Line at mean with 
standard error means (SEM).
a b
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we tested whether this SNP could have an impact on DNA 
damage, measured in this case by γH2AX, a DNA damage 
marker of DSB [30].
Using the LCL panel, we compared the percentage 
of damaged cells and its nuclear γH2AX signal intensity 
among different genotypes at basal conditions (first 
passage and no irradiation). Despite we found a similar 
percentage of damaged cells among LCLs with and 
without the variant (5.8% and 6.3%, respectively), 
we could detect that those LCLs harboring the SNP, 
presented significantly higher γH2AX signal intensity at 
the nucleus, pointing to a more profound DNA damage 
(p=0.010) (Figure 4b). These results are similar to other 
reported in the literature establishing association between 
SNPs in OGG1 at the same gene region with an increased 
DNA damage/genome instability due to an impaired BER 
performance [6, 25-27, 31, 32]
In summary, we have identified that the OGG1 SNP 
itself contributes to a higher nuclear DNA damage intensity, 
probably due to a defective BER performance triggered 
by OGG1 transcriptional down regulation. Additionally, 
our results suggest a synergistic effect between BRCA1 
or BRCA2 mutations with the SNP rs2304277 on specific 
telomere instability hallmarks, such as telomere shortening 
and the accumulation of short telomeres, when both genetic 
events are present in the cell. These molecular processes 
could explain the relation between this SNP and BRCA1 or 
BRCA2 mutations, on cancer risk.
MATERIALS AND METHODS
Familial breast and ovarian cancer (FBOC)
We studied two different set of samples: A first 
group, was composed by 223 individuals belonging to 
121 families meeting high risk criteria and screened for 
deleterious mutations in BRCA1 and BRCA2 genes, as 
previously reported [1]. 24 carried a deleterious mutation 
in BRCA1, 25 in BRCA2, 1 family harbored both BRCA1 
and BRCA2 mutations and 71 did not carry any mutation 
(BRCAX).
Sixty individuals were used as non-carrier controls: 
They were relatives of BRCA1/2 carriers, who didn’t 
have any personal cancer antecedent and didn’t harbor 
the corresponding familial mutation in BRCA1 or BRCA2 
genes. General characteristic of this series are described 
in Table 1.
All cases and controls signed an appropriate 
informed consent and the proposal was approved by the 
ethics committee at the Fuenlabrada University Hospital.
We used this set of samples (BRCA1/2 carriers, 
BRCAX cases and controls) to calculate the percentage of 
heterozygotes harboring the SNP, to quantify the OGG1 
mRNA levels in peripheral blood, and to perform telomere 
studies using fresh blood cells, Table 1.
Lymphoblastoid cell lines
A second set of 23 LCLs was established by Epstein 
Barr virus transformation of peripheral blood lymphocytes 
from sixteen healthy women carrying heterozygous 
mutations in BRCA1 and seven non-carrier relatives used as 
controls. Mutational analysis had been previously performed 
by Sanger sequencing, Supplementary Table S2. None of 
the women included in the study had personal antecedents 
of cancer. This LCL panel has been previously described 
by our group [33]. Cell lines were cultured in RPMI-1640 
media (Sigma-Aldrich) supplemented with non-heat-
inactivated 20% fetal bovine serum (Sigma-Aldrich), 
penicillin-streptomycin (Gibco) and Fungizone (Gibco). 
The cultures were carried out in 25 cm2 flasks (Corning) at 
37°C in 5% CO2 atmosphere and cell lines were maintained 
in exponential growth by daily dilution to 106 cells/ml of 
full media.
Table 1: Description of the analyzed series and the different studies performed
Families (n) Healthy carriers
Affected 
carriers
c Non-carriers 
controls Total
Median 
age, 
(range)
SNP 
Genotyping
Expression 
studies
dTL 
studies
BRCA1, (24) 18 20 13 51 45, (23-78y) 51 48 30
BRCA2, (25) 27 21 25 73 50, (22-87y) 73 64 46
aBRCA1 + BRCA2, (1) 1 2 1 4 54, (42-61y) 4 4 3
b BRCAX, (71) - 74 21 95 49, (20-85y) 95 92 53
Total FBOC, (121) 46 117 60 223 49, (18-87y) 223 209 132
a Refers to a family harboring mutations in both BRCA1 and BRCA2 genes.
b Non BRCA1 or BRCA2 families.
c Non carrier controls were composed by family relatives without any antecedents of cancer and negative for BRCA1 or 
BRCA2 mutations.
d Sample size used in TL studies after heritability correction and exclusion of patients who were undertaking chemotherapy 
(see manuscript in results section, TL studies in FBOC).
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We used this set of samples to measure OGG1 
mRNA expression levels, DNA damage at basal conditions 
and whenever possible telomere shortening and the 
percentage of short telomeres gained/lost after 55 passages 
of cell culture.
SNP genotyping
The SNP rs2304277, showed the strongest 
association to cancer risk among all the SNP covering 
the gene (tagged or imputed) that were included in our 
previous study [5]. This SNP is located 1.8 kb downstream 
the 3′UTR (untranslated region) of the gene. Despite we 
did not find better results for a more plausible causal SNP, 
we could detect that SNPs in high linkage disequilibrium 
(LD) with rs2304277, presented similar cancer association 
direction and p-values [5]. Hence, we considered 
rs2304277 as a good representative of that gene region, 
which is detailed in Supplementary Table S5.
DNA was extracted from patient’s peripheral blood 
(FBOC) and from cultured LCLs using MagNAPure LC 
2.0 (Roche Diagnostics, Indianapolis, Indiana) following 
manufacturer’s conditions. DNA quantification and quality 
was assessed by NanoDrop® (ND-1000 V3.7.1).
Flanking region of the rs2304277 was amplified 
using PCR method with the following primers: OGG1 
“rs2304277-G>A”-F: 5’ GACCTTTCTCGGACCCCATA 
3’OGG1 “rs2304277-G>A”-R: 5’ ACTCCTCCCCAT 
CCCTACC 3’ and the product was genotyped using 
Sanger method using ABI3700.
RNA expression analysis
Using TRIzol Reagent (Ambion®, Life Techonogies) 
according to manufacturer’s instructions, RNA was 
extracted from peripheral blood cells. Both RNA quantity 
and quality were assessed by NanoDrop® (ND-1000 
V3.7.1).
1 µl of cDNA at a final concentration 10-20 ng/µl 
was loaded in triplicate, with GoTaq® qPCR MasterMix 
1x (Promega); OGG1 cDNA primers (F/R) and GAPDH 
cDNA primers (F/R) in final concentration of 500nM. All 
the mentioned reagents were used following manufacture’s 
conditions. Delta Delta Ct method was run in ABI quant 
studio S7.
cDNA-OGG1-F:5’ CTCCACTCCTGCCCTGTG 3’
cDNA-OGG1-F:5’ 
AGAGAAAAGGCATTCGATGG 3’
cDNA-GAPDH-F: 5’ CTCCACTCCTGCCCTGTG 3’
cDNA-GAPDH-F: 5’ AGAGAAAAGGCATTCGA 
TGG3’
Telomere length measurement (TL)
High throughput quantitative fluorescence in situ 
hybridization (HT-QFISH) with automated fluorescence 
microscopy was performed as previously described [34]. 
Briefly, Peripheral Blood Mononuclear cells (PBMCs) 
were separated by Histopaque-1070 (Sigma-Aldrich) 
gradient centrifugation. Cells were then counted and 
plated (80 000 – 100 000 cells/well in clear bottomed 
black-well 96-well plates precoated with 0.001% (poly)
L-lysine solution (Sigma-Aldrich, St. Louis, MO) for 30 
minutes at 37ºC. 4´,6-diamino-2-phenylindole (DAPI) 
was used for nucleus staining and a fluorescent peptide 
nucleic acid (PNA) Cy3 probe against telomeric repeats 
was used for telomere detection. TL values were analyzed 
using individual telomere spots in a per cell basis 
(Approximately 90000 telomere spots per sample, which 
represents around 3500 cells). Fluorescence intensities 
were then converted into Kb using L5178-R, L5178-S 
and CCRF-CEM cells as calibration standards, which have 
stable telomere lengths of 79.7 Kb, 10.3Kb and 7.5 kb, 
respectively[35]. Samples were analyzed in duplicate, or 
triplicate in the case of calibration standards. A TL <3Kb 
was defined as short. The load of short telomeres was 
estimated as the percentage of short telomeres (number 
of short telomeres divided by total number of measured 
telomeres) in each participant.
DNA damage
LCLs were cultured 4 hours before fixation with 
4% paraformaldehyde (Electron Microscopy Sciences, 
Hatfield, Philadelphia, USA). Two hours before fixation, 
cells were counted and seeded into a poly-L-lysine-coated 
(Sigma-Aldrich) µCLEAR bottom 96-well plate (Greiner 
Bio-One) at a density of 75,000 cells per 100ul full 
media per well. LCL were then left for 2 hours in order 
to attach to the surface of the wells, fixed for 15 min at 
room temperature, permeabilized in 0.5% Triton X-100 in 
PBS for 20 minutes at 4°C and stained with primary and 
secondary antibodies and 4′,6-Diamidino-2-phenylindole 
dihydrochloride (DAPI) to visualize nuclei. To detect 
γ-H2AX we used mouse monoclonal anti-phospho-
histone H2AX antibody (Millipore; #05-636). Alexa 
Fluor 488 from molecular probes (Invitrogen; #A-11034) 
was used, and fluorescent images were automatically 
taken for each well of the 96-well plate using an Opera 
High-Content Screening System (Perkin Elmer). Pictures 
were taken under non-saturating conditions using a 40x 
magnification lens to calculate the γ-H2AX nuclear signal 
intensity.
Statistical analysis
Pearson's chi-squared test was used to calculate 
whether differences in the frequency of the SNP among the 
FBOC groups were significant, Supplementary Table S1.
Telomere length (Kb) was adjusted to the age, using 
the best fit line controls (y= -0.067* age (years) +12.785). 
The difference between the actual and the predicted value 
was calculated for each sample.
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For the comparative analysis we have considered 
healthy or affected (patients with cancer antecedents) 
BRCA1 and BRCA2 mutation carriers in a single 
group BRCA1/2. We performed an independent linear 
regression analysis, using cancer status as a binary 
variable to test whether it could affect significantly OGG1 
mRNA expression, TL or percentage of short telomeres 
(Supplementary Table S3).
Kolmogorov-Smirnov test was used to evaluate 
if the data sets were normally distributed. For the 
comparative analysis (OGG1 mRNA expression, Telomere 
studies and γH2AX nuclear intensity signal), statistically 
significant differences were assessed by Mann-Whitney 
U test for not normal distributions (Figures: 1a, 1b, 2a, 
2b, 3a, 3b, 4b) and complementary, using lineal regression 
analysis whenever necessary:
· Regarding the expression studies, lineal regression 
model including as explanatory variable OGG1 SNP, was 
run to test whether this variable could affect OGG1 mRNA 
levels in each FBOC group (BRCA1/2 carriers, BRCAX 
cases and non-carriers  controls).
· In relation with the TL studies, a linear regression 
model was created including as explanatory variables 
age and the SNP among the different genotypes. Then, 
if significant differences were found, a separate model 
was created for each of the genotypes: i) Controls (all) 
ii) BRCA1/2 carriers harboring the variant iii) BRCA1/2 
carriers without the variant. Significant differences among 
the models were tested with F-test (Figure 2c).
For all the analysis, bilateral p values less than 
p<0.05 where considered significant.
Statistical calculations were done by SPSS version 
18 (SPSSI« Inc, Chicago, Illinois), the R project for 
statistical computing, GraphPad Prim 5.03 (San Diego, 
California), and graphics were performed by GraphPad 
Prim 5.03 (San Diego, California)
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SUPPLEMENTARY FIGURES AND TABLES
Supplementary Figure S1: TL distribution in peripheral blood leukocytes as a function of age for the control women 
population (n = 60), measured by HT QFISH. The regression line for control is drawn controls (y= -0.067* age + 12.785).
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Supplementary Table S1: List of lymphoblastoid cell lines (LCL)
LCL a BRCA1 mutationb Mutation typec Exon dAge ers2304277
06S179-L1 Wild type - - 31 Wt
09S797-L2 Wild type - - 27 Wt
10S889-L3 Wild type - - 20 Wt
11S66-L4 Wild type - - 30 G>A
11S534-L5 Wild type - - 50 G>A
11S954-L Wild type - - 35 Wt
11S375-L Wild type - - 23 Wt
05S1303-L1 p.Ala1708Glu Missense 18 59 Wt *
06S1159-L c.5123C > A; p.Ala1708Gluf Missense 18 37 G>A
10S1202-L c.5123C > A; p.Ala1708Glu Missense 18 53 Wt
10S890-L3 c.5123C > A; p.Ala1708Glu Missense 18 25 Wt *
11S65-L6 c.5117G > A; p.Gly1706Glug Missense 18 31 G>A
11S67-L6 c.5117G > A; p.Gly1706Glu Missense 18 34 Wt
07S1291-L c.3239T > A; p.Leu1080X Nonsense/TRC 11 34 G>A *
09S798-L2 c.2410C > T; p.Gln804X Nonsense/TRC 11 24 Wt
09S546-L c.212 + 1G > A; p.? Splice/TRC 5 42 G>A *
11S376-L7 c.212 + 1G > A; p.? Splice/TRC 5 39 Wt *
11S384-L7 c.212 + 1G > A; p.? Splice/TRC 5 75 Wt *
06S1167-L c.3331_3334delCAAG; p.Gln1111 Frameshift/TRC 11 33 Wt
09S491-L c.815_824dup10; p.Thr276 Frameshift/TRC 11 24 G>A
10S1177-L4 c.68_69delAG; p.Glu23 Frameshift/TRC 2 27 G>A *
10S44-L c.4309delT; p.Ser1437 Frameshift/TRC 13 22 Wt *
11S1004-L5 c.981_982delAT; p.Cys328X Frameshift/TRC 11 25 G>A
a 1–7 LCL from relatives of the same family (sisters or mother & daughter).
b Mutation nomenclature based on GenBank reference sequences NM_007294.3 with numbering starting at the A of the first 
ATG, following the journal guidelines (www.hgvs.org/mutnomen); p.?, unknown protein nomenclature (variant causing 
skipping of exon 5 of BRCA1).
c -: Refers to the non-carrier control; TRC: Stands for truncating mutation.
d Age of the woman at the time of extraction of the blood sample from which the LCL was established.
e G>A indicate the polymorphism (rs2304277).
* For those cells used in the experiment of telomere shortening along 55 passages.
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Supplementary Table S2: Table with information regarding the SNPs within the block of Linkage disequilibrium 
(LD) >0.8 with the SNP rs2304277
SNP in LD>0.8 with rs2304277
SNPs Gene Location* r^2(LD)
rs3219008 OGG1 intronic 0.86
rs2075747 OGG1 intronic 0.93
rs2072668 OGG1 intronic 0.85
rs1052133 OGG1 Missense/ 3-UTR 0.83
rs4021704 OGG1/ CAMK1 intronic 0.98
rs2304277 OGG1/ CAMK1 Downstream 3-UTR(OGG1) 1.00
rs7609858 OGG1/ CAMK1 intronic 0.99
rs6763347 OGG1/ CAMK1 intronic 1.00
rs73021455 OGG1/ CAMK1 intronic 0.90
rs66482970 - - 0.89
rs57081507 - - 0.89
rs67055061 - - 0.90
rs14204 TADA3 3’-UTR 0.83
rs6809452 TADA3 intronic 0.88
rs7610826 TADA3 intronic 0.87
rs7618535 TADA3 intronic 0.87
rs7618636 TADA3 intronic 0.88
rs7621556 TADA3 intronic 0.88
*In some cases the SNP can cover more than 1 location depending on the gene isoform. (due to limited space only one gene 
location is available at the table).
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Supplementary Table S3: Samples distribution and heterozygous frequency of the OGG1 variant rs2304277
FBOC Sample size Heterozygotes frequency (%)
FBOC* 220
FBOC rs2304277 81 36
Controls 60
Controls rs2304277 26 43
BRCA1 38
BRCA1 rs2304277 13 36
BRCA2 48
BRCA2 rs2304277 16 34
BRCAX 74
BRCAX rs2304277 26 35
No significant differences were found among the groups. * We have excluded individuals harboring mutations in both 
BRCA1 and BRCA2 genes simultaneously (n=3), none of them harbor the SNP. Hence, the total sample size is 223.
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Supplementary Table S4: Lineal regression analysis in BRCA1/2 mutation carriers
Dependent variables Independent 
variables
β coeff p-values 95% C.I ((Lower)-
(Upper limit))
OGG1 mRNA
SNP -0.591 0.027 ((-1.113)-(-0.070))
Cancer 0.148 0.549 ((-0.342)-(0.639))
TL(Kb)
SNP -1.438 0.013 ((-2.554)-(-0.323))
Cancer -0.115 0.832 ((-1.199)-(0.969))
Short telomeres (%)
SNP -0.030 0.990 ((-4.886)-(4.825))
Cancer -0.908 0.700 ((-5.625-(3.810))
We included as dependent variables OGG1 mRNA, TL (Kb) and percentage of short telomeres (%), and as independent 
variables, the SNP and the cancer status. β coefficients quantify how much the 2 independent variables (OGG1 SNP and 
cancer status) modify OGG1 mRNA levels, TL (Kb) and the percentage of short telomeres and also the modification 
direction. C.I stands for confidence interval.
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Supplementary Table S5: Gtex information summary, regarding OGG1 transcriptional down regulation when 
rs2304277 is present (5 different tissues)
Gene Symbol SNP ap-value Tissue
OGG1 rs2304277 0.57 Cells - EBV-transformed lymphocytes
OGG1 rs2304277 0.22 Uterus
OGG1 rs2304277 0.16 Vagina
OGG1 rs2304277 0.45 Whole Blood
OGG1 rs2304277 0.023 Ovary
aNominal eQTL p-values were generated for each SNP-gene pair using a two-tailed t test, testing the alternative hypothesis 
that the beta (slope of the linear regression model) deviates from the null hypothesis of β=0.
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We have recently shown how common genetic variations in some genes of the Base 
Excision Repair (BER) pathway can modify breast and ovarian cancer susceptibility risk for 
BRCA1 and BRCA2 mutation carriers. Previously, we studied one of these cancer variants in the 
DNA glycosylase OGG1 gene, and we found that cancer susceptibility risk might be explained 
by a transcriptional down-regulation associated with the Single Nucleotide Polymorphism (SNP) 
and its contribution to a higher telomere and genome instability. In this report, we studied a second 
variant (rs804271) localized in the promoter region of the DNA glycosylase gene NEIL2 that also 
acts as a cancer risk modifier We studied the role of this polymorphism on transcriptional 
regulation and enzyme activity to establish possible associations with oxidative DNA damage, 
telomere dysfunction and oxidative stress. 
To that end, we used a series of 88 BRCA1 and BRCA2 mutation carriers, 87 BRCAX 
cases and 86 non-carrier controls. We found that SNP rs804271 is associated with significant 
NEIL2 transcriptional upregulation independently of the BRCA mutational status and telomere 
instability in carriers of BRCA1 mutation. In addition, we found that this SNP is associated, for 
BRCA2 mutation carriers, with a significant accumulation of oxidative lesions at the telomere 
which suggest that for this specific group the SNP could have an impact on the performance of 
the NEIL2 enzyme, which may help to explain the cancer risk association. 
Our results suggest that cancer risk association of this SNP among BRCA2 mutation 
carriers, could be driven by a deficient NEIL2 enzyme performance, and its contribution on 
oxidative DNA damage. 
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We have recently shown how common genetic variations in some genes of the Base 
Excision Repair (BER) pathway can modify breast and ovarian cancer susceptibility for BRCA1 
and BRCA2 mutation carriers.  
In this report, we studied a second variant (rs804271) localized at the promoter region of 
the DNA glycosylase gene NEIL2 that also acts as a “cancer risk modifier” for BRCA2 mutation 
carriers. To understand the molecular basis of this association, we studied the role of this 
polymorphism on transcriptional regulation and enzyme activity to establish possible associations 
with oxidative DNA damage, telomere dysfunction and oxidative stress. 
To that end, we used a series of 88 BRCA1 and BRCA2 mutation carriers, 87 BRCAX 
cases and 86 non-carrier controls. We found that SNP rs804271 is associated with significant 
NEIL2 transcriptional up-regulation independently of the BRCA mutational status and with 
telomere instability for BRCA1 mutation carriers. In addition, we found that for BRCA2 mutation 
carriers, this SNP is associated with a significant accumulation of oxidative lesions at the 
telomere, suggesting that for this specific group the SNP could have a negative impact on the 
performance of the NEIL2 enzyme. Such changes may help to explain this SNP in relation with 
its cancer risk modifier effect for BRCA2 mutation carriers. 
INTRODUCTION 
 
The tumor suppressor genes BRCA1 and BRCA2 maintain genomic stability through their 
involvement in homologous recombination double-stranded break DNA repair 1. 
Carrying a mutation in the BRCA1 or BRCA2 genes increases a woman's lifetime risk of 
developing breast and ovarian cancer, although there are considerable differences in disease 
manifestation. At the age of 70, cumulative cancer risk for BRCA1 and BRCA2 mutation carriers 
ranges from 43% to 88% for breast cancer development, and from 11% to 59% for ovarian cancer 
2,3. This high variability is the consequence of other genetic modifiers and/or environmental 
factors. 
Given the relation of synthetic lethality that exists between one of the components of the 
Base Excision Repair (BER) pathway, PARP1 (poly[ADP-ribose] polymerase 1), and both 
BRCA1 and BRCA2 4 genes, it is likely that other members of the BER pathway exhibit a similar 
behavior. Following this hypothesis, we recently described that common genetic variants in genes 
involved in BER might increase a woman's lifetime risk of developing breast and ovarian cancers 
if she is a BRCA1 or BRCA2 mutation carrier 5. In particular, two Single Nucleotide 
Polymorphisms (SNPs) located in the OGG1 and NEIL2 genes were identified as cancer risk 
modifiers in BRCA1 and BRCA2 mutation carriers, respectively 5. Although the molecular 
mechanism underlying the cancer risk association is not clear yet, both SNPS were in 
transcriptional regulatory regions of genes encoding DNA glycosylase enzymes, which  play an 
important role in the first steps of the BER pathway. 
The BER pathway is responsible for correcting oxidative and alkylation lesions in DNA 
bases, and these lesions represent the majority of endogenous DNA damage due to chemical 
reactions during cellular metabolism 6. If they are not repaired, these lesions can evolve into DNA 
single-strand breaks (SSBs) or DNA double-strand breaks (DSBs), which are the principal source 
of genomic instability 7,8. In addition, due to the strong tropism for guanine (G) oxidation at the 
telomere sequence (TTAGGG) the BER pathway is essential for maintaining telomere integrity 
in mammals 9,10. In humans, there are several DNA glycosylases with different DNA-
structure/substrate affinities. The OGG1enzyme, is active only on duplex DNAs 11. In contrast, 
NEIL2 shows preferential activity on bubble DNA or single-stranded DNA regions12. 
Since genetic and telomere instability are associated with cancer risk 13,14,15, it is likely 
that if cancer risk modifiers SNPs in DNA glycosylase genes could alter normal transcriptional 
levels or function, they could affect negatively to the general performance of the BER pathway. 
This would contribute to increased levels of genome/telomere instability and hence to a higher 
cancer risk, especially in individuals harboring mutations in the BRCA1 or BRCA2 gene. 
 
As an example, we previously observed that the variant rs2304277, located in the 3'-
untranslated region (UTR) of OGG1, was associated with a constitutive transcriptional down-
regulation of the gene. Moreover, in individuals harboring the OGG1 polymorphism together with 
a mutation in either BRCA1 or BRCA2, the transcriptional down-regulation resulted in both, 
genome and telomere instability 16, which could explain the increased cancer risk associated with 
the presence of this SNP among BRCA1 mutation carriers. 
Similarly, the breast cancer variant rs804271 is localized within the NEIL2 
promoter region (5'- UTR), and forms part of several transcription-factor binding motifs 
that are responsive to oxidative stress 17. It has previously been reported that common 
genetic variation within this region is associated with transcriptional downregulation of 
NEIL2 mRNA levels or with higher levels of mutagen-induced genetic damage and 
repression of the transcriptional response to oxidative stress 18.  
Hence, we have explored in a set of familial breast and ovarian cancer (FBOC) 
patients with a heterogeneous BRCA status, the role of this cancer polymorphism in 
relation to NEIL2 transcriptional dysregulation, telomere oxidative DNA damage, 
oxidative stress susceptibility and telomere shortening to explain its cancer risk modifier 
effect.  
 
MATERIAL AND METHODS 
 
Familial breast and ovarian cancer (FBOC) group 
We studied a group composed of 261 individuals belonging to 144 families 
meeting high-risk criteria, and screened for deleterious mutations in the BRCA1 and 
BRCA2 genes, as reported previously 3. Of these families, 25 carried a deleterious 
mutation in the BRCA1 gene, 25 in BRCA2, 1 family harbored both BRCA1 and BRCA2 
mutations, and 94 did not carry any mutation in neither of these two genes (BRCAX).  
Eighty-six   individuals were used as non-carrier controls: they were relatives of 
BRCA1/2 mutation carriers who did not have personal cancer antecedents and did not 
harbor the corresponding familial mutation in the BRCA1 or BRCA2 genes.  
All cases and controls signed an appropriate informed consent form and the ethics 
committee of the hospital involved (Fuenlabrada University Hospital) approved the 
proposal.  
We used this set of samples to calculate the SNP frequency, to quantify NEIL2 
mRNA levels in peripheral blood, to perform telomere studies using fresh blood cells, to 
measure the accumulation of oxidative DNA damage at telomeres (blood DNA), and to 
evaluate susceptibility to oxidative stress in plasma samples (Table 1). 
 
SNP genotyping  
 
Single Nucleotide Polymorphism  rs1466785, located in the NEIL2 gene is a 
cancer risk modifier for BRCA2 mutation carriers 5. Imputation using 1000 Genomes data 
showed that there were several SNPs in strong linkage disequilibrium (LD) with 
rs1466785, the original SNP reported in Osorio et al5. Of these, we considered rs804271 
to be the best candidate, given that it showed the most significant associations and that 
there existed epidemiological and functional data supporting its putative role in cancer 5.  
The SNP rs804271 is located at the promoter region of the NEIL2 gene, within a 
previously described transcriptional regulatory region17. Indeed, 18 proteins are predicted 
to interact with that region and 3 motifs, all of which are binding regions for transcription 
factors (E2F, Sin3Ak-20 and YY1), are predicted to be altered in the presence of this 
polymorphism (http://archive.broadinstitute.org/mammals/haploreg/haploreg.php).  
DNA was extracted from peripheral blood of FBOC patients using MagNAPure 
LC 2.0 (Roche Diagnostics, Indianapolis, Indiana) following the manufacturer’s 
instructions. DNA quantification and quality was assessed by NanoDrop® (ND-1000 
V3.7.1). A specific Taqman probe for rs804271 was used to genotype the 
presence/absence of the polymorphism among the sample collection. Allelic 
discrimination assays were conducted using the 7900HT Fast Real-Time PCR System 
(Applied Biosystems).  
 
RNA expression analysis  
 
RNA was extracted from peripheral blood cells using TRIzol Reagent (Ambion®, 
Life Techonogies) according to the manufacturer’s instructions. 
 NanoDrop® (ND-1000 V3.7.1) was used to assess both RNA quantity and 
quality. Two microliters of cDNA at a final concentration of 10-20 ng/μl were mixed in 
triplicate with GoTaq® qPCR MasterMix 1x (Promega), NEIL2 cDNA primers (F/R) and 
GAPDH cDNA primers (F/R) at final concentrations of 500nM. Primers used were: 
NEIL2 (F: GTCACACCCACCTGTGACAT; R: GCACTCAGGACTGAACCGAG) and 
GAPDH (F: CCTGCACCACCAACTGCTTA; R: CCATCACGCCACAGTTTCC). 
All reagents were used following the manufacturer’s instructions. qPCR was done 
using the QuantStudio S6 system (Applied Biosystems). 
 
Oxidative stress studies 
 
Oxidative DNA damage within telomeres 
 
We used a qPCR-based method to evaluate the oxidative DNA damage within 
telomeric DNA 19, based on differences in PCR kinetics between DNA template digested 
by formamidopyrimidine-DNA glycosylase (FPG) and undigested DNA. Quantitative 
real-time amplification of genomic DNA was performed as described by O’Callaghan et 
al20. 
 
Immunodetection of oxidized proteins  
 
Oxidized proteins in plasma samples were detected as previously described 21 by 
measuring the levels of carbonylated proteins. Carbonyl groups on the side chains of 
proteins in plasma samples were derivatized to 2,4-dinitrophenylhydrazone (DNP-
hydrazone) by reaction with 2,4-dinitrophenylhidrazine (DNPH), according to the 
procedure of Shacter et al22. Briefly, 5 μg of proteins were denatured with 5 μl of 12% 
SDS. Next, 10 μl of 10 mM DNPH in 10% (v/v) trifluoroacetic acid was added to the 
protein solution. The reaction mixture was neutralized and prepared for SDS–PAGE by 
adding 7.5 μl of 2 M Tris base containing 30% (v/v) glycerol. Derivatized samples were 
spotted onto a nitrocellulose membrane. 
The membrane was blocked with 5% bovine serum albumin (BSA) prepared in 
phosphate-buffered saline (PBS)–0.1% Tween 20 for 1 h. Afterwards, the membrane was 
incubated with a rabbit anti-DNP antibody as described by the manufacturer of the 
OxyBlot kit (OxyBlot Protein Oxidation Detection kit; Millipore, Billerica, MA, USA). 
Images were captured using an ImageQuant LAS-4000 (GE Healthcare Life Sciences; 
Chicago IL, USA). Signal density of each sample was analyzed with ImageJ software 
(NIH Image, NIH, Bethesda, USA). 
 Analysis of lipid peroxidation by HPLC-UV detection  
 
Lipid peroxidation was determined by measuring malondialdehyde (MDA) as 
described previously23. Plasma samples were mixed with 0.44 M phosphoric acid and 42 
mM thiobarbituric acid (TBA) and incubated in a water bath at 95 ºC for 1 h to hydrolyze 
lipoperoxides and liberate malondialdehyde. Samples were cooled immediately and 
diluted 1:1 with alkaline methanol, allowing MDA-TBA2 adduct formation. Afterwards, 
samples were centrifuged (13,000 g, 5 min at 4 ºC) and 200 μL of supernatant was mixed 
1:1 with 50 mM KH2PO4 pH 3.5. The supernatant was separated by HPLC on RP C18 
columns using an isocratic method (Phase A consisting of 50 mM KH2PO4, pH 6.8, and 
acetonitrile (ACN); KH2PO4:ACN 83:17; and Phase B consisting of an ACN:water 70:30 
mixture). MDA-TBA2 adduct was detected under UV-vis at 532 nm.  
 
Telomere length measurement (TL)  
 
High throughput quantitative fluorescence in situ hybridization (HT-QFISH) with 
automated fluorescence microscopy was performed as previously described24. 
Briefly, Peripheral Blood Mononuclear cells (PBMCs) were separated by 
Histopaque-1070 (Sigma-Aldrich) gradient centrifugation. Cells were counted and plated 
(80 000 – 100 000 cells/well in clear bottomed black-well 96-well plates pre-coated with 
0.001% (poly) L-lysine solution (Sigma-Aldrich, St. Louis, MO) for 30 minutes at 37ºC. 
4´,6-diamino-2-phenylindole (DAPI) was used for nucleus staining and a fluorescent 
peptide nucleic acid (PNA) Cy3 probe against telomeric repeats was used for telomere 
detection. TL values were analyzed using individual telomere spots in a per cell basis 
(Approximately 90000 telomere spots per sample, which represents around 3500 cells).  
Fluorescence intensities were then converted into Kb using L5178-R, L5178-S 
and CCRF-CEM cells as calibration standards, which have stable TL of 79.7 Kb, 10.3Kb 
and 7.5 kb, respectively. Samples were analyzed in duplicate, or triplicate in the case of 
calibration standards. A TL <3Kb was defined as short telomere. The load of short 
telomeres was estimated as the percentage of short telomeres (number of short telomeres 
divided by total number of measured telomeres) in each participant. 
 
Statistical analysis  
 Pearson's chi-squared test was used to calculate whether differences in the frequency of 
the SNP among the FBOC groups were significant. 
We performed linear regression analysis to test whether cancer antecedents in 
BRCA1 and BRCA2 mutation carriers were associated with any of the variables we 
evaluated in this report, but we did not find significant differences (Significant p-values 
<0.05) between healthy BRCA1 and BRCA2 carriers or cancer cases. Hence, we did not 
stratify for cancer status in these groups (Supplementary Table S1). 
We considered heterozygotes and homozygotes (GT/TT)  as a single group, to evaluate 
the effect of the SNP for each of the studied variables, as the cancer modifier effect of 
rs804271 is dominant for BRCA2 mutation carriers5. 
In the supplementary tables, from 4 to 7, linear regression analysis was used to 
test whether the SNP (model 1), the BRCA status (model 2) or the combination of both 
events (model 3) significantly modified each of the studied variables among FBOC 
individuals. In addition, the SNP effect within BRCA groups or controls was tested in 
model 4. Two-sided p-values less than p<0.05 where considered significant.  
The Kolmogorov-Smirnov test was used to evaluate if the data sets were normally 
distributed. For comparative analysis (Figure 1a), significance was assessed by the Mann-
Whitney U test for non-normal distributions. Two-sided p-values less than p<0.05 where 
considered significant.  
Statistical calculations were done using SPSS version 18 (SPSS Inc., Chicago, 
Illinois) and GraphPad Prism 5.03 (San Diego, California); graphs were made using 
GraphPad Prism 5.03. 
 
RESULTS  
 
SNP frequency in FBOC  
 
We genotyped rs804271 among FBOC individuals and we found a SNP frequency 
of 0.40 as reported in ensemble for European population (http://www.ensembl.org). This 
frequency, was similar among the different case/control groups (Supplementary Table 
S2). 
 
Expression of NEIL2 in FBOC and GTEx 
 The GTEx eQTL web server (http://www.gtexportal.org) was used to evaluate 
whether rs804271 was associated with changes on NEIL2 mRNA levels for different 
tissues. We found significant increased NEIL2 mRNA levels for several tissues, including 
breast (p<0.0001), ovary (p<0.0001), and blood (p<0.0001) (Supplementary Table S3). 
Next, we evaluated BRCA and/or SNP status over NEIL2 mRNA transcriptional 
levels in our FBOC series. To that end, we performed linear regression analysis to confirm 
that the rs804271 was also associated with significant higher NEIL2 mRNA levels 
(β=0.023; p= 0.003). The SNP effect (upregulation) on NEIL2 mRNA levels was similar 
for each BRCA mutational group, and is detailed on (Supplementary Table S4). 
These results suggest that rs804271, in the NEIL2 promoter region, activates 
NEIL2 transcription, and that potential inter-individual variability could be partially 
explained by the presence or absence of common genetic variants in the NEIL2 gene 
promoter.  
 
DNA glycosylase activity at the telomere 
 
Because the NEIL family is involved in the recognition and excision of oxidized 
bases at the telomeres 10,25 and this region is especially susceptible to DNA oxidation26, 
we evaluated the SNP effect on DNA glycosylase activity by measuring the accumulation 
of oxidative DNA damage at the telomere in our FBOC sample set (Figure 1a). 
Linear regression analysis revealed that the genotype combining the BRCA2 
mutation together with rs804271 was significantly associated with oxidative DNA 
damage accumulation at the telomeres, as compared to any other group (β=0.51; p= 
6.9*10-6).   
These results suggest that among BRCA2 mutation carriers the presence of the 
variant reduces NEIL2 enzyme activity, leading to an accumulation of oxidative DNA 
damage that can be detected at the telomere region (Figure 1b). 
A detailed table with the complete lineal regression analysis can be found at 
Supplementary Table S5 with all genotype combinations. 
 
Oxidative stress studies 
 
Since oxidative stress induces oxidative DNA damage 27, we evaluated whether 
higher levels of oxidative DNA damage could be explained by chronic oxidative stress 
susceptibility for BRCA2 mutations carriers harboring the variant.  
To that end, we used plasma from FBOC individuals to evaluate two oxidative 
stress biomarkers widely used 28,29 consisting on  plasma oxidized proteins (protein 
carbonylation) and lipid hydroperoxide malondialdehyde (MDA).  
We performed linear regression analysis to evaluate the effect of the SNP on these 
two biomarkers. The analysis was performed among the different FBOC genotypes, and 
results are detailed in Supplementary Table S6. 
Among BRCA2 mutations carriers, we found no significant association of the SNP 
with higher levels of oxidative stress susceptibility, suggesting that the accumulation of 
oxidative DNA damage at the telomere, observed for this specific group is not caused by 
basal oxidative stress susceptibility, but as consequence of a deficient activity of 
glycosylases, as described in the previous section. 
Interestingly, we found higher MDA levels for BRCA1 mutation carriers 
harboring the SNP in NEIL2. Supplementary Table S6. 
 
Telomere length (TL) studies in FBOC 
 
We decided to explore the possible involvement of the SNP in NEIL2 (rs804271) 
on telomere instability by measuring TL, percentage of short telomeres and telomerase 
activity in blood cells of FBOC series. 
Because mean TL is strongly heritable 30 and our series is mainly composed of 
families, we decided to use a single genotype for both the BRCA and SNP status for each 
family:  
When a genotype was repeated in several members within the same family, only 
the index-case was considered; whenever the index-case was not available only the last 
family member registered to participate in the study, from a group of redundant 
genotypes, was included to perform statistical analyses.  
We previously demonstrated that chemotherapy shortens TL 31, and we therefore 
corrected for chemotherapy status in this analysis. We excluded patients who were 
undergoing chemotherapy from the analysis, as well as those for whom less than 2 years 
had passed since their last cycle of chemotherapy. Chemotherapy effect on TL in FBOC 
cases, was also tested by linear regression analysis (β=-0.14; p=0.024). 
Telomere length (Kb) was adjusted for age using a best-fit line (y= -0.0674*age 
(years) +12.631; (Figure S1)). The difference between the actual and the predicted value 
was calculated for each sample.  
In addition, since TL is significantly correlated with telomerase activity in our 
series (R=+0.29; p= 0.01), we evaluated the possible effect of the rs804271 on telomerase 
activity. Cancer cases treated with chemotherapy were excluded for this analysis. 
After the correction of these variables, we performed lineal regression analysis to 
test the effect of the SNP on TL, among the different FBOC genotypes. 
Overall, we found that the presence of the SNP was associated to a decreased TL 
(β=-0.26; p= 0.004), increased levels of short telomeres (β=+0.25; p= 0.005) and lower 
telomerase activity (β=-0.17; p= 0.16).  
When rs804271 was tested for each BRCA mutational group, we only found a 
significant effect among BRCA1 mutation carriers: Reduced TL (adjusted by age) among 
BRCA1 (β=-0.54; p= 0.007), accumulation of short telomeres (β=0.45; p= 0.02) and 
telomerase activity (β=-0.57; p= 0.034).  
A detailed table with the complete linear regression analysis can be found at 
(Supplementary Table 7), with all genotype combinations. 
 
DISCUSSION 
 
We have previously shown that the SNP (rs2304277) located in the 3’UTR  of the OGG1 
gene, and encoding a DNA glycosylase from the BER pathway, can increase cancer risk 
in BRCA1 mutation carriers 5, by reducing OGG1 mRNA levels and increasing 
genome/telomere instability in a synergistic way with the BRCA1 mutation 14. 
In the present study, we have tried to gain molecular insights into the breast cancer 
modifier SNP (rs804271) in the gene NEIL2, in a set of 261 FBOC patients with a 
heterogeneous BRCA status (BRCA1 and BRCA2 mutation carriers, BRCAX, and non-
carrier controls). This SNP, which is located in the promoter region of the gene, increases 
the risk of developing breast cancer among BRCA2 mutation carriers 5, but the molecular 
mechanism underlying this association is unknown. Previous characterization of the 
NEIL2 promoter region showed that NEIL2 transcription is influenced by certain SNPs 
located 5′ upstream of the start site 18. The results presented in this report, support these 
findings and suggest that rs804271 is associated with constitutive transcriptional 
activation of NEIL2.  
 
First, we checked the effect of rs804271 on NEIL2 mRNA levels in different 
tissues using Gtex eQTL dB (http://www.gtexportal. org), and we found a significant 
upregulation associated with the presence of the SNP in several tissues including breast, 
ovary and blood (p<0.0001) (Supplementary Table S3). 
Then, we validated these results in our FBOC series and we found significantly 
increased NEIL2 mRNA levels in individuals harboring the SNP (p=0.003), suggesting 
that it is associated with transcriptional activation of the NEIL2 gene (Supplementary 
Table S4).  
Since NEIL2 is an important enzyme of the BER, and it has been recently reported 
to be the gene most frequently displaying copy number variation loss, and is significantly 
down-regulated in several tumors 32,  it is unlikely that  NEIL2 transcriptional activation 
could be the causal explanation for the cancer modifier effect of this polymorphism 
among BRCA2 mutation carriers. 
As an alternative hypothesis, it could be possible that this SNP reduced the activity 
of NEIL2 leading to an accumulation of oxidative lesions at telomeres and a NEIL2 
transcriptional activation by a positive feedback mechanism.  
Because NEIL2 is involved in oxidative DNA damage repair at the telomeres 
10,25 and this region is very susceptible from being oxidized, we have evaluated the 
telomere oxidation levels to assess the constitutive oxidative DNA repair capacity 
among the different FBOC genotypes. Strikingly, we have found that BRCA2 mutation 
carriers presented significantly higher levels of oxidation at the telomeres 
(Supplementary Table S5 and/or Figure 1a), and those levels were mainly explained by 
the subgroup of patients harboring the NEIL2 SNP (Figure 1a & Figure 1b), suggesting 
that oxidative DNA repair is compromised when the rs804271 is present together with a 
BRCA2 mutation.  Because oxidative stress induces oxidative DNA damage 27, we 
evaluated whether higher levels of oxidative DNA damage for BRCA2 mutations 
carriers harboring the variant, could be explained by chronic oxidative stress 
susceptibility. We found no association with basal oxidative stress susceptibility for 
BRCA2 mutation carriers, with or without the SNP (Supplementary Table S6).  In 
support for a functional role of this polymorphism on the performance of the NEIL2 
enzyme, it was previously reported in the literature that this polymorphism rs804271 
(previously ss74800505 ) was associated with significantly increased  mutagen-induced 
genetic damage 18.  
Although, a functional effect on transcription was initially expected, since this 
SNP is in the promoter region of NEIL2, our result suggest that this polymorphism may 
be associated with a reduced enzymatic activity exclusively for BRCA2 mutation 
carriers, which lead to an accumulation of oxidative DNA damage. This scenario, could 
be the molecular mechanism explaining the cancer modifier effect of this SNP for 
BRCA2 mutation carriers.  
In relation with the role of this SNP among BRCA1 mutation carriers, we found 
to be significantly associated with higher MDA levels in plasma. This result, correlated 
with a higher telomere instability reflected on reduced TL (β=-0.34; p= 0.01), 
accumulation of short telomeres (β=0.45; p= 0.024) and lower telomerase activity levels 
(β=-0.57; p= 0.034), Supplementary Table S7. In relation with these results, previous 
studies have demonstrated that BRCA1 protein is also involved in the response to 
oxidative stress 32–34 through its interaction with NFR2, a key player that regulates 
antioxidant signaling response and cell proliferation35. Since oxidative stress correlates 
with telomere shortening33, it was not surprising to find this telomere phenotype for 
BRCA1 mutation carriers, although the SNP is not associated with cancer risk for this 
group. 
Altogether, our results suggest that rs804271, located in the promoter region of 
the gene NEIL2, has a functional effect on NEIL2 mRNA transcription and on telomere 
maintenance, although is unlikely to be related to the cancer risk modifier effect of the 
SNP for BRCA2 mutation carriers. In contrast, we have found that the SNP contributes 
significantly to oxidative DNA damage at telomeres exclusively for BRCA2 mutation 
carriers, suggesting that the effect of this SNP on cancer risk could be driven by its 
effect on the enzyme activity.    
ACKNOWLEDGMENTS  
We thank Alicia Barroso and Victoria Fernandez for their technical assistance.  
The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund 
of the Office of the Director of the National Institutes of Health. Additional funds were 
provided by the NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. Donors were enrolled 
at Biospecimen Source Sites funded by NCI/SAIC-Frederick, Inc. (SAIC-F) subcontracts 
to the National Disease Research Interchange (10XS170), Roswell Park Cancer Institute 
(10XS171), and Science Care, Inc. (X10S172). The Laboratory, Data Analysis, and 
Coordinating Center (LDACC) were funded through a contract (HHSN268201000029C) 
to The Broad Institute, Inc. Biorepository operations were funded through an SAIC-F 
subcontract to the Van Andel Institute (10ST1035). Additional data repository and project 
management were provided by SAIC-F (HHSN261200800001E). The Brain Bank was 
supported by supplements to University of Miami grants DA006227 & DA033684 and to 
contract N01MH000028. Statistical Methods development grants were made to the 
University of Geneva (MH090941 & MH101814), the University of Chicago 
(MH090951, MH090937, MH101820, MH101825), the University of North Carolina - 
Chapel Hill (MH090936 & MH101819), Harvard University (MH090948), Stanford 
University (MH101782), Washington University St Louis (MH101810), and the 
University of Pennsylvania (MH101822). The data used for the analyses described in this 
manuscript were obtained from: [insert, where appropriate] the GTEx Portal on 
01/12/2015 and/or dbGaP accession number phs000424.vN. pN on 01/12/2015. 
FUNDING  
J.B.'s laboratory is partially funded by the Spanish Ministry of Health 
PI12/00070, supported by FEDER funds, and the Spanish Research Network on Rare 
diseases (CIBERER). C.B-B is supported by FIS PI12/00070. J.M.B is supported by 
grant FPU15/01978 from the Spanish Ministry of Education, Culture and Sport. 
M.A.B.'s laboratory is funded by the Spanish Ministry of Science and Innovation, 
projects SAF2008-05384 and 2007-A-200950 (TELOMARKER), European Research 
Council Advanced Grant GA#232854, the Körber Foundation, Fundación Botín and 
Fundación Lilly. MU is supported by the Spanish Ministry of Health PI14/00459 with 
FEDER funds. FVP’s laboratory is partially funded by the Spanish Research Network 
on rare diseases (CIBERER) and Fundación INCLIVA and the Generalitat Valenciana. 
The study was partially supported by the Spanish Ministry of Economy and 
Competitiveness (MINECO) SAF2014-57680-R. 
BIBLIOGRAPHY 
1.  Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common 
pathway of genome protection. Nat Rev Cancer [Internet] 2012;12:68–78. 
Available from: http://www.nature.com.ezp-
prod1.hul.harvard.edu/nrc/journal/v12/n1/full/nrc3181.html 
2.  Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman 
N, Olsson H, Johannsson O, Borg Å, Pasini B, Radice P, et al. Average Risks of 
Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations 
Detected in Case Series Unselected for Family History: A Combined Analysis of 
22 Studies. Am J Hum Genet [Internet] 2003;72:1117–30. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/S0002929707606405 
3.  Milne RL, Osorio A, Cajal TRY, Vega A, Llort G, De La Hoya M, Díez O, 
Carmen Alonso M, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, et al. The 
average cumulative risks of breast and ovarian cancer for carriers of mutations in 
BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer 
Res 2008;14:2861–9.  
4.  Helleday T. The underlying mechanism for the PARP and BRCA synthetic 
lethality: Clearing up the misunderstandings. Mol. Oncol.2011;5:387–93.  
5.  Osorio A, Milne RL, Kuchenbaecker K, Vaclov?? T, Pita G, Alonso R, 
Peterlongo P, Blanco I, de la Hoya M, Duran M, D??ez O, Ram??n y Cajal T, et 
al. DNA Glycosylases Involved in Base Excision Repair May Be Associated with 
Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genet 2014;10.  
6.  Wallace SS. Base excision repair: A critical player in many games. DNA Repair 
(Amst) 2014;19:14–26.  
7.  Caldecott KW. Single-strand break repair and genetic disease. Nat Rev Genet 
[Internet] 2008;9:619–31. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2756414&tool=pmce
ntrez&rendertype=abstract\nhttp://www.ncbi.nlm.nih.gov/pubmed/18414403\nhtt
p://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC2756414\nhttp://w
ww.nature.com/doifinder/10.103 
8.  Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the 
cancer connection. Nat Genet [Internet] 2001;27:247–54. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/11242102 
9.  Wang Z, Rhee DB, Lu J, Bohr CT, Zhou F, Vallabhaneni H, de Souza-Pinto NC, 
Liu Y. Characterization of oxidative guanine damage and repair in mammalian 
telomeres. PLoS Genet 2010;6:28.  
10.  Zhou J, Fleming AM, Averill AM, Burrows CJ, Wallace SS. The NEIL 
glycosylases remove oxidized guanine lesions from telomeric and promoter 
quadruplex DNA structures. Nucleic Acids Res 2015;43:4039–54.  
11.  Hazra TK, Das A, Das S, Choudhury S, Kow YW, Roy R. Oxidative DNA 
damage repair in mammalian cells: A new perspective. DNA Repair (Amst) 
2007;6:470–80.  
12.  Dou H, Mitra S, Hazra TK. Repair of Oxidized Bases in DNA Bubble Structures 
by Human DNA Glycosylases NEIL1 and NEIL2. J Biol Chem 2003;278:49679–
84.  
13.  Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability--an evolving 
hallmark of cancer. Nat Rev Mol Cell Biol [Internet] 2010;11:220–8. Available 
from: 
http://www.ncbi.nlm.nih.gov/pubmed/20177397\nhttp://www.nature.com/nrm/jo
urnal/v11/n3/pdf/nrm2858.pdf 
14.  Sarek G, Marzec P, Margalef P, Boulton SJ. Molecular basis of telomere 
dysfunction in human genetic diseases. Nat Struct Mol Biol [Internet] 
2015;22:867–74. Available from: http://dx.doi.org/10.1038/nsmb.3093 
15.  Kong CM, Lee XW, Wang X. Telomere shortening in human diseases. FEBS J 
[Internet] 2013;280:3180–93. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23647631 
16.  Benitez-Buelga C, Vaclová T, Ferreira S, Urioste M, Inglada-Perez L, Soberón 
N, Blasco MA, Osorio A, Benitez J. Molecular insights into the OGG1 gene, a 
cancer risk modifier in BRCA1 and BRCA2 mutations carriers. Oncotarget 
[Internet] 2016;Available from: http://www.ncbi.nlm.nih.gov/pubmed/27015555 
17.  Kinslow CJ, El-Zein RA, Rondelli CM, Hill CE, Wickliffe JK, Abdel-Rahman 
SZ. Regulatory regions responsive to oxidative stress in the promoter of the 
human DNA glycosylase gene NEIL2. Mutagenesis 2010;25:171–7.  
18.  Kinslow CJ, El-Zein RA, Hill CE, Wickliffe JK, Abdel-Rahman SZ. Single 
nucleotide polymorphisms 5??? upstream the coding region of the NEIL2 gene 
influence gene transcription levels and alter levels of genetic damage. Genes 
Chromosom Cancer 2008;47:923–32.  
19.  O’Callaghan NJ, Dhillon VS, Thomas P, Fenech M. A quantitative real-time 
PCR method for absolute telomere length. Biotechniques 2008;44:807–9.  
20.  O’Callaghan N, Baack N, Sharif R, Fenech M. A qPCR-based assay to quantify 
oxidized guanine and other FPG-sensitive base lesions within telomeric DNA. 
Biotechniques 2011;51:403–12.  
21.  García-Giménez JL, Ledesma AMV, Esmoris I, Romá-Mateo C, Sanz P, Viña J, 
Pallardó F V. Histone carbonylation occurs in proliferating cells. Free Radic Biol 
Med 2012;52:1453–64.  
22.  Shacter E, Williams JA, Lim M, Levine RL. Differential susceptibility of plasma 
proteins to oxidative modification: Examination by western blot immunoassay. 
Free Radic Biol Med 1994;17:429–37.  
23.  Breusing N, Grune T, Andrisic L, Atalay M, Bartosz G, Biasi F, Borovic S, 
Bravo L, Casals I, Casillas R, Dinischiotu A, Drzewinska J, et al. An inter-
laboratory validation of methods of lipid peroxidation measurement in UVA-
treated human plasma samples. Free Radic Res 2010;44:1203–15.  
24.  Canela A, Vera E, Klatt P, Blasco M a. High-throughput telomere length 
quantification by FISH and its application to human population studies. Proc 
Natl Acad Sci U S A [Internet] 2007;104:5300–5. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1828130&tool=pmce
ntrez&rendertype=abstract 
25.  Chakraborty A, Wakamiya M, Venkova-Canova T, Pandita RK, Aguilera-
Aguirre L, Sarker AH, Singh DK, Hosoki K, Wood TG, Sharma G, Cardenas V, 
Sarkar PS, et al. Neil2-null mice accumulate oxidized DNA bases in the 
transcriptionally active sequences of the genome and are susceptible to innate 
inflammation. J Biol Chem 2015;290:24636–48.  
26.  Raschenberger J, Lamina C, Haun M, Kollerits B, Coassin S, Boes E, Kedenko 
L, Köttgen A, Kronenberg F. Influence of DNA extraction methods on relative 
telomere length measurements and its impact on epidemiological studies. Sci Rep 
[Internet] 2016;6:25398. Available from: 
http://www.nature.com/articles/srep25398 
27.  Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. 
FEBS Lett 1995;358:1–3.  
28.  Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P. Plasma 
malondialdehyde as biomarker for oxidative stress: Reference interval and effects 
of life-style factors. Clin Chem 1997;43:1209–14.  
29.  Pirinccioglu AG, G??kalp D, Pirinccioglu M, Kizil G, Kizil M. Malondialdehyde 
(MDA) and protein carbonyl (PCO) levels as biomarkers of oxidative stress in 
subjects with familial hypercholesterolemia. Clin Biochem 2010;43:1220–4.  
30.  Broer L, Codd V, Nyholt DR, Deelen J, Mangino M, Willemsen G, Albrecht E, 
Amin N, Beekman M, de Geus EJC, Henders A, Nelson CP, et al. Meta-analysis 
of telomere length in 19 713 subjects reveals high heritability, stronger maternal 
inheritance and a paternal age effect. Eur J Hum Genet [Internet] 2013;21:1163–
8. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3778341&tool=pmce
ntrez&rendertype=abstract 
31.  Benitez-Buelga C, Sanchez-Barroso L, Gallardo M, Apellaniz-Ruiz M, Inglada-
Perez L, Yanowski K, Carrillo J, Garcia-Estevez L, Calvo I, Perona R, Urioste 
M, Osorio A, et al. Impact of chemotherapy on telomere length in sporadic and 
familial breast cancer patients. Breast Cancer Res Treat 2015;149:385–94.  
32.  Hildrestrand G a, Neurauter CG, Diep DB, Castellanos CG, Krauss S, Bjørås M, 
Luna L. Expression patterns of Neil3 during embryonic brain development and 
neoplasia. BMC Neurosci 2009;10:45.  
33.  Houben JMJ, Mercken EM, Ketelslegers HB, Bast A, Wouters EF, Hageman GJ, 
Schols AMWJ. Telomere shortening in chronic obstructive pulmonary disease. 
Respir Med 2009;103:230–6.  
 
 
Figure 1 
a) 
 
 
b) 
 
 
 
 
 Table 1:  FBOC series information.                                                                         
 
Information regarding number of healthy BRCA1 and BRCA2 mutation carriers or cancer cases and the sample size for each experimental section.* Telomere studies: The 
same sample size was used for both TL and percentage of short telomeres quantification. 
 
 Families 
(n) 
Healthy 
carriers (n) 
Cancer 
cases (n) 
rs804271 
genotyped (n) 
NEIL2 
mRNA (n) 
Telomere 
oxidation 
(n) 
  
Carbonylation 
(n) 
Malondihal
dehyde (n) 
*Telomere 
studies (n) 
Telomerase 
(n) 
BRCA1 25 22 20 42 24 25 29 16 42 27 
BRCA2 25 23 23 46 30 19 27 16 46 30 
BRCAX 94 0 87 87 55 70 27 12 87 31 
Controls na 0 0 86 29 63 15 17 53 23 
  
Supplementary Figure 1 TL distribution in peripheral blood leukocytes as a function of age for the 
control women population (n = 60), measured by HT QFISH. The regression line for control is drawn 
controls (y= 0.067* age +12.785) 
 
Supplementary Table S1: Lineal Regression analysis in FBOC Samples: Cancer effect on the 
studies variables 
 
 
 
 
 
 
 
 
We included as dependent variables NEIL2 mRNA levels, telomere oxidation, carbonylation and MDA, 
TL (Adjusted by age) & % of short telomeres, telomerase. As independent variables, we included cancer 
status. β coefficients quantify how much the independent variable (cancer status) modifies the dependent 
variables, and it shows the direction of the modification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Independent 
Variable 
Dependent variable β coeff  p-value 
Cancer status 
NEIL2 mRNA -0.13 0.111 
Telomere Oxidation -0.079 0.238 
Carbonylation -0.091 0.356 
Malondihaldehyde -0.197 0.241 
Telomere length 0.005 0.938 
Short Telomeres (%) 0.122 0.061 
Telomerase -0.151 0.111 
Supplementary Table S2: Heterozygous/ homozygous frequency of the NEIL2 variant rs804271 
(G>T). 
 
 
 
 
 
* Familial breast and ovarian cancer patients.   
 GG GT TT 
FBOC* 0.36 0.49 0.16 
BRCA1 0.40 0.45 0.15 
BRCA2 0.43 0.43 0.14 
BRCAX 0.30 0.59 0.11 
Controls 0.34 0.50 0.16 
Supplementary Table S3: Gtex information summary, regarding NEIL2 transcriptional up-
regulation when rs804271 is present (17 different tissues). 
 
aNominal eQTL p-values were generated for each SNP-gene pair using a two-tailed t test, testing the 
alternative hypothesis that the beta (slope of the linear regression model) deviates from the null hypothesis 
of β=0. 
 
Gencode Id Gene 
Symbol 
SNP Id P-Value Effect Size Tissue 
ENSG00000154328.11 NEIL2 rs804271 2.6e-20 0.49 Nerve - Tibial 
ENSG00000154328.11 NEIL2 rs804271 3.8e-15 0.42 Artery - Tibial 
ENSG00000154328.11 NEIL2 rs804271 2.3e-14 0.48 Heart - Atrial 
Appendage 
ENSG00000154328.11 NEIL2 rs804271 3.3e-14 0.38 Adipose - 
Subcutaneous 
ENSG00000154328.11 NEIL2 rs804271 1.2e-12 0.36 Thyroid 
ENSG00000154328.11 NEIL2 rs804271 1.4e-12 0.33 Cells - 
Transformed 
fibroblasts 
ENSG00000154328.11 NEIL2 rs804271 1.6e-11 0.39 Artery - Aorta 
ENSG00000154328.11 NEIL2 rs804271 3.9e-11 0.69 Ovary 
ENSG00000154328.11 NEIL2 rs804271 4.6e-11 0.34 Whole Blood 
ENSG00000154328.11 NEIL2 rs804271 9.3e-11 0.29 Muscle - 
Skeletal 
ENSG00000154328.11 NEIL2 rs804271 5.6e-7 0.46 Brain - 
Caudate 
(basal ganglia) 
ENSG00000154328.11 NEIL2 rs804271 7.6e-7 0.62 Pituitary 
ENSG00000154328.11 NEIL2 rs804271 0.0000048 0.29 Heart - Left 
Ventricle 
ENSG00000154328.11 NEIL2 rs804271 0.0000084 0.39 Vagina 
ENSG00000154328.11 NEIL2 rs804271 0.000014 0.22 Esophagus - 
Muscularis 
ENSG00000154328.11 NEIL2 rs804271 0.000016 0.28 Breast - 
Mammary 
Tissue 
ENSG00000154328.11 NEIL2 rs804271 0.000021 0.23 Stomach 
Supplementary Table S4: Linear regression models to test the SNP effect on NEIL2 transcription.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model 1: Where NEIL2 mRNA levels is the dependent variable, and rs804271, the independent variable. 
Model 2: Where NEIL2 mRNA levels is the dependent variable, and BRCA mutational status the 
independent variable (Controls, BRCA1, BRCA2, BRCAX). Model 3: Where NEIL2 mRNA levels is the 
dependent variable, and the rs804271 is the independent variable. The model is applied after stratification 
in each mutational group (Controls, BRCA1, BRCA2, BRCAX). Model 4: Where NEIL2 mRNA levels is 
the dependent variable, and the BRCA status, the SNP and combination of both genetic events together, 
(interaction terms: Controls*SNP; BRCA1*SNP; BRCA2*SNP and BRCAX*SNP) are independent 
variables. The table shows the β value & the p-value of the interaction term. β coefficients quantify how 
much the dependent variable (NEIL2 mRNA levels) modifies the dependent variables, and it shows the 
direction of the modification.  
 
 
   Dependent variable 
   NEIL2 mRNA Expression 
  
Independent 
Variable β coeff  p-value 
Model 1 rs804271 0.23 0.003 
Model 2 
Controls 0.04 0.580 
BRCA1 -0.06 0.401 
BRCA2 -0.02 0.732 
BRCAX 0.03 0.678 
Model 3   β coeff  p-value 
Controls 
rs804271 
0.12 0.4 
BRCA1 0.42 0.04 
BRCA2 0.18 0.322 
BRCAX 0.28 0.03 
Model 4 
Controls*rs804271 -0.14 0.31 
BRCA1*rs804271 -0.083 0.55 
BRCA2*rs804271 -0.014 0.91 
BRCAX*rs804271 0.0091 0.543 
Supplementary Table S5: Linear regression models to test the SNP effect on telomere oxidation.  
 
   Dependent variable 
  Telomere oxidation 
  
Independent 
Variable β coeff  p-value 
Model 1 rs804271 -0.06 0.372 
Model 2 
Controls 0.24 0.746 
BRCA1 -0.13 0.06 
BRCA2 0.22 4.41*10exp-4 
BRCAX -0.08 0.248 
Model 3   β coeff  p-value 
Controls 
rs804271 
-0.16 0.18 
BRCA1 -0.11 0.622 
BRCA2 0.60 0.008 
BRCAX -0.03 0.81 
Model 4 
Controls*rs804271 -0.14 0.301 
BRCA1*rs804271 -0.05 0.552 
BRCA2*rs804271 0.51 6.9*10exp-6 
BRCAX*rs804271 -0.14 0.331 
 
Model 1: Where telomere oxidation levels is the dependent variable, and rs804271, the independent 
variable. Model 2: Where telomere oxidation levels is the dependent variable, and BRCA mutational status 
the independent variable (Controls, BRCA1, BRCA2, BRCAX). Model 3: Where telomere oxidation levels 
is the dependent variable,  and the rs804271 is independent variable. This model is applied for each BRCA 
mutational group (Controls, BRCA1, BRCA2, BRCAX) after stratification for each mutational group. 
Model 4: Where telomere oxidation levels is the dependent variable, and the BRCA status, the SNP and 
combination of both genetic events together (Controls*rs804271; BRCA1* rs804271; BRCA2* rs804271 
and BRCAX*SNP) are independent variables. Although in the table is only shown the β value & the p-
value of the combined variable. β coefficients quantify how much the dependent variable (telomere 
oxidation levels) modifies the dependent variables, and it shows the direction of the modification.  
 
Supplementary Table S6: Linear regression models to test the SNP effect on protein carbonylation and lipid peroxidation (MDA).  
 
   Dependent variables 
   Carbonylation MDA 
  
Independent 
Variable β coeff  p-value β coeff  p-value 
Model 1 rs804271 -0.07 0.499 0.19 0.202 
Model 2 
Controls 0.11 0.226 0.15 0.287 
BRCA1 -0.15 0.869 0.082 0.574 
BRCA2 -0.08 0.355 -0.13 0.367 
BRCAX -0.09 0.315 -0.12 0.390 
Model 3   β coeff  p-value β coeff  p-value 
Controls 
rs804271 
-0.24 0.241 -0.11 0.679 
BRCA1 0.12 0.499 0.65 0.042 
BRCA2 0.00 0.971 0.012 0.974 
BRCAX -0.27 0.121 -0.34 0.301 
Model 4 
Controls*rs804271 -0.33 0.054 -0.31 0.251 
BRCA1*rs804271 0.11 0.466 0.64 0.002 
BRCA2*rs804271 0.06 0.411 -0.21 0.285 
BRCAX*rs804271 -0.03 0.837 -0.26 0.165 
 
Model 1: Where protein carbonylation and lipid peroxidation (MDA) are the dependent variables, and rs804271, the independent variable. Model 2: Where protein 
carbonylation and lipid peroxidation (MDA) are the dependent variables, and BRCA mutational status the independent variable (Controls, BRCA1, BRCA2, BRCAX). Model 
3: Where protein carbonylation and lipid peroxidation (MDA) are the dependent variables, and the rs804271 is independent variable. This model is applied for each BRCA 
mutational group (Controls, BRCA1, BRCA2, BRCAX) after stratification for each mutational group. Model 4: Where protein carbonylation and lipid peroxidation (MDA) are 
the dependent variable, and the BRCA status, the SNP and combination of both genetic events together (Controls*rs804271; BRCA1* rs804271; BRCA2* rs804271 and 
BRCAX*SNP) are independent variables. Although in the table is only shown the β value & the p-value of the combined variable. β coefficients quantify how much the 2 
dependent variables (protein carbonylation and lipid peroxidation (MDA) modifies the dependent variables, and it shows the direction of the modification 
Supplementary Table S7: Lineal regression models to test the SNP effect on telomere length, accumulation of short telomeres and telomerase activity.  
   Dependent variables 
   TL % short telomeres Telomerase 
  Independent Variable β coeff  p-value β coeff  p-value β coeff  p-value 
Model 1 rs804271 -0.26 0.004 0.25 0.005 -0.17 0.16 
Model 2 
Controls 0.15 0.063 -0.09 0.27 -0.03 0.761 
BRCA1 -0.13 0.13 0.04 0.89 0.13 0.18 
BRCA2 -0.03 0.691 -0.017 0.83 -0.06 0.58 
BRCAX -0.02 0.81 0.08 0.34 -0.11 0.28 
Model 3   β coeff  p-value β coeff  p-value β coeff  p-value 
Controls 
rs804271 
-0.29 0.06 0.27 0.17 -0.07 0.63 
BRCA1 -0.54 0.007 0.45 0.02 -0.57 0.035 
BRCA2 -0.12 0.52 0.14 0.71 0.09 0.742 
BRCAX -0.09 0.69 -0.06 0.813 na na 
Model 4 
Controls*rs804271 -0.027 0.56 -0.019 0.903 0.14 0.395 
BRCA1*rs804271 -0.26 0.056 0.22 0.14 -0.10 0.457 
BRCA2*rs804271 0.15 0.30 -0.12 0.394 -0.18 0.242 
BRCAX*rs804271 0.15 0.405 -0.10 0.572 -0.21 0.15 
 
Model 1: Where telomere length, accumulation of short telomeres and telomerase activity are the dependent variables, and rs804271, the independent variable. Model 2: Where 
telomere length, accumulation of short telomeres and telomerase activity are the dependent variables, and BRCA mutational status the independent variable (Controls, BRCA1, 
BRCA2, BRCAX). Model 3: Where telomere length, accumulation of short telomeres and telomerase activity are the dependent variables, and the rs804271 is independent 
variable. This model is applied for each BRCA mutational group (Controls, BRCA1, BRCA2, BRCAX) after stratification for each mutational group. Model 4: Where telomere 
length, accumulation of short telomeres and telomerase activity are the dependent variables, and the BRCA status, the SNP and combination of both genetic events together 
(Controls* rs804271; BRCA1* rs804271; BRCA2* rs804271 and BRCAX*SNP) are independent variables. Although in the table is only shown the β value & the p-value of the 
combined variable. β coefficients quantify how much the 2 dependent variables (protein carbonylation and lipid peroxidation (MDA) modifies the dependent variables, and it 
shows the direction of the modification.  
 
FIGURE LEGENDS 
 
Figure 1 Telomere oxidation comparative analysis among FBOC series. 
a) Left panel: Telomere oxidation in the different groups according to the BRCA mutational status 
(BRCA1, BRCA2 or BRCAX) was compared with controls. Middle panel: Telomere oxidation in the 
according the BRCA mutational status (BRCA1, BRCA2 or BRCAX) and controls, stratified according the 
absence or presence of the variant in NEIL2 (non-carriers (GG) / carriers (GT/TT). Right panel: 
Telomere oxidation in all FBOC individuals stratified according to the absence or presence of the variant 
in NEIL2. Bars show the mean and the standard deviation. 
b) BRCA2 harboring the rs804271 (n=11) mutation carriers compared to the mean telomere oxidation 
values from the whole FBOC series (n=166). 
Supplementary figure Figure 1 TL distribution in peripheral blood leukocytes as a function of age for 
the control women population (n = 60), measured by HT QFISH. The regression line for control is drawn 
controls (y= 0.067* age +12.785) 
TABLE LEGENDS 
Table 1:  FBOC series information. Information regarding number of healthy BRCA1 and BRCA2 
mutation carriers or cancer cases and the sample size for each experimental section.* Telomere studies: 
The same sample size was used for both TL and percentage of short telomeres quantification. 
Supplementary Table S1: Lineal Regression analysis in FBOC Samples 
We included as dependent variables NEIL2 mRNA levels, telomere oxidation, carbonylation and MDA, 
TL (Adjusted by age) & % of short telomeres, telomerase. As independent variables, we included cancer 
status. β coefficients quantify how much the independent variable (cancer status) modifies the dependent 
variables, and it shows the direction of the modification.  
 
Supplementary Table S2: Heterozygous/ homozygous frequency of the NEIL2 variant rs804271 
(G>T).* Familial breast and ovarian cancer patients.   
 
Supplementary Table S3: Gtex information summary, regarding NEIL2 transcriptional up-
regulation when rs804271 is present (16 different tissues). 
aNominal eQTL p-values were generated for each SNP-gene pair using a two-tailed t test, testing the 
alternative hypothesis that the beta (slope of the linear regression model) deviates from the null hypothesis 
of β=0. 
 
Supplementary Table S4: Linear regression models to test the SNP effect on NEIL2 transcription. 
Model 1: Where NEIL2 mRNA levels is the dependent variable, and rs804271, the independent variable. 
Model 2: Where NEIL2 mRNA levels is the dependent variable, and BRCA mutational status the 
independent variable (Controls, BRCA1, BRCA2, BRCAX). Model 3: Where NEIL2 mRNA levels is the 
dependent variable, and the rs804271 is the independent variable. The model is applied after stratification 
in each mutational group (Controls, BRCA1, BRCA2, BRCAX). Model 4: Where NEIL2 mRNA levels is 
the dependent variable, and the BRCA status, the SNP and combination of both genetic events together, 
(interaction terms: Controls*SNP; BRCA1*SNP; BRCA2*SNP and BRCAX*SNP) are independent 
variables. The table shows the β value & the p-value of the interaction term. β coefficients quantify how 
much the dependent variable (NEIL2 mRNA levels) modifies the dependent variables, and it shows the 
direction of the modification.  
 
Supplementary Table S5: Linear regression models to test the SNP effect on telomere oxidation. 
Model 1: Where telomere oxidation levels is the dependent variable, and rs804271, the independent 
variable. Model 2: Where telomere oxidation levels is the dependent variable, and BRCA mutational status 
the independent variable (Controls, BRCA1, BRCA2, BRCAX). Model 3: Where telomere oxidation levels 
is the dependent variable,  and the rs804271 is independent variable. This model is applied for each BRCA 
mutational group (Controls, BRCA1, BRCA2, BRCAX) after stratification for each mutational group. 
Model 4: Where telomere oxidation levels is the dependent variable, and the BRCA status, the SNP and 
combination of both genetic events together (Controls*SNP; BRCA1*SNP; BRCA2*SNP and 
BRCAX*SNP) are independent variables. Although in the table is only shown the β value & the p-value of 
the combined variable. β coefficients quantify how much the dependent variable (telomere oxidation levels) 
modifies the dependent variables, and it shows the direction of the modification.  
 
Supplementary Table S6: Linear regression models to test the SNP effect on  protein carbonylation 
and lipid peroxidation ( MDA). Model 1: Where protein carbonylation and lipid peroxidation ( MDA) 
are the dependent variables, and rs804271, the independent variable. Model 2: Where protein carbonylation 
and lipid peroxidation ( MDA) are the dependent variables, and BRCA mutational status the independent 
variable (Controls, BRCA1, BRCA2, BRCAX). Model 3: Where protein carbonylation and lipid 
peroxidation (MDA) are the dependent variables,  and the rs804271 is independent variable. This model is 
applied for each BRCA mutational group (Controls, BRCA1, BRCA2, BRCAX) after stratification for each 
mutational group. Model 4: Where protein carbonylation and lipid peroxidation ( MDA) are the dependent 
variable, and the BRCA status, the SNP and combination of both genetic events together (Controls*SNP; 
BRCA1*SNP; BRCA2*SNP and BRCAX*SNP) are independent variables. Although in the table is only 
shown the β value & the p-value of the combined variable. β coefficients quantify how much the 2 
dependent variables (protein carbonylation and lipid peroxidation ( MDA)) modifies the dependent 
variables, and it shows the direction of the modification.  
 
Supplementary Table S7: Lineal regression models to test the SNP effect on telomere length, 
accumulation of short telomeres and telomerase activity. Model 1: Where telomere length, 
accumulation of short telomeres and telomerase activity are the dependent variables, and rs804271, the 
independent variable. Model 2: Where telomere length, accumulation of short telomeres and telomerase 
activity are the dependent variables, and BRCA mutational status the independent variable (Controls, 
BRCA1, BRCA2, BRCAX). Model 3: Where telomere length, accumulation of short telomeres and 
telomerase activity are the dependent variables, and the rs804271 is independent variable. This model is 
applied for each BRCA mutational group (Controls, BRCA1, BRCA2, BRCAX) after stratification for each 
mutational group. Model 4: Where telomere length, accumulation of short telomeres and telomerase 
activity are the dependent variables, and the BRCA status, the SNP and combination of both genetic events 
together (Controls*SNP; BRCA1*SNP; BRCA2*SNP and BRCAX*SNP) are independent variables. 
Although in the table is only shown the β value & the p-value of the combined variable. β coefficients 
quantify how much the 2 dependent variables (protein carbonylation and lipid peroxidation ( MDA)) 
modifies the dependent variables, and it shows the direction of the modification.  
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Synthetic lethality in BRCA1 deficient breast cancer cell lines 
after OGG1 drug inhibition. 
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Journal: - 
Publication Date: In preparation 
Personal contribution: Sample preparation, proliferation studies, telomere oxidation protocol, 
phosphorylated γH2AX Immunofluorescence, statistical analysis and manuscript preparation.  
 
We have recently shown that the Single Nucleotide Polymorphism (SNP) rs2304277, 
located in the 3´ untranslated region (UTR) of the DNA glycosylase OGG1 from the Base 
Excision Repair Pathway (BER), modify cancer risk in patients harboring mutations in the BRCA1 
gene (Osorio et al. 2014). This association may be explained by a synthetic lethal/sickness 
interaction between these 2 genes. Indeed, we identified that the SNP, was associated to a 
constitutive OGG1 transcriptional downregulation that leads to both, genome and telomere 
instability in those patients harboring BRCA1 and BRCA2 mutations, explaining the contribution 
of this polymorphism to cancer risk (Benitez-Buelga et al. 2016). In order to explore the biological 
link between BER and the homologous recombination (HR) DNA repair pathway, we have tested 
the pharmacological inhibition of OGG1 enzyme, by using a panel of novel OGG1 inhibitors,  in 
a set of BRCA1 and BRCA2 deficient cancer cell lines. 
We have identified that in cells with the same genetic background, the inactivation of 
BRCA1 make cells very sensitive to OGG1 inhibitors. This inhibition in proliferation, after the 
treatment with OGG1 inhibitors, correlated with oxidative DNA damage accumulation and with 
phosphorylated γH2AX-foci formation at the nucleus in BRCA1 deficient cancer cells. 
These preliminary results, points to a synthetic lethal interaction between BRCA1 and 
OGG1, and open a new framework for the treatment of BRCA1 derived tumors. 
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 SYNTHETIC LETHALLITY IN BRCA1 DEFICIENT BREAST CANCER CELL LINES AFTER OGG1 DRUG 
INHIBITION 
Carlos Benitez-Buelga1; Torkild Visnes2; Armando Cázares-Körner2; Juan Miguel Baquero1; Tereza 
Vaclova1; Ana Osorio1,*; Thomas Helleday2; Javier Benitez1,* 
1 Human Genetic Group, Spanish National Cancer Research Institute (CNIO), and 3 Spanish Network on 
Rare Diseases (CIBERER) Madrid, Spain. 
2Medical Biochemistry and Biophysics, Division of Translational Medicine and Chemical Biology, Karolinska 
Institutet, Stockholm, Sweden.  
 *Spanish Network on Rare Diseases (CIBERER), Madrid 28029, Spain 
 
We have recently shown that the Single Nucleotide Polymorphism (SNP) rs2304277, 
located in the 3’ untranslated region (UTR) of the DNA glycosylase OGG1 from the Base Excision 
Repair Pathway (BER), modify cancer risk in patients harboring mutations in the BRCA1 gene 1. 
This association is likely explained by a synthetic lethal/sickness interaction between these two 
genes. Indeed, we identified that the SNP was associated to a constitutive hOGG1 transcriptional 
downregulation that leads to both genome and telomere instability in those patients harboring 
BRCA1 and BRCA2 mutations explaining the contribution of this polymorphism to cancer risk2. 
In order to explore the biological link between BER and the homologous recombination (HR) 
DNA repair pathway, we have tested the pharmacological  inhibition of OGG1 enzyme by using 
a panel of novel OGG1 inhibitors*  in a set of BRCA1 and BRCA2 deficient cancer cell lines. 
 
We have identified that in cells with the same genetic background, the inactivation of 
BRCA1 make cells very sensitive to OGG1 inhibitors. This inhibition in proliferation, after the 
treatment with OGG1 inhibitors, correlated with oxidative DNA damage accumulation and with 
GammaH2AX-foci formation at the nucleus in BRCA1 deficient cancer cells. 
These preliminary results point to a synthetic lethal interaction between BRCA1 and 
OGG1, and open a new framework for the treatment of BRCA1 mutated tumors. 
*OGG1 inhibitors have been develop entirely by Thomas Helleday lab (Scilifelab, KI). And are currently in process of being patented. 
 
INTRODUCTION 
 
Synthetic lethality can be defined as a type of genetic interaction where the co-
occurrence of two genetic events results in organism or cellular death3. Similarly, a genetic 
combination that yields non-lethal growth impairment is called synthetic sickness, and it is 
usually grouped together with synthetic lethal interactions. Although it is best known in the 
context of loss-of-function mutants, combinations of other types of perturbations such as 
genetic polymorphisms (SNPs), gene over-expression, action of chemical compounds or 
environmental changes can also result in synthetic lethality/sickness2,4. 
 
One of the most representative examples is the synthetic lethal interaction displayed by 
BRCA1 or BRCA2 loss of-function mutants and pharmacological inhibition of the Poly [ADP-
ribose] polymerase 1 (PARP-1). While BRCA1 and BRCA2 are key enzymes of the homologous 
recombination (HR) pathway, PARP1 enzyme assists in the repair of single-strand DNA nicks at 
the latest steps of the base excision repair (BER) and it is also able to repair double strand breaks 
when necessary. In the presence of a defective BRCA1 or BRCA2 background and PARP 
inhibitors, accumulation of double-strand DNA breaks (DSBs) can persist and lead to cell cycle 
arrest or cell death, making BRCA-deficient cells extremely sensitive to PARP inhibitors 
(PARPi)5,6.  
Recently, the PARP inhibitor Olaparib was FDA-approved for mono-therapy, in BRCA1 
and/or BRCA2 ovarian cancer patients7. However, resistance to PARPi has been observed in an 
important number of patients and at least 5 independent mechanisms of resistance to PARP 
inhibitors have been described in vivo until now 8–10. Hence, it is important to find alternative 
treatments and in this regard it is likely that other members of the BER pathway could have the 
potential of being targeted to generate novel inhibitors, with similar anticancer properties as 
Olaparib based on synthetic lethality/sickness for BRCA1 and/or BRCA2 derived tumors. 
 
Recently, we identified one SNP in a DNA glycosylase gene (OGG1) whose activity is 
required at the early steps of BER pathway. This SNP confers a higher risk to develop ovarian 
cancer among BRCA1 mutation carriers1.  
 
We have tried to explain this cancer association at a molecular level and we have found 
that the OGG1 SNP is associated with a constitutive OGG1 transcriptional down-regulation, 
which contributes to a higher genome and telomere instability, especially in those cells 
harboring mutations in BRCA1 and BRCA2 genes 2, pointing to a synthetic lethal interaction 
between both genetic events. Similarly to the action of PARP inhibitors, OGG1 and DNA 
glycosylase could be a potential therapeutic target for BRCA1 and BRCA2 related tumors. 
In general, inhibitors of BER show clinical benefit in two very different treatment protocols: 
 
The first, and similar to PARP inhibitors, applies as mono-therapy for tumors that have 
specific genetic deficiencies, usually in another DNA repair pathway11–13.For example, AP 
endonuclease-1 (APE1) inhibitors were shown to be synthetically lethal in BRCA and ATM 
deficient cancer cells resulting in accumulation of DNA DSBs and G2/M cell cycle arrest14. 
 
 The second approach is the combination of BER inhibitors with other drugs. For example, 
several groups have shown that the loss of the DNA glycosylase OGG1 sensitized cells to PARP1 
inhibitors15,16. 
 
Taking all this information together we have targeted theDNA glycosylase OGG1  using 
a novel set of small molecule OGG1 inhibitors developed at  Thomas Helleday’s laboratory, to 
test if BRCA1/2 deficient cancer cells are sensitized by these novel compounds. 
 
MATHERIAL & METHODS 
 
BRCA1 AND BRCA2 DEFICIENT CELLS 
 
Breast cancer cell line MDA-MB-231, derived from a sporadic breast cancer tumor, was 
obtained from the Cancer Epigenetics Group at the Bellvitge Institute for Biomedical Research 
(Barcelona, Spain). MDA-MB-231 was transduced by BRCA1-specific short-hairpin RNAs 
(shRNAs) or control shRNA (shScramble) and these newly generated cell lines were then used to 
confirm a synthetic lethal interaction between BRCA1 and OGG1. BRCA1 gene down-regulation 
was performed in MDA-MB-231 cell line using shRNAmir target gene set obtained from Open 
Biosystems (13 human GIPZ lentiviral shRNAmir individual clones; #RHS4531). 
 
Six different shRNA constructs were transduced, and one of them (sh1), which provided 
the best knockdown efficiency, was selected to silence BRCA1 in the breast cancer cell line 
(MDA-MB-231shBRCA1).  
 
Details in Supplementary figure 1a and figure1b/ Tereza Vaclová, Doctoral Thesis,2015 
. https://repositorio.uam.es/bitstream/handle/10486/665000/vaclova_tereza.pdf?sequence=1 
The BRCA1 deficient commercial breast cancer cell line MDA-MB-436, was obtained 
from ATCC (ATCC® HTB-130™). Finally, pancreatic BRCA2 deficient PL45 was obtained from the 
Epithelial Carcinogenesis Group, at the Spanish Cancer Research Center (CNIO). 
 
VIABILITY ASSAY 
 
MDA-MB-231 and MDA-MB-231 shBRCA1 or MDA-MB-436 and PL45 cells were 
seeded in 96- or 384-well plates (in duplicates) 4 h prior to OGG1 inhibitors treatment for 5 
days. The treatment consisted of a dilution series of active and control inactive OGG1 
inhibitors (16 different molecules) starting at 100 M. This initial concentration was used to 
generate a 1:2 dilution series, including 8 points. These dilution series was used to evaluate 
and compare the half maximal inhibitory concentration (IC50) for each cell line. Three 
independent experiments were performed. 
 
RESAZURIN PROLIFERATION ASSAY 
 
Resazurin sodium salt (Sigma-Aldrich) was added at a final concentration of 0.1 
mg/ml to the cell growth media. The plates were then incubated for 6 h before fluorescence 
readout at 535/590 nm in an Hidex Sense plate reader. The absorbance was normalized 
against background levels and the data processed in MS Excel by standard techniques before 
statistical analysis in XLfit (ID Business Solutions, Surrey, UK) to generate combination index 
plots.  
 
OXIDATIVE DNA DAMAGE WITHIN TELOMERES 
 
We used a qPCR-based method to evaluate the oxidative stress within telomeric DNA 
17, based on differences in PCR kinetics between DNA template digested by human purified 
Oxoguanine glycosylase (OGG1) plus Apurinic/apyrimidinic endonuclease (APE1) and 
undigested DNA. OGG1is a monofunctional DNA glycosylase that is specific for oxidized 
purines, principally 8-oxoG, producing apurinic sites (AP), which APE1 converts into single-
strand breaks (SSBs). 
 
These SSBs inhibit PCR reactions, thus, the ∆CT after digesting DNA by OGG1 / APE1 
(CT digested – CT undigested) is proportional to the oxidative damage in the amplified 
region. 
 
A total amount of 400 ng of genomic DNA was incubated with 12 and 6 units of OGG1or 
APE1, respectively in OGG1/APE1 buffer. Also, a control incubated with OGG1/APE1 buffer 
but without OGG1/APE1 (replaced with H2O), was prepared. All samples were set up on ice, 
then incubated at 37°C overnight (i.e., for 16 h) to allow complete digestion to occur. The 
digestion was verified by gel electrophoresis. 
 
The quantitative real-time amplification of genomic DNA was performed as described 
by O’Callaghan et al17. Delta Ct method was run in an ABI Quant studio 7 and all samples 
were loaded and analyzed in triplicate. Cycling conditions were 10 min at 95°C, followed by 
40 cycles of 95°C for 15 s and 60°C for 1 min. Three independent experiments were 
performed. 
 
γH2AX IMMUNOFLUORESCENCE 
 
MDA-MB-231 or MDA-MB-231 shBRCA1 cells were seeded on glass coverslips in 24-
well plates. Once cells attached to the coverslip (12 hours), cells were treated for 5d with 
TH5487 OGG1 inhibitor. Then cells were washed and incubated for 30 s with ice cold 0.1% 
Triton-X in PBS to pre-extract soluble protein and then fixed in 4% paraformaldehyde at room 
temperature for 10 min.  
 
Cells were washed again with PBS and incubated for 10 min with 5% bovine serum 
albumin (BSA), 0.1% Tween-20 in PBS. Cells were then incubated overnight at 4°C with primary 
antibody, anti-phospho-γH2AX (S139; 1:1000; Millipore) .The cells were then washed and 
incubated with secondary antibody anti-mouse IgG Alexa Fluor® 488 (1:1000, Life 
technologies). DNA was stained with 100 nM 4, 6 diamidino-2-phenylindole for 15 min. 
Finally, coverslip were mounted over the microscope slides and were processed for confocal 
microscope analysis. A total of 10 field were evaluated, each field contained around 50 cells. 
Pictures of each field were taken and measured using ImageJ software. 
 
INHIBITORS 
 
OGG1 inhibitors are in the process of being patented. Hence, chemical structures 
and/or biochemical information from these compounds is strictly confidential and protected 
under a material transfer agreement (MTA) signed between CNIO and Scilifelab, KI. 
 
RESULTS 
 
OGG1 INHIBITORS SENSITIZE BRCA1 INACTIVATED BREAST CANCER CELL LINES 
 
First we compared the drug inhibitory effect of 16 active and inactive control OGG1 
inhibitors, in MDA-MB-231 with functional BRCA1 protein versus MDA-MB-231 with 
constitutive small hairpin-mediated BRCA1 knockdown. We found that all but one OGG1 
inhibitor with sub-micromolar potency in the biochemical assay sensitize significantly more 
MDA-MB-231shBRCA1 compared to MDA-MB-231 with functional BRCA1 protein 
(p=0.00097)) (Figure 1 & Table 1), while OGG1 inhibitors with poorer biochemical potency 
(TH1796 and TH8020 were not toxic at all. Inactive control compounds were generally 
tolerated well by both cell lines. We repeated the proliferation studies including two 
additional commercial cells lines; MDA-MB-436 is a BRCA1 deficient breast cancer cell line, 
while PL45 is a pancreatic BRCA2 deficient cancer cell line. This time we used a 10 M single 
dose of TH5487 during 5 days to compare OGG1 inhibitor sensitivity among these BRCA1/2 
deficient cell lines. 
 
We have validate that MDA-MB436 breast cancer cells were significantly sensitized 
after 5 days of TH5487 exposure (p=0.002) (Figure 2). In contrast, we were not able to see 
the same effect in BRCA2 deficient PL45 pancreatic cancer cells (Figure 2). 
 
OGG1 INHIBITORS INDUCES TELOMERE OXIDATIVE DAMAGE 
 
We have adapted the original method from Nathan 2011 to detect oxidation at the 
telomere as a double strategy18. First, to detect oxidative DNA damage as a constitutive hallmark 
of genome instability, and second as a method for detecting the efficacy of the inhibitor in living 
cells. Since OGG1 remove 8-oxodG lesions, we expect that during the cell culture, in the 
presence of OGG1 inhibitors cells will accumulate more oxidative lesions in the DNA compared 
to those cells growing without OGG1 inhibitors. Since BER is active throughout the entire cell 
cycle19,  we expected to see changes in oxidative damage accumulation after 24hours of OGG1 
inhibitor exposure, equivalent to one doubling round for MDA-MB-231 and MDA-MB-
231shBRCA1 cells. 
 
When we compared MDA-MB-231 & MDA-MB-231shBRCA1 cells we observed similar 
levels of telomere oxidative DNA damage. After 24 hours of OGG1 inhibitor treatment, both cell 
types presented an increased accumulation of telomere oxidative DNA damage although this 
increment was not significant (Figure 3). On the other hand we have observed that telomere 
DNA oxidation was significantly increased in BRCA1 inactivated cells after the treatment with 
OGG1 inhibitors, compared to those with functional BRCA1 protein,(p=0.003) (figure3).These 
results suggest that in living cells the inhibitors are blocking the OGG1 enzymatic activity, 
especially in BRCA1 deficient cells. 
 
γH2AX IMMUNE-FLUORESCENCE (IF) 
 
Because oxidative lesions can be converted into DSBs if not repaired in a BRCA1 or 
BRCA2 deficient setting20, and we have detected a significant accumulation of oxidative lesions 
after 24hours exposure to TH5487 in BRCA1 inactivated MDA-MB-231 we have evaluated γH2AX 
as marker for DSBs. 
 
We have used the same set of cells (MDA-MB-231 & MDA-MB-231shBRCA1) in two 
different conditions: Cells unexposed or exposed to TH5487 during 5 days, time that was 
previously used to see an effect on proliferation. We have evaluated the contribution of TH5487 
on DNA damage. These two cell lines have an identical genetic background, but the BRCA1 
inactivation in the case of MDA-MB-231shBRCA1. 
 
We have detected that in MDA-MB-231 the exposure to TH5487 lead to γH2AX 
induction. In contrast in the case of the MDA-MB-231shBRCA1 it was possible to observe a basal 
γH2AX induction, in both untreated  and treated cells, likely caused by a defective HR DNA repair 
system (shBRCA1) (Figure 4). 
 
Finally, we could confirm a decrease in proliferation after the treatment with OGG1 
inhibitors that for both cell types; although it was more severe for MDA-MB-231shBRCA1. 
 
DISCUSSION 
 
Previously we have described that common polymorphisms in transcriptional regulatory 
regions of OGG1 DNA glycosylase, can modify ovarian cancer risk for BRCA1 mutation carriers1. 
The molecular mechanism underlying this association is unclear although this polymorphism is 
also associated with lower OGG1 transcript levels and with genome and telomere instability 
among BRCA1 and BRCA2 mutations carriers2. Under the hypothesis of a possible synthetic 
lethal/sickness interaction between BRCA1 and OGG1 to explain the molecular basis of this 
cancer association, we tested whether the pharmacological inhibition of OGG1 could sensitize 
BRCA1 or BRCA2 deficient cancer cells, similar as occurred with the recent FDA-approved 
Olaparib (PARP1 inhibitors) for BRCA1 and BRCA2 derived tumors. 
 
We have tested a set of novel molecules that effectively inhibit OGG1 enzymatic activity 
in vitro (Data not shown) in a breast cancer cell line (MDA-MB-231) with functional BRCA1 
protein and in the same cell line with BRCA1 inactivated through shRNA constructs, MDA-MB-
231shBRCA1.   
 
We have observed, that for this specific model the entire set of molecules sensitized 
preferentially MDA-MB-231shBRCA1 after 5 days of treatment compared to MDA-MB-231 with 
functional BRCA1 protein (Figure & Table1). In addition, we have confirmed this result in another 
BRCA1 deficient breast cancer commercial cell line (MDA-MB-436); in contrast, the pancreatic 
BRCA2 deficient cancer cell line PL45 was not sensitized at all by OGG1 inhibitors (Figure2).  
To explain the sensitization observed in BRCA1 deficient cells after pharmacological 
inhibition of OGG1, we have evaluated oxidative DNA damage accumulation and its conversion 
into DSBs in both MDA-MB-231 & MDA-MB-231shBRCA1 cells (Figure3). 
To study the accumulation of oxidative DNA damage,  we have modified a previously described 
protocol to detect oxidative lesions (8-oxoG) at the telomere region17. We can use this method 
to quantify the effectiveness of the OGG1 inhibitor molecule TH5487 in cultured cells.  
 
After 24 hours exposure to 10 µM TH5487 we could observe higher levels of oxidative 
damage at the telomere in both MDA-MB-231 and MDA-MB-231shBRCA1, suggesting that cells 
exposed to OGG1 inhibitor TH5487 cannot effectively repair endogenous oxidative DNA damage 
generated during cell culture, leading to an accumulation of these lesions at the telomere (Figure 
3).  
Accumulation of oxidative lesions was significantly higher in MDA-MB-231 shBRCA1 
compared to MDA-MB-231 breast cancer cells which suggest a role for BRCA1 in the repair of 
oxidative lesions at the telomere region. In relation with this, BRCA1  contributes to the repair 
of the 8-oxoguanine oxidative damage in human cells21 protecting against oxidative DNA 
damage being converted into double-strand breaks during DNA replication20. Hence, it is likely 
that BRCA1 could be involved in the oxidative DNA damage repair at telomeres, since there are 
evidence of BRCA1 protein interacting at telomeric regions 22,23. 
Finally, we could confirm by IF that after 5 days of TH5487 exposure, MDA-MB-231 
presented an induction of γH2AX nuclear signal and foci formation, figure 4. This may suggest 
that the inhibition of OGG1 could first lead to an accumulation of oxidative damage, that later 
is converted into DSBs contributing to a higher genome instability.  
Taking into account that DSBs are the most dangerous perturbation for DNA, and because BRCA1 
is a protein essential in the HR DNA that repairs DSBs, we believe that this could be the 
mechanistic explanation behind the effects observed in proliferation in MDA-MB-231shBRCA1 
when exposed to TH5487, OGG1 inhibitor. 
 
In summary, in the present report we have described how in cells with the same genetic 
background, inactivation of BRCA1 make cells very sensitive to OGG1 inhibitors. This effect in 
proliferation correlates with an accumulation of oxidative damage and γH2AX nuclear induction, 
and all together these evidences, together with previous ones1 points to a synthetic lethal 
interaction between OGG1 and BRCA1.   
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Figure1, A set of 16 molecules were initially tested. Proliferation curves, with decreasing concentration of different compounds are plotted in this figure.  In the first and 
the second panel were cells treated with decreasing concentration of DMSO (TH001796 and TH002840), and in the last panel cells were treated with an analog that has not 
any OGG1 inhibition properties (TH008020). Then, 13 molecules with in vitro OGG1 inhibition properties, were tested for MDA-MB-231 (Blue lines) and MDA-MB-
231shBRCA1. In most of the cases, the molecules showed a stronger and specific inhibition properties for MDA-MB-231shBRCA1 compared with MDA-MB-231 with both 
BRCA1 functional alleles. 
 Figure 2 Comparative analysis regarding the effect of TH5487 OGG1 inhibitor in the 
proliferation of 2 commercial BRCA1 and BRCA2 deficient cancer cells. A single dose of 10 
µMolar of TH5487 was exposed to cancer cells during 5 days, and fluorescence values 
(Resazurin) were compared between treated cells, non-treated (0 µMolar) or treated just with 
the vehicle in which the drug is dissolved (DMSO).BRCA1 defective breast cancer cells are 
significantly sensitive to OGG1 inhibitor TH5487 (p=0.002), while BRCA2 deficient cells were 
not significantly sensitive to the compound. 
 Figure 3 Accumulation of oxidative DNA damage in MDA-MB-231 Vs MDA-MB-231 (sh1) 
against BRCA1 in basal conditions, and after 5days treatment with the OGG1 inhibitor 
(TH5487). OGG1 inhibitor TH5487 induces telomere oxidation in BRCA1 inactivated cells after 
24hours of treatment at a 10µM single dose of TH5487.  
  
Figure 4 γH2AX immune-fluorescence in MDA-MB-231 Vs MDA-MB-231 (sh1) against BRCA1 in 
basal conditions, and after 5days treatment with the OGG1 inhibitor (TH5487). 
 
 
 
 
Compound ID Biochemical 
IC50 (µM) 
Cellular EC50 (µM) 
MDA-MB-231 
IC50 (µM)/MDA-MB-
231shBRCA1 
TH1796 9.5 >99 >99 
TH2840c > 99 >99 >99 
TH5411c > 99 34.78 43.53 
TH5487 0.465 14.37 3.54 
TH5680 0.848 11.02 2.7 
TH5682 0.728 21.82 12.1 
TH5793 0.488 34.61 22.6 
TH5796 0.766 14.03 7.79 
TH6744 0.683 34.32 29.5 
TH6747b > 99 >99 6.76a 
TH6748 0.886 13.08 5.77 
TH6830 0.603 33.65 3.8 
TH6840 0.551 9.84 2.73 
TH6850 0.379 6.25 1.31 
TH6943 0.149 12.17 5.75 
TH8020 2.92 >99 >99 
 
Table1 Comparision of biochemical IC50 values of tested OGG1 inhibitors to cellular EC50 
values for MDA-MD-231 with or without BRCA1 knockdown. TH5487, used for follow up 
experiments, is displayed in red.  a) Plateau at 40% viability. b) TH6748 is inactive in vitro, but 
have the possibility to be converted to an active compound in cellulo. c) TH2840 and TH5411 
are inactive compounds that are structural similar chemical controls for the active OGG1 
inhibitors. 
 
  
Supplementary figure 1. BRCA1 silencing ability of a set of human GIPZ lentiviral shRNAmir. A) 
Western blot analysis of BRCA1 protein expression in MDA-MB-231 cells, parental or transduced with 6 
BRCA1-specific shRNA clones (sh1–6) or control shRNA (shScramble). Nucleolin was used as a loading 
control for nuclear proteins. B) Relative BRCA1 mRNA expression in cells overexpressing non-targeting 
shRNA or BRCA1-specific sh1 or sh5.  
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EXAMPLES OF TELOMERE LENGTH DYSREGULATION 
AS A CAUSE OF CANCER/DISEASE DEVELOPMENT 
 
Defects in genes involved in telomere maintenance (shelterin complex or telomerase) 
result in a wide spectrum of overlapping symptoms (Kirwan & Dokal 2008), which converge in 
disruption of telomere length regulation and end protection, and finally in disease manifestation.  
In article 5 and article 6, two examples of telomere length dysregulation caused by defects in 
genes from the shelterin or telomerase complex are described. In these examples, disease 
manifestation is not exclusively associated with telomere shortening. Telomere length 
equilibrium is maintained by both telomerase and the shelterin complex, and aberrant telomere 
elongation or shortening can converge in disease manifestation. 
 
Personal contribution 
In these two articles, I contributed by measuring TL (qPCR) in samples of interest, and doing the 
corresponding statistical analyses. 
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A mutation in the POT1 gene is responsible for cardiac 
angiosarcoma in TP53-negative Li-Fraumeni-like families. 
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Cardiac angiosarcoma (CAS) is a rare malignant tumour whose genetic basis is unknown. 
Here we show, by whole-exome sequencing of a TP53-negative Li–Fraumeni-like (LFL) family 
including CAS cases, that a missense variant in POT1 (protection of telomeres 1) gene is 
responsible for CAS. The same gene alteration is found in two other LFL families with CAS, 
supporting the causal effect of the identified mutation. We extend the analysis to TP53-negative 
LFL families with no CAS and find the same mutation in a breast AS family. The mutation is 
recently found once in 121,324 studied alleles in ExAC server but it is not described in any other 
database or found in 1,520 Spanish controls. In silico structural analysis suggests how the 
mutation disrupts POT1 structure. Functional and in vitro studies demonstrate that carriers of the 
mutation show reduced telomere-bound POT1 levels, abnormally long telomeres and increased 
telomere fragility.  
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Cardiac angiosarcoma (CAS) is a rare malignant tumour whose genetic basis is unknown.
Here we show, by whole-exome sequencing of a TP53-negative Li–Fraumeni-like (LFL) family
including CAS cases, that a missense variant (p.R117C) in POT1 (protection of telomeres 1) gene
is responsible for CAS. The same gene alteration is found in two other LFL families with CAS,
supporting the causal effect of the identiﬁed mutation. We extend the analysis to
TP53-negative LFL families with no CAS and ﬁnd the same mutation in a breast AS family. The
mutation is recently found once in 121,324 studied alleles in ExAC server but it is not
described in any other database or found in 1,520 Spanish controls. In silico structural analysis
suggests how the mutation disrupts POT1 structure. Functional and in vitro studies
demonstrate that carriers of the mutation show reduced telomere-bound POT1 levels,
abnormally long telomeres and increased telomere fragility.
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T
he incidence of primary cardiac tumours is estimated to be
between 0.001 and 0.003% in general population1. Cardiac
angiosarcoma (CAS) is a very rare malignant tumour that
represents o10% of cardiac malignancies Patients are generally
diagnosed at advanced stages with very poor prognosis and short
survivals2. Patients with sporadic AS had a 5-year survival rate of
14% while familial cancer patients had a mean survival time of
4 months. Age of familial CAS onset shows a wide range but most
patients affected are younger than 65 years of age2. Information
about familial CAS is very scarce and as far as we now, only two
families have been reported presenting both an earlier age of
onset than sporadic3,4 No genes responsible for these cases have
been identiﬁed so far, thus humpering early diagnosis and
effective treatment, which involves surgical excision combined
with chemotherapy, and heart transplantation only for patients
with no evidence for metastasis.
On the other hand, Li–Fraumeni syndrome (LFS) is
characterized by the presence of different types of tumours
including sarcomas and ASs in multiple locations such as liver,
spleen, breast, head and neck, and rarely heart5. In most cases,
LFS is triggered by the mutations in the TP53 gene (480%),
which is the causal gene that confers susceptibility to the
development of different tumours. In addition, Li–Fraumeni-like
(LFL) families have similar clinical presentation and family
characteristics. However, they are generally diagnosed at a
later age of onset and rarely associated with mutations in TP53
(o20% of cases)6,7.
Here we describe the identiﬁcation by whole-exome
sequencing of POT1 (protection of telomeres 1) gene as
responsible of TP53-negative LFL families with CAS, as well as
other tumour types.
POT1 is a component of the so-called shelterin complex
(POT1, TRF1, TRF2, TIN2, TPP1 and RAP1) that binds to
telomeres and has fundamental roles in chromosome stability and
regulation of telomerase activity at chromosome ends8,9.
POT1 possesses two N-terminal OB domains, which confer to
this protein high speciﬁcity for single-stranded DNA sequence
50-TAGGGTTAG-30, thereby binding to the telomeric G-strand
overhang10–12. In addition, POT1 binds through its C terminus
to TPP1 and anchors POT1 to the shelterin complex at
telomeres13–15. POT1 regulates telomere length (TL) by
preventing telomerase access to telomeres by sequestering the
DNA terminus12,16,17. POT1 loss-of-function mutations have
been related with telomere lengthening and chromosomal
instability18,19. Recently, germline mutations in the POT1 gene
were found in familial melanoma and glioma tumours20–22,
as well as in somatic chronic lymphocytic leukemia (CLL)23.
Here we identify a new missense variant in POT1 (p.R117C) as
responsible of LFL locus speciﬁcally associated with CAS and
demonstrate that mutation carriers show reduced telomere-
bound POT1 levels, abnormally long telomeres and increased
telomere fragility, highlighting a new role of POT1 as a high
susceptibility gene in familial cancer and opening therapeutical
opportunities for prognosis and treatment in families with CAS.
Results
Whole-exome sequencing (WES) and candidate variant studies.
A TP53-negative LFL Spanish family with three CAS cases and
eight members with different tumours across generations were
ascertained from the Cancer Genetic Consultancy of CNIO,
(Fig. 1 and Table 1). Two members affected by CAS (II-10 and
III-13) were selected for WES (Fig. 1; Methods for details). About
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Figure 1 | Pedigrees of TP53-negative LFL families. Families 1, 2 and 3 have three, two and one members with cardiac angiosarcomas (CAS),
respectively. CAS and other tumours are shown (colour code below the Fig.). Exomes of blue-squared CAS cases were sequenced. One member of family
4 presented with breast angiosarcoma. Only family members of whom DNA samples were available are numbered (1–19) in bold and italics. Age of
onset (CAS cases) and age of sample (mutation carriers) is shown in brackets. Age of onset of other tumours is shown in the Table 1. ‘*’ indicates
immortalized lymphocyte cell lines from family 1: II-1 and II-4 (64- and 65-years old, respectively) and III-15 and III-16 (34- and 35-years old, respectively).
‘**’ indicates parafﬁn-embedded tumour tissue available. Black arrows show the probandus for each family.
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85% of target regions were observed with coverage420 . After
ﬁltering according to our homemade pipeline and GATK-based
variant calling (Methods), we only found 394 variants in common
between both samples, which were used for downstream
ﬁltering. Ten variants fulﬁlled our prioritization criteria, taking
forward annotation and putative damaging effects into account
(Supplementary Table 1). After Sanger validation and segregation
studies in other members of this family, variants annotated
in POT1 (Chr7:124503601G4A), SPEG (chr2:220355477) and
EIF2AK (chr2:37347280) were validated. We decided to further
study POT1, as other germline and somatic mutations of this
gene were recently found in familial melanoma and glioma
tumours20–22, as well as in CLL23, respectively. POT1 variant
found in both CAS members (p.R117C) was highly deleterious
and was neither described in the Exome variant server, Ensembl,
dbSNP, 1000 genomes and COSMIC databases nor present
in melanoma and glioma families with POT1 mutations20–22.
The variant was recently found once (heterozygous) in 121,324
studied alleles (frequency: 8.2 10 6) in ExAC server. p.R117C
mutation was not found in 1,520 Spanish control individuals.
We could study the complete POT1 gene in two additional
Spanish LFL families with CAS (Fig. 1, families 2 and 3) and
strikingly, we found the same variant p.R117C. Then, we
extended the study of the POT1 gene to 19 probands belonging
to TP53-negative LFL families, with no CAS. Nine of them had
developed different AS types and 10 presented with sarcomas
(Table 1). We found one Spanish family with breast AS and other
tumours carrying the same mutation.
We assessed the founder effect of the mutation, by performing
haplotype studies with seven single nucleotide polymorphisms
(SNPs) covering the gene (Methods). Six different haplotypes
were found from the analysis of control Spanish families. Only
families 1 and 2 had enough members for this study and both
presented the most frequent haplotype (42%) (Supplementary
Table 2).
In silico studies. The p.R117 position is highly conserved across
selected representative species that suggest the same residue for
the last common ancestor within the phylogeny (Fig. 2a).
Table 1 | Tumour types of different members of the studied families.
p.R117C Family Tumour type
Sarcoma Breast CNS Melanoma Lung Other Multiple primary
tumours*
Angiosarcoma Soft Bone NS
Present 1 Carriers 3 CAS
(24,45,58)**
1 (69) 1 (93) 1 (48) 2 (47,61) 1
melanomaþCAS
NT 1 (56) 1 (43)
2 Carriers 2 CAS (32,41)
NT 1 liver (54) 1
kidney (50)
3 Carriers 2 CAS (40)
4 Carriers 1 breast (32) 1 PTC (35) 1 BAþ PTC
NT 1 lymphoma
(38)
Not
Present
5 3
(41,45,50)
1 (U) 2
astroc.
(12,24)
1 NHL
neuroﬁbromas
(24)
1 astroc.
þNHLþCM
6 1 (42) 1
astroc.
(12)
1 CRC (40)
7 2 (45,49) 2 stomach
(65,68), 2 CCR
(27,71)
8 1 (2) 1 (44) 1 (63) 1 CRC (58)
9 1 (21) 2 (45, 45)
10 2 (2,15) 1 (45) 1 EC (16) 1 CRC
(26)
1
STSþ ECþCRC
11 2 (13,38) 1 (35) 1 STSþ BC
12 2 (54,68)
13 1 (7) 1 (28) 1
bilateral
(35,39)
1 (54) 1 kidney 1 CM
14 1 (U) 2 (U) 1 GBM
(U)
1 stomach, 1
ovarian 1 NHL
1 BCþ STS
15 1 breast (22) 2 (43,50) 1 head&neck
(45) 1CRC (70)
16 1 chest wall
(56)
1 bilateral
(48,61) 1
(80)
1 peritoneum
(58)
1 CMþAS
17 1 breast (32) 1 ALL (15) 1 ALLþ BA
18 1 breast (57) 2 (49,58) 1 prostate (51) 1 CMþ BA
19 2 bilateral
breast (37,39)
1 (50) 1 (60)
20 1 breast (42) 1 bilateral
(37,45) 1
(64)
1 CMþ BAþ BC
21 1 thigh (17) 1 (U)
22 1 breast (15)
ALL, acute lymphoblastic leukemia; AS, angiosarcoma; astroc., astrocytic tumour; BA, breast angiosarcoma; BC, breast cancer; CAS, cardiac angiosarcoma; CM, cutaneous melanoma; CNS, central
nervous system; CRC, colorectal cancer; EC, endometrial cancer; GBM, glioblastoma multiforme; NHL, non-Hodgkin Lymphoma; NS, not speciﬁed; NT, not tested; PTC, papillary thyroid carcinoma;
STS, soft tissue sarcoma; U, unknown.
Tumours of the members of family 1 without DNA sample were NT. Age at diagnosis is shown in brackets.
*Multiple primary tumours refer to tumour types described in one individual.
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p.R117C mutation was located within the OB1/OB2 domains of
the protein, similarly to the germline mutations found in familial
melanoma and glioma20–22 (Table 2). Tolerance to independent
amino acid (aa) substitutions was calculated in a heat map
representation using PredictProtein24 showing a highly
deleterious effect (Fig. 2b).
Position p.117 was found to be part of a short linear peptide
motif of a disordered/unstructured region based on previous
predictions10 (hot loops), which have a critical conformation25
and are related to alterations in predicted accessibility and protein
ﬂexibility. Thus, the PACC (predicted solvent accessibility in
square Angstroem) was calculated for the residues of POT1R117C
protein model that were described to be located within the
OB fold (from p.142 to p.152) and with stacking interaction to
DNA (p.31, p.62, p.89, p.161, p223, p.245, p.266 and p.271) in
POT1 protein according to the study by Lei et al.10 Two residues
(p.152 and p.266) had signiﬁcantly different PACC scores in
POT1R117C protein model (Supplementary Table 3). p.152 and
p.266 are oriented closed together and located at the border of
domains OB1 and OB2. The consequence of this accessibility
change predicts a disruption of the interaction between OB1 and
OB2 in a putative three-dimensional model of the POT1R117C
protein (Fig. 2c).
To complete the study of these putative conformational
changes observed in POT1R117C, PACC scores for the
same residues were calculated for predicted protein models
encompassing previously described mutations in the OB1 domain
in melanoma and glioma tumours (p.Y89C and p.Q94E20,
p.G95C22, and p.R137H21). Moreover, we also included a
protein model with a deletion from p.1 to p.126 residues
(POT1DOB1) as described by Loayza and De Lange12 and a
second protein model encompassing a deletion of the whole OB1
domain (cd04497: hPOT1_OB1_like (E-value: 3.43e-45); interval
from p.10 to p.141). Both p.152 and p.266 PACC score changes
observed in POT1R117C were not found in the rest of the studied
protein models (Supplementary Table 3).
Finally, we searched for the putative protein–protein-binding
regions of wild-type (wt) POT1 protein and 14 positions
were found to be signiﬁcantly relevant (threshold420)
(Supplementary Table 4). The same positions were studied in
all mutated protein models. A putative protein-binding region
annotated in position p.499 was signiﬁcantly lost in the
POT1R117C protein model (Supplementary Table 4). p.499 is a
well-conserved position with high deleterious tolerance to aa
change (86,4) at the conserved POT1 C terminus within the
TPP1-binding domain (Fig. 2b)13. Interestingly, this protein-
binding region was lost in the protein model with the deletion of
the whole OB1 domain (from p.10 to p.141) but was unaffected in
the other mutant models and POT1DOB1 (with a deletion in OB1
domain from p.1 to p.126) (ref. 12).
Expression and protein studies. To study whether the missense
variant (p.R117C) affects POT1 transcriptional and protein levels,
we performed quantitative PCR (qPCR) from complementary
DNA (cDNA) and western blot (WB) analyses from primary
lymphocytes (PL) from carriers and in non-carriers. We found no
signiﬁcant differences in POT1 mRNA levels in PL from carriers
compared with non-carriers (Supplementary Fig. 1). Similarly,
we did not ﬁnd signiﬁcant differences in POT1 protein levels
(two-tailed student’s t-test, P¼ 0.1) as determined by WB
(Supplementary Fig. 1). Next, we set to determine POT1 levels
localized at telomeres by double immunoﬂuorescence with POT1
and TRF1 antibodies (another telomere-binding protein from the
shelterin complex used here to localize telomeres)26. To this end,
we used immortalized lymphoblastoid cell lines (LCLs) derived
from members II-1, II-4, III-15 and III-16 (Fig. 1, family 1).
Immunoﬂuorescence levels with anti-TRF1 antibody were similar
for all family members independently of the carrier status
(Fig. 3a,b). In contrast, the intensity of POT1 telomeric foci was
signiﬁcantly lower in p.R117C carriers (two-tailed student’s t-test,
Po0.0001) than controls and there was also a decrease in the
number of co-localizations (Fig. 3a,b).
To address the effect of this mutation on the binding of POT1
to telomeric chromatin in vivo, we performed chromatin
immunoprecipitation (ChiP) with the four LCLs using antibodies
against POT1, TRF1 and TRF2 (Methods). The hybridization
signal of telomeric DNA immunoprecipitated with anti-TRF1 and
anti-TRF2 (positive telomeric controls) was not signiﬁcantly
different in mutation carriers compared with non-carriers
(Fig. 3c). However, a signiﬁcant reduction of hybridization
signal was observed in mutation carriers when telomeric DNA
was immunoprecipitated with anti-POT1 antibodies (two-tailed
student’s t-test, P¼ 0.004).
POT1 is recruited to telomere through interaction with TPP1
(ref. 13). The reduced levels of telomere-bound POT1 observed in
mutation carriers (Fig. 3a–c), as well as the in silico analysis
(Supplementary Table 4) suggest that POT1R117C might be
defective in TPP1 binding. To test this, we performed co-
immunoprecipitation assays with in vitro-translated MYC-tagged
POT1R117C and FLAG-tagged TPP1. As controls, we used
MYC-tagged wt POT1 and a mutant MYC-POT1DOB1 that has
been shown to be defective in single strand DNA binding but
functional in its interaction with TPP1 (ref. 12). In addition, we
also used a FLAG-tagged mutant TPP1OBD that lacks both the
POT1 and TIN2 interaction domain27. Equal amounts of the
different MYC-POT1 and FLAG-TPP1 variants were mixed as
indicated and TPP1-POT1 complexes immunoprecipitated
with anti-MYC antibody (Fig. 3d; Supplementary Fig. 2). As
expected, FLAG-TPP1 was pulled down with MYC-POT1 and
MYC-POT1DOB1 while FLAG-TPP1OBD was not detected with
any of the POT1 variants used in the assay. However, immuno-
precipitation of MYC-POT1R117C recovered FLAG-TPP1 to a
much lesser extent than wt MYC-POT1. Indeed, FLAG-TPP1 was
only faintly detected when the immunoblots were developed
under long exposure time (Fig. 3d). These results conﬁrmed that
mutant POT1R117C is affected in its ability to bind TPP1.
We next sought to determine whether the p.R117C substitution
affected the ability of POT1 to bind to the 30 end of the G-rich
telomeric overhang, as suggested by the in silico analysis. In vitro-
translated MYC-POT1, MYC-POT1DOB1 and MYC-POT1R117C
were incubated with radio-labelled telomeric single-stranded
DNA (ssDNA) and with c-MYC (9E10) antibody. Visualization
of the protein-DNA complexes by electrophoretic mobility
shift assay conﬁrmed that wt POT1 efﬁciently bound telomeric
ssDNA, whereas POT1R117C bound telomeric ssDNA less
efﬁciently (Fig. 3e; Supplementary Fig. 2). As expected,
POT1DOB1 was unable to bind to the telomeric sequence.
Studies in telomeres. In line with dysfunctional POT1 that is
usually associated with increased DNA damage at telomeres
(the so-called telomere-induced foci (TIF)) and occurrence of
telomere fragility, we observed signiﬁcantly increased multi-
telomeric signal events (MTS) in mutation carriers compared
with non-carriers (two-tailed student’s t-test, Po0.0001) (Fig. 3f)
and an increase of positive cells for gH2AX (two-tailed student’s
t-test, P¼ 0.05) a DNA damage marker (Fig. 3g). Double
immunoﬂuorescence staining with gH2AX and TRF1 antibodies
was performed to determine TIFs. The results showed a sig-
niﬁcant increase in the percentage of cells with more than ﬁve
TIFs in carriers as compared with non-carriers (two-tailed
student’s t-test, P¼ 0.003) (Fig. 3g). Of note, we did not observe
end-to end fusions in mutation carriers.
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We evaluated the effect of the p.R117C mutation in TL.
We measured it by qPCR in peripheral blood lymphocytes
from members of family 1. TL values were adjusted for age.
We consistently found longer telomeres in mutation carriers
compared with non-carriers (two-tailed student’s t-test, P¼ 0.02)
(Fig. 4a). TL was also calculated with ﬂuorescence in situ
hybridization quantitative detection (quantitative ﬂuorescence
in situ hybridization (qFISH))28 and we validated that TL was
signiﬁcantly longer in mutation carriers compared with controls
(two-tailed student’s t-test, Po0.0001) (Fig. 4b). In addition, a
higher percentage of short telomeres o3 kb was found in non-
carriers compared with p.R117C mutant carriers comparing older
members (II-1 and II-4, 64.5 old in average) (Fig. 4c). Otherwise,
no signiﬁcant differences among members of family 1 were found
regarding in vitro telomeric repeat ampliﬁcation (TRAP)
telomerase activity (Fig. 4d).
Abnormal telomeres elongation could be the consequence of
increased telomere recombination, to the so-called alternative
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Figure 2 | In silico studies. (a) Amino acid conservation across representative phylogeny of POT1 orthologues (tet, Tetraodon nigroviridis; xen, Xenopus
laevis; gal, Gallus gallus; hum, Homo sapiens; mou, Mus musculus). The mouse POT1a gene sequence was used in the alignment. Position p.117 is shown in
blue; mutations described in previous studies are shown in yellow. Triangles indicate positions with putative conformational changes (red) and loss of
TPP1-binding site (green) due to the p.R117C mutation. ‘*’ indicates amino acid (aa) conserved in all POT1 orthologues. (b) Heat map representation shows
the tolerance to independent aa substitutions (y-axis) for each position of the protein (x-axis). Dark red indicates the highest score for a deleterious effect
(score 100); white indicates a small effect; green indicates a neutral effect/no effect (score  100); and black represents the corresponding wild-type
residue. Deleteriousness effect score is shown for highlighted positions. (c) Putative tertiary structure. p.152 and p.266 residues change PACC score value
driving a putative protein conformation change. Left: homology-based three-dimensional model of human POT1 (Uniprot, Q9NUX5). Right: structural
impact of the p.R117C mutation using the same algorithm from Protein Model Portal (Uniprot, PSI_SBKB). Black triangle shows the loop where p.117 is
located. Red triangles show the principal detected structural changes (p.152 and p.266). Blue arrows show OB1 and OB2 domains.
Table 2 | Deleterious germinal mutations described in the POT1 gene.
Position Allele Exon Amino acid change Domain Source
g.124503601 G4A 4 p.Arg117Cys OB1 *
g.124503684 T4C 4 p.Tyr89Cys OB1 Robles-Espinoza et al.20
g.124503670 G4C 4 p.Gln94Glu OB1
g.124493077 C4A 6 p.Arg273Leu OB2
g.124465412 C4T 14 Splice site Telomere/TPP1 binding
g.124503540 C4T 4 p.Arg137His OB1 Shi et al.21w
g.124499043 C4T 5 p.Asp224Asn OB2
g.124493086 C4T 6 p.Ser270Asn OB2
g.124469308 C4G 13 p.Ala532Pro Telomere/TPP1 binding
g.124464052 C4G 15 p.Gln623His Telomere/TPP1 binding
g.124503667 C4A 4 p.Gly95Cys OB1
g.124481048 C4A 10 p.Glu450z Telomere/TPP1 binding Bainbridge et al.22
g.124464068 TTA4T 15 p.Asp617Glu (fs) Telomere/TPP1 binding
fs, frame shift; POT1, protection of telomeres 1.
*Mutation described in the present study.
wFounder mutation.
zStop codon.
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Figure 3 | POT1R117C mutation affects telomere binding and induces telomeric damage. (a) Quantiﬁcation of telomere-bound TRF1 (left panel) and POT1
(right panel) protein levels in immortalized LCLs corresponding to p.R117C carriers and non-carriers. Two independent experiments with replicated samples
were performed. a.u.f., arbitrary units of ﬂuorescence. (b) Representative images of TRF1 (red) and POT1 (green) double immunoﬂuorescence in wild-type
and p.R117C carriers. White arrows indicate colocalization of both proteins (yellow spots). Scale bar, 5 mm. (c) Quantiﬁcation of telomeric DNA bound to
POT1, TRF1 and TRF2 by ChIP analysis. IgG was used as negative control. Results were normalized to input chromatin. Black bars, wild-type; grey bars,
p.R117C carriers. Two independent experiments from each genotype were performed. Lower panel: representative ChIP dot-blot is shown. (d) Left panel:
western blot analysis of in vitro-translated FLAG-TPP1, FLAG-TPP1OBD, MYC-POT1, MYC-POT1R117C and MYC-POT1DOB1. Right Panel: p.R117C substitution
decreased POT1 binding capacity to TPP1. Co-immunoprecipitation assays of the in vitro-translated proteins. FLAG-TPP1 was pulled down with MYC
antibody and revealed by FLAG antibody. FLAG-TPP1 lacking the TIN2 and POT1 binding domain, FLAG-TPP1OBD, and a POT1 mutant lacking its OB1
domain were used as controls. Two exposures are showed. (e) p.R117C substitution decreased POT1 binding capacity to telomeric ssDNA. Electrophoretic
mobility shift assay of [32P]-labelled oligonucleotide (50-TTAGGG-30)7 in the presence of the indicated in vitro-translated POT1 proteins. Data from two
independent experiments are shown in d,e. (f) Upper panel: quantiﬁcation of multitelomeric signal (MTS) events per metaphase in primary lymphocytes
by telomeric FISH (n¼ 2 in triplicate). Lower panel: example of MTS (white arrows). Red ﬂuorescence shows telomere signals. Scale bar, 5 mm.
(g) Quantiﬁcation of cells positive for gH2AX (left) and per cent of cells with 45 telomeric induced foci (TIFs) (right) in immortalized LCLs (n¼ 2 in
triplicate). Lower panel: representative images of gH2AX and TRF1 immunoﬂuorescence. White arrows show examples of TIFs (yellow spots) with
anti-TRF1 (green ﬂuorescence) and anti-gH2AX (red ﬂuorescence). Scale bar, 5mm. Values are expressed as meanþ s.e. The two-tailed student’s unpaired
t-test was used for the statistical analysis, NS, not signiﬁcant. DAPI (blue) was used for DNA labelling.
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lengthening of telomeres (ALT). We evaluated this possibility by
quantiﬁcation of recombination events speciﬁcally at telomeric
repeats, the so-called telomere sister chromatid exchanges
(T-SCEs). We observed a similar frequency of T-SCE in
mutations carriers (0.43±0.14) compared with wt controls
(0.29±0.19) (Fig. 4e) ruling out a possible ALT mechanism of
telomere elongation in lymphocytes.
Finally, parafﬁn-embedded tissues were also studied. Loss of
heterozygosity of POT1 locus was evaluated in four CAS tumours
from families 1 and 2. Loss of heterozygosity was observed in only
one of the studied cases while the other three cases presented a
heterozygosis proﬁle. The three CAS tumours from families 2 and
3 (one also with normal cardiac tissue) were also studied for
ultra-bright spots (ubs) in telomeres. FISH for ubs in telomeres
showed an increased number of ubs-positive signals (5.56 positive
signals 100/total signals on average) compared with normal
tissue (0.68 positive signals 100/total signals; Fig. 4f). This
alteration correlated with the TL of tumours, which was highly
increased compared with wt samples (P¼ 0.0001) and mutation
carriers (P¼ 0.0075) adjusted for age (two-tailed student’s t-test)
(Fig. 4g).
In vitro experiments. As the identiﬁed mutation is present in
heterozygosis in all the analysed carriers, we hypothesize that
POT1R117C protein functions in a dominant-negative manner.
To further validate this possibility, we create heterologous Hela
cell lines using retroviral vectors to express wt MYC-POT1,
MYC-POT1R117C and MYC-POT DOB1 alleles26 in the presence of
endogenous POT1. Double immunoﬂuorescence microscopy
analysis with MYC and TRF1 antibodies of Hela cells showed
that wt and mutant Myc-POT1DOB1 proteins but no cells
expressing the MYC epitope alone (empty vector) show
colocalization of both telomeric proteins MYC-POT1 and
TRF1. Hela cells expressing MYC-POT1R117C showed a similar
pattern than those expressing the vector alone and only few cells
presented few MYC foci that colocalized with TRF1 (Fig. 5a,b).
Quantiﬁcation of TRF1 nuclear intensity revealed no signiﬁcant
differences among Hela cells expressing either the empty vector
or the wt and mutant POT1 alleles (Fig. 5a,b). Decreased amount
of telomere bound of MYC-POT1R117C protein in Hela cells is in
agreement with the decreased amount of protein observed in
lymphocytes by immunoﬂuorescence and ChIP analysis using
POT1 antibodies (Fig. 3a–c).
To address, whether heterologously MYC-POT1R117C over-
expression recapitulates the observed effects in lymphocytes
we analysed the functional effects of POT1R117C expression
in Hela cells. TL in Hela cells infected with retroviral empty
vector, MYC-POT1, MYC-POT1R117C and MYC-POT1DOB1 was
measured by quantitative telomere FISH on metaphase spreads.
Increased TL was observed in both Hela cells expressing
MYC-POT1DOB1 and MYC-POT1R117C compared with both cells
infected with empty vector and MYC-POT1 after 30 population
doublings (Fig. 5c,f).
Finally, analysis of chromosome aberrations in metaphase
spreads of the different transduced Hela cells, revealed a moderate
but signiﬁcant increase in MTS events in those expressing
MYC-POT1R117C and MYC-POT1DOB1 as compared with those
expressing either the empty vector or wt MYC-POT1 (Fig. 5d,f).
In addition, an increase in gH2AX-positive cells was detected
in Hela cells infected with MYC-POT1R117C as compared with
those harbouring either the empty vector, MYC-POT1 wt or
MYC-POT1DOB1 (Fig. 5e).
Discusion
We have found a novel damaging missense variant (p.R117C) in
the POT1 gene in TP53-negative LFL families with CAS and other
tumours. Mutations in POT1 were recently associated with
familial melanoma20,21 and glioma22 and as a driver for CLL23,
uncovering a new role of this gene not only as telomere protector,
but also as one of the main responsible genes for development of
different familial cancer types. The mutation was the same in the
four studied families. Haplotype studies suggested a possible
founder effect within the Spanish population although larger
studies are necessary to conﬁrm this issue.
There are several consequences of this mutation that we have
demonstrated by in silico, in vivo and in vitro studies. Thus,
in silico studies showed that the p.R117C substitution putatively
disrupted the interaction between OB1 and OB2 (Fig. 2d) and
affect the protein-binding site to TPP1 (Supplementary Table 4),
which might result in the loss of capability of the POT1R117C
protein to interact with ssDNA and to be recruited to telomeres.
The predicted conformation change might be explained as a
consequence of the substitution of a polar basic aa (Arginine)
with a non-polar thiol aa (Cysteine) at position p.117 with the
capability to generate disulﬁde bonds.
In silico analyses were conﬁrmed by in vivo assays analysing
the binding of mutated POT1 protein to telomeres. Double
immunoﬂuorescence with POT1 and TRF1 in immortalized LCLs
suggests that the variant has an important effect on the levels of
POT1 at telomeres by showing signiﬁcant decreased levels in
mutation carriers. In vitro assays demonstrated that POT1R117C is
deﬁcient at both, in TPP1 interaction and in telomeric ssDNA
binding, affecting POT1 function.
Although the mutation was located within the OB1/OB2
domains of the protein, similarly to the germline mutations found
in familial melanoma and glioma20–22 (Table 2), it was speciﬁc of
CAS. In fact, only a member from family 1 carrying the mutation
(II-6) developed melanoma, and no members from reported
families with melanoma or gliomas carrying POT1 mutations
presented CAS20–22. The fourth family (Fig. 1, family 4) did not
have any member with CAS but the family structure was small
and we cannot rule out the possibility that asymptomatic carriers
of the mutation will develop a CAS in the future.
These ﬁndings stress the importance of POT1 domains in
cancer development and raise the intriguing open question about
the correlation between the genotype and the phenotype. Our
in silico studies suggest that the putative conformational changes
in POT1 proteins due to the mutations described in melanoma
and glioma tumours are different from those observed for
POT1R117C (Supplementary Tables 3 and 4). Because POT1 is
described in tight coordination with the rest of shelterin complex
proteins, we cannot rule out that different conformational changes
might have different effects on the shelterin complex function.
Similarly to other members of the shelterin complex, disrup-
tion of POT1 function was associated to increased DNA damage
at telomeres and occurrence of telomere fragility23. In our case,
defective POT1R117C function has shown to lead to a moderate
increase in MTS, and in telomere DNA damage, that could
account for the genomic instability that these cases present.
Moreover, increased TL was conﬁrmed in mutation carriers. This
is in agreement with previously described POT1 mutations in
CLL and familial melanoma and glioma patients that showed
abnormally elongated telomeres20–23. In our cases, TL was
markedly different between mutation carriers and non-carriers
within older members, suggesting that there was a cumulative
effect in telomere elongation with age (Fig. 4b,c). Differences
observed in the amount of telomeres shorter than 3Kb in older
members suggest a downfall in the telomere shortening through
aging, indicating abnormal telomere biology in mutation carriers.
We showed similar in vitro TRAP telomerase activity levels in
both carriers and non-carriers, indicating no defects in telomerase
assembly or function (Fig. 4d). Thus, the longer telomeres
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observed in mutation carriers are rather due to alterations in
in vivo telomerase recruitment and function on telomeres. In fact,
POT1 has been shown to be important to prevent telomerase
access to telomeres by sequestering the DNA terminus12,16,17. We
show that POT1R117C is defective in both binding to TPP1 and
binding to ssDNA telomeric DNA. It is therefore tempting to
speculate that POT1R117C fails to inhibit telomerase due to the
reduced telomere-bound POT1R117C, as well as to defective
binding to telomeric G-strand overhang. In addition, given the
defective binding of POT1R117C to single G-strand overhang
(Fig. 3d,e), telomeric damage could also stem from defective
maintenance of the 30 G-strand overhang needed for proper
T-loop formation. Indeed, abnormal telomere elongation due to
the consequence of increased telomere recombination (ALT) was
ruled out as no differences in T-SCE were found in lymphocytes
between carriers and non-carriers. Thus, lack of functional POT1
seems to affect telomere structure and expose them to abnormal
elongation by a normal telomerase activity.
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Figure 4 | POT1R117C carriers present longer telomeres. (a) Telomere length (TL) analysis by qPCR (t/s ratio) for family 1 members (n¼ 29).
(b) TL analysis by qFISH of primary immortalized LCLs corresponding to non-carriers (II-1 and III-16) and p.R117C carriers (II-4 and III-15). (c) Percentage
of telomeres shorter than 3 kb of primary immortalized LCLs corresponding to non-carriers (II-1 and III-16) and p.R117C carriers (II-4 and III-15). (d) TRAP
Tel/IC ratio values for telomerase activity calculated from primary lymphocytes of different members of family 1 (n¼ 7). In b–d two independent
experiments with samples in triplicate were performed. (e) Left panel: number of telomere sister chromatid exchange (T-SCE) events/metaphase in
primary lymphocytes by CO-FISH (n¼ 2 individuals per genotype in triplicate). Right panels: representative CO-FISH images showing the leading (green)
and lagging (red) telomere strands. T-SCEs are indicated with arrows. DAPI (blue) was used for DNA labelling. Below a magniﬁed merge image is shown.
Scale bar, 1mm. (f) Upper panel: per cent of cells positive for ultra-bright spots (ubs) at telomeres by FISH in three different parafﬁn-embedded cardiac
tumour (T) and normal (N) tissue samples carrying the mutation from members of family 2 (F2) and 3 (F3). Lower panel: examples of large red spots
corresponding to positive signals (white arrows). DAPI (blue) was used for DNA labelling. Scale bar, 10mm. (g) TL adjusted for age of wt and p.R117C
carriers of all members of families 1, 2 and 3 and the 3 CAS tumours. DNA from CAS samples was extracted from parafﬁn-embedded tissues. Values are
expressed as meanþ s.e. and the two-tailed student’s unpaired t-test was used for the statistical analysis, NS, not signiﬁcant.
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Figure 5 | Heterologous POT1R117C expression induces telomere lengthening. (a) Representative images of MYC (green) and TRF1 (red) double
immunoﬂuorescence in Hela cells with endogenous expression of POT1 protein infected with retroviral empty vector, MYC-POT1, MYC-POT1R117C and
MYC-POT1DOB1. DAPI (blue) was used to DNA labelling. Scale bar, 5 mm. (b) Quantiﬁcation of MYC-POT1 and TRF1 colocalization foci (left panel) and of
nuclear TRF1 foci intensity (right panel) (a.u.f., arbitrary units of ﬂuorescence) in Hela cells infected with retroviral empty vector, MYC-POT1, MYC-POT1R117C
and MYC-POT1DOB1. (c,d) Quantiﬁcation of nuclear telomere length per metaphase (a.u.f) (c) and of multitelomeric signal (MTS) events/metaphase
(d) in Hela cells infected with retroviral empty vector, MYC-POT1, MYC-POT1R117C and MYC-POT1DOB1. (e) Per cent of gH2AX-positive cells in Hela cells
infected with retroviral empty vector, MYC-POT1, MYC-POT1R117C and MYC-POT1DOB1. (f) Representative qFISH images of metaphase spreads. Examples of
MTS are shown in the magniﬁed insets (arrow). Red ﬂuorescence shows telomere signal. DAPI (blue) was used for DNA labelling. Scale bar, 5 mm.
Two independent infections were performed. Values are expressed as meanþ s.e. The two-tailed student’s unpaired t-test was used for the statistical
analysis, NS, not signiﬁcant.
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The telomeric phenotypes observed in lymphocytes from
p.R117C variant carriers were validated by in vitro studies in
Hela cell lines created using retroviral vectors expressing wt
MYC-POT1, MYC-POT1R117C and MYC-POT1DOB1 (ref. 26)
in the presence of endogenous POT1. We conﬁrmed that
the POT1R117C protein acts in a dominant-negative manner,
analogous to that previously reported for the POT1DOB1
mutant26, as well as for others POT1 variants found in CLL23.
In this system, we also detected decreased POT1R117C protein
levels at telomeres, moderate increase in MTS incidence, higher
telomeric DNA damage and a telomere lengthening effect. So, it is
tempting to speculate that telomere elongation induced by this
mutation in POT1 may constitute the underlying molecular
mechanism favouring tumour incidence.
The identiﬁcation of POT1 mutation in CAS is important,
since it provides the possibility for earlier diagnosis of people at
risk. Currently this tumour is diagnosed in advanced stages when
distant metastases are present and the survival is very poor, as
surgical resection is not effective. Larger studies are necessary to
fully assess the clinical spectrum associated with this mutation
and other mutations along the whole POT1 gene. Future work is
needed to address POT1R117C relation not only with familial but
also with sporadic CAS and its role in LFL cases including ASs
other than cardiac.
Methods
Patients. Index cases from LFL families negative for mutations and large deletions
of the TP53 gene were selected for this study. Three of our families had members
affected with CAS plus other tumours (Fig. 1). The rest of the families fulﬁlled the
LFL criteria but they did not have any member with a CAS tumour (Table 1).
Families were selected from the Spanish National Cancer Research Center (CNIO),
Hospital Puerta de Hierro and Clara Campal Center (Spain), and Rouen University
Hospital (France). DNA from most of the family members and whenever possible
total mRNA and protein were collected from lymphocytes.
A group of 1,520 samples from a Spanish control population was used
for genotyping the POT1 variant by denaturing high performance liquid
chromatography29. Heteroduplex was ampliﬁed with primers of the exon 4, which
encompassed the candidate variant (Supplementary Table 5). Genotyping was
performed with WAVE Nucleic Acid Fragment System from Transgeomics and
Navigator Software. Ampliﬁcation was performed with standard conditions
((95 C, 5min; (44 C, 30 seg.; 64 C, 30 seg.; 72 C, 45 seg.) 30 cycle; 72 C,
10min.).
The study was approved by the ethics committee of the different centres and
informed consent was obtained from all participants.
Establishment of B LCLs. Lymphoblasts from different members of family 1 were
immortalized: II-1 (aged 64), II-4 (aged 65), III-15 (aged 35) and III-16 (aged 34).
LCLs were established by Epstein–Barr virus (EBV) transformation/infection
of peripheral blood mononuclear cells (PBMC)30. PBMCs were incubated with
B95-8 cell supernatant (containing EBV in the presence of 10 mgml 1 of
phytohemagglutinin in R.P.M.I1640 supplemented with 20% (v/v) heat-inactivated,
foetal calf serum, 2mM of L-Glutamine, 100Uml 1 of penicillin, 100mgml 1 of
streptomycin and 0.5 mgml 1 of Amphotericin B (Gibco, Invitrogen)). Cells were
plated and incubated at 37 C, 5% CO2 and routinely grown in R.P.M.I1640 culture
medium supplemented with 10% heat-inactivated foetal calf serum, 2mM of
L-Glutamine, 100Uml 1 of penicillin and 100 mgml 1 of streptomycin.
Parafﬁn-embedded tissue samples. Parafﬁn-embedded tissue samples of CAS
members from families 2 and 3 were collected (Fig. 1). DNA was extracted using
the DNeasy Blood & Tissue Kit (Cat. No. 69504, Qiagen) following the manu-
facturer’s instructions. Selected tumour tissue was evaluated a pathologist (C.S.).
Whole-exome sequencing. Exomes from two members of family 1 with CAS
(II-10 and III-13) were captured and enriched using the SureSelect Human All
Exon Kit (78Mb) (Agilent Technologies). Enriched samples were paired-end
sequenced on an Illumina Genome Analyzer II sequencing platform, using two
lanes per sample and generating 78-bp-long reads. Filtering of reads and variant
calling were done with the Rubioseq software suite of parallelized pipelines31. PCR
duplicates, overrepresented sequences and low quality reads were ﬁltered with a
modular set of analyses considering per base and per sequence quality scores
(Fastqc 430) and N content.
BWA ﬁles of short reads were aligned with the genome of reference
(GRCh37/hg19). GATK-based variant calling was performed for aligned reads
considering DP (read depth) values of430 and QD (quality by depth) scores for a
variant conﬁdence of 41.00. A MAF o3% of was considered. Variants were also
ﬁltered by position (non-synonymous, essential splice site, frame shift or gain/loss
of stops). Their potential damaging effect was assessed using the VEP32 script
software package (including Sift, Polyphen and Condel damage predictors) from
Ensembl.
Filtered variants were prioritized for segregation studies when they were
(i) previously described in other pathogenic processes (COSMIC database),
(ii) annotated in genes with related functions or involved in tumourogenetic
processes, and (iii) annotated in genes suggested to be related to cardiac function.
Prioritized variants from 10 candidate genes were validated by Sanger
sequencing and segregation studies were performed among the different members
of family 1. Candidate variants that were found in the three CAS cases and
mediastinal tumour patients were selected. PCR was performed using standard
conditions (95 C, 5min; (44 C, 30 s.; * C, 30 s.; 72 C, 45 s) 30 cycle; 72 C,
10min). *: C annealing of the corresponding primer. Sequences of the primers are
listed in Supplementary Table 5.
POT1 gene study. Sanger sequencing of the candidate POT1 variant was
performed in 19 probands from LFL families negative for TP53 mutations. The
entire POT1 gene was sequenced for cases negative for the candidate mutation. The
primers used for Sanger sequencing of the 15 exons are listed in Supplementary
Table 5. PCR was performed using standard conditions ((95T C, 5min; (44T C,
30 s; *T C, 30 s; 72 C, 45 s) 30 cycle; 72T C, 10min). *: T C annealing of the
corresponding primer.
Haplotype study. A haplotype study was performed to conﬁrm the possible
founder effect of our variant. Seven SNPs covering the gene were used
(Supplementary Table 2). Selected trios (parent and two offspring) from families
1 and 2 were studied to establish the haplotype carrying the mutation. Trios from
15 healthy Spanish families were used to determine the different haplotypes in the
Spanish population and their frequencies. The primers used for Sanger sequencing
of the seven SNPs are listed in Supplementary Table 5.
Real-time qPCR. Expression studies for POT1 gene genes was performed with
Real-Time qPCR with cDNA obtained from reverse transcription of 1,200 ng of
total RNA from PBMCs using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems #4368814). PCR was carried out with B25 ng ml 1 of cDNA
and the POWER SYBR green PCR Master Mix (Applied Biosystems #4367659).
Quantiﬁcation was performed using Sequence Detection System 7900HT (Applied
Biosystems). Expression levels were evaluated with the DDCt method33 in triplicate
and normalized to the expression levels of GAPDH, which was used as a standard.
PCR was run with exon 10 forward primer and exon 11 reverse primer to avoid
ampliﬁcation of genomic DNA (Supplementary Table 5). PCR was performed
using standard conditions (95T C, 5min; (44T C, 30 seg.; 58T C, 30 seg.; 72 C,
45 seg.) 30 cycle; 72T C, 10min).
Western blotting. WB was performed with 50 mg of total protein isolated
from lysed PBMCs. Protein expression levels of POT1 were determined using
rabbit polyclonal anti-POT1 antibody and normalized to GAPDH levels using
anti-GAPDH antibody (Supplementary Table 6). The hybridization signal was
quantiﬁed using ImageJ 1.43 u software (W. Rasband, the National Institutes of
Health). Protein expression was evaluated with the DDCt method33.
ChIP assay. ChIP assays were performed with LCLs from family 1. Cells in culture
were cross-linked with formaldehyde (1%) during 15min at room temperature.
The cross linking reaction was stopped by addition of glycine (0.125M) during
5min. Cells were washed twice with cold PBS, collected by centrifugation and lysed
in lysis buffer (1%SDS, 10mM EDTA, 50mM Tris-HCl pH 8.0, protease inhibitors
(P8340, Sigma)). Protein/DNA extracts were sonicated and centrifuged at
14,000 r.p.m. for 15min. Protein concentration was determined (DC protein
assay, Bio-Rad), and chromatin from 200 mg total protein extract was used per
immunoprecipitation with 4 ml of either anti-POT1, anti-TRF2 or anti-TRF1
antibody (Supplementary Table 6) and protein A/G PLUS-agarose beads (Santa
Cruz Biotechnology, sc-2003)34. The immunoprecipitated DNA was transferred to
a Hybond Nþ membrane using a dot-blot apparatus. The membrane was then
hybridized with a telomeric probe containing 1.6 kb of 50-TTAGGG-30 repeats.
Quantiﬁcation of the signal was performed with ImageQuant software (Molecular
Dynamics). The amount of telomeric DNA after ChIP was normalized to the total
input telomeric DNA.
Bioinformatics tools to assess the in silico studies. Heat map representation of
independent substitutions for each position of the protein and aa tolerance test was
performed with PredictProtein24. Secondary structures (b-strands, a-helix and
loops) of the putative POT1 model were based on REPROFSec prediction. The
predictions of the annotation (minimum REPROFSEc score of 5) of conserved
secondary structures and evolutionary proﬁles for POT1 carrying the p.R117C
mutation were based on several original prediction methods (NORSnet,
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DISOPRED2, PROFbval and Ucon) implemented in PredictProtein24. Solvent
accessibility notation (PACC) was annotated using the PROFAcc prediction
algorithm35 also implemented in ProteinPredict24. Protein binding regions were
found using the ISIS algorithm36 and SomeNA predictor method (also
implemented in ProteinPredict24). Annotation of residues was based on
crystallography studies of POT1 (ref. 10). A homology-based three-dimensional
model of human POT1 was taken from Uniprot (Q9NUX5). Protein modelling for
POT1 carrying the p.R117C mutation (PSI_SBKB) was performed using the
Protein model portal (available at http://www.proteinmodelportal.org/).
Real-time qPCR of TL. TL was measured by qPCR using DNA from blood
samples. Quantiﬁcation of TL (t/s ratio) was done through quantiﬁcation of
telomere repeat copy number (t) and the 36B4 reference gene (s)37. Telomere
repeats were ampliﬁed with TEL primers (tel 1, 50-GGTTTTTGAGGGTGAGG
GTGAGGGTGAGGGTGAGGGT-30 ; tel 2, 50-TCCCGACTATCCCTATCCCTA
TCCCTATCCCTATCC-CTA-30), and 36B4 gene was ampliﬁed with 36B4u
(50-CAGCAAGTGGGAAGGTGTAATCC-30) and 36B4d (50-CCCATTCTATCA
TCAACGGGTACAA-30) primers37. The ﬁnal TL value for each sample was
determined under standard conditions in three independent measurements.
Independent measurements had a correlation of r 0.80. The coefﬁcient of variation
was obtained for telomere (average 5%, range 1–50%) and 36B4 (average 1.7%,
range 0.02–16%). TL values were adjusted for age by calculating a regression line
with 330 DNA controls38. Each sample was adjusted for the difference between the
observed TL and the predicted value using the regression line. Following this
method we adjusted t/s values obtained by qPCR (y¼  0.0174xþ 1.96). PCR was
performed using standard conditions (see real-time qPCR section).
High-throughput qFISH. Mononuclear cells (150,000) from PBMCs were plated
in triplicate onto Poly-L-Lysine pre-coated Greiner 96-well plates for 4 h at 37 C.
Poly-L-Lysine was removed before cell addition (100,000 lymphocytes per well).
When lymphocytes attached to the wells, cells were washed three times with
PBS and then ﬁxed during 1 h at room temperature with methanol/acetic acid
(3:1 vol/vol). The plates were overnight dried at 37 C. The cells were rehydrated in
PBS during 15min, ﬁxed for 1min in 4% formaldehyde, treated with pepsin
(1mgml 1, pH 2.0) at 37 C for 10min, washed with PBS, ﬁxed for 1min in 4%
formaldehyde, washed with PBS and dehydrated in a ethanol series (70, 90, 100%).
The Cy-3-labelled (C3TA2)3 PNA probe (Perseptive Biosystems, Bedford, MA) was
dissolved in a hybridization buffer containing 70% formamide/10mM Tris pH
7.0/0.25% (w/v) blocking reagent (0.5 mgml 1) (Dupont, Boston, MA). The
hybridization mixture was placed onto the wells, followed by DNA denaturation
(5min, 85 C). After hybridization (2 h, room temperature), slides were
washed twice with 70% formamide/0.1% BSA/10mM Tris pH 7.2 for 15min,
followed by three washes of 5min in TBS-Tween 0.08% containing DAPI
(40 ,6-diamidino-2-phenylindole). The cells were dehydrated in a ethanol series
(70, 90, 100%) and air dried. Finally, Moviol mounting medium was added to
the wells28. Wells were sealed (Alumaseal; Sigma-Aldrich) and stored at 4 C in
the dark. Samples were processed by High-throughput microscopy within 48 h
after sample preparation by using the Opera-Acapella system (Perkin Elmer) for
image acquisition and analysis28. TL values were calculated using individual
telomere spots.
Telomeric FISH on metaphase spreads. Primary mononuclear cells from
peripheral blood (PBMCs) were stimulated with 7.5 ngml 1 12-O-
tetradecanoylphorbol-13-acetate in R.P.M.I medium supplemented with FBS,
penicillin-streptomycin, b-mercaptoethanol, sodium pyruvate, nonessential aa and
L-glutamine. Colcemid was added at a concentration of 0.1 mgml 1 during 12 h.
Cells were then recovered, subjected to hypotonic shock and ﬁxed in methanol/
acetic acid (3:1). QFISH hybridization on metaphase spreads was performed as
described above for HT-QFISH39. Metaphase spreads were captured on a Leitz
Leica DMRB ﬂuorescence microscope. At least 10 metaphase spreads per subject
were analysed, and chromosomal aberrations were quantiﬁed and represented as
frequency per metaphase.
Measurement of T-SCE events by chromosome orientation FISH. Measurement
of sister telomere recombination events (T-SCE) was performed using chromo-
some orientation FISH (CO-FISH). Mononuclear cells from peripheral blood
(PBMCs) were stimulated as above and sub-cultured in the presence of BrdU
(50-bromo-20-deoxyuridine; Sigma) at a ﬁnal concentration of 1 10 5M, and
then allowed to replicate their DNA once at 37 C for 24 h. Colcemid was added at
a concentration of 0.1 mgml 1 during the last 6 h. Cells were then recovered,
subjected to hypotonic shock and ﬁxed in methanol/acetic acid (3:1). CO-FISH was
performed using ﬁrst a telomeric (50-CCCTAA-30)7 PNA probe labelled with Cy3
and then a second telomeric (50-TTAGGG-30)7 PNA probe labelled with Alexa-488
(Supplementary Table 6)40. Metaphase spreads were captured on a ﬂuorescence
microscope (DMRB).
Retroviral expression. The pLPC-human MYC-POT1 and pLPC-human MYC-
POT1DOB1 (deleted OB1 domain) plasmids were a gift of de Lange (Addgene
plasmid 12387 and 13241)12. The POT1 variant encoding p.R117C change,
MYC-POT1R117C, was generated by site-directed mutagenesis of the pLPC-human
MYC-POT1 using the QuickChange XL site-directed mutagenesis kit (Agilent
Technologies) using oligonucleotides hPOT1-R117C-F (50-gggagcccctatcatacctTgc
acttcaagcaagtat-30) and hPOT1-R117C-R (50-atacttgcttgaagtgcAaggtatgataggggct
ccc-30). Retroviruses were packaged in 293T cells (ATCC-CRL-3216) using
pCL-Ampho packaging vector. Hela cells (ATCC-CCL-2) were seeded onto p-10
plates to 30% of conﬂuency 24 h before infection. Three consecutive infections
every 12 h were performed by adding 5ml of viral supernatant. Cells were allowed
to recover for 24 h in growth medium before undergoing selection with puromycin
for 3 days. Cells then underwent serial passaging and collected at the indicated
population doubling points.
Inmunoﬂuorescence staining techniques. Lymphoblastoid (this work) and Hela
(ATCC-CCL-2) cells were plated onto Poly-L-Lysine pre-coated coverslips, treated
for 5min with Triton X-100 buffer41 for nuclear extraction, ﬁxed for 10min in 4%
buffered formaldehyde, permeabilized with 0.2% PBS-Triton for 5min and blocked
with foetal bovine serum in PBS for 1 h. Samples were incubated o/n at 4 C with
the primary antibody at 1:250 dilution. TIFs were detected using rabbit polyclonal
anti-TRF1 and a mouse monoclonal antibody raised against phospho-histone2
H2AX-Ser139 (gH2AX) (Supplementary Table 6). Telomeric POT1 and TRF1 foci
were detected using a rabbit polyclonal anti-POT1 and a mouse monoclonal
antibody anti-TRF1 (Supplementary Table 6). MYC-POT1 was detected using a
mouse monoclonal c-MYC antibody. Slides were further incubated with 488-Alexa
or 555-Alexa-labelled secondary antibodies (Supplementary Table 6). Slides were
mounted in Vectashield with DAPI. Confocal microscopy was performed at room
temperature with a laser-scanning microscope (TCS SP5; Leica) using a Plan Apo
63Å-1.40 numerical aperture oil immersion objective (HCX; Leica). Maximal
projection of Z-stack images generated using advanced ﬂuorescence software (LAS)
was analysed with the Deﬁniens XD software package. The DAPI images were used
to detect signals inside the nuclei.
TRAP analysis. Telomerase activity was measured using protein extract from
PBMCs cultured in RPMI supplemented with 20% FBS and phytohemagglutinin
during 4–5 days. Telomerase activity was determined under recommended
standard conditions of the TRAPEZE Telomerase Detection S7700 Kit (Millipore)
for TRAP using radioisotopic detection. Telomerase activity was determined in
each sample using 0.5, 0.25 and 0.125mg of protein extract and normalized with the
internal control included in the assay38.
Ultra-bright telomere spots in parafﬁn-embedded tissue. Ultra-bright telomere
spots were detected by FISH on parafﬁn-embedded tissue slides. The Histology
FISH Accessory Kit (DAKO) was used following the manufacturer’s instructions.
A telomere-speciﬁc PNA-Cy3-labelled probe (DAKO) was used for the detection
of ubs42. Tissue images were captured using a CCD camera with focus motor
(Photometrics SenSys camera) connected to a PC running the Cytovision image
analysis system (Applied Imaging Ltd., UK) and Z-stack software.
G-strand binding and co-immunoprecipitation assays. The TNT-coupled
reticulocyte lysate kit (Promega) was used to in vitro synthesize MYC-POT1,
MYC-POT1R117C, MYC-POT1DOB1, FLAG-TPP1 and FLAG-TPP1OBD
(refs 12,27). For co-immunoprecipitation assays, 3 ml of either MYC-POT1,
MYC-POT1R117C or MYC-POT1DOB1 with either 3 ml of either FLAG-TPP1 or
FLAG-TPP1OBD translation reaction and incubated at 37 C for 20min. About
500 ml of NETN buffer (20mM Tris pH 8.0, 100mM NaCl, 1mM EDTA, 0.5%
NP-40) and 1 mg of anti-MYC (9E10) were added to each protein mix and
incubated at 4 C. The antibody complexes were pulled down with protein A/G
agarose beads, washed four times with NETN and eluted with 40 ml 2 SDS
loading buffer. The eluted proteins (10 ml) were separated by SDS–PAGE, trans-
ferred to nitrocellulose membranes and probed with a monoclonal FLAG antibody.
DNA-binding assays were performed in 20 ml reaction mixtures, 5 ml of each
translation reaction was incubated with 10 nM 50-[32P]-labelled telomeric
oligonucleotide containing seven TTAGGG repeats, 1 mg of the nonspeciﬁc
competitor DNA poly (dI-dC) and 2 ml of anti c-MYC (9E10) (C-40, Santa Cruz
Biotechnology) in binding buffer (25mM HEPES-NaOH pH 7.5, 100mM NaCl,
1mM EDTA and 5% glycerol)23. Reactions were incubated for 10min at room
temperature, and protein-DNA complexes were analysed by electrophoresis on a
6% polyacrylamide Tris-borate EDTA gel run at 80V for 3 h.
Statistics. Signiﬁcance of expression differences among individuals grouped
according to genotype (wt versus mutation carriers) was evaluated with the
non-parametric Kolmogorov–Smirnov test to determine normal distribution of
values within the groups. Student’s t-test was used for comparison of normally
distributed values among genotypes. Differences were considered to be signiﬁcant
when the exact P value was o0.05.
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Study approval. Written informed consent was received from participants prior to
inclusion in the study.
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Supplementary Figure 1: Analyses of family 1 members. The T-student’s t –test was used for the statistical analysis of normal 
distributed values. a) Comparison of mRNA expression levels between POT1 wild type (wt) and p.R117C mutation carriers.    
normalized with GAPDH as control b) Values of POT1 protein levels for several members of family 1 (n=7) normalized for GAPDH 
control . There was a trend towards decreased POT1 levels in mutation carriers (1.91±0.69) compared with non-carriers (1.21±0.2) 
(p=0.1). 
 
 
Supplementary Figure 2: Uncropped scans of the gels/blots. (a) Western blots presented in 
Figure 3d and (b) of the electrophoretic mobility shift assay (EMSA) presented in Figure 3e. 
The molecular weight ladder is shown to the right of each blot. 
Supplementary Table 1: Candidate variants to study further segregation in members of family 1. 
 
Prioritization 
Criteria Variant position GENE 
Protein 
change 
 
Function 
Tissue 
expression COSMIC/Pathology/ 
Described in 
COSMIC 
 
 
chr1:1238583 ACAP3 Arg62Cys 
arf-GAP with coiled-coil, ANK repeat 
and PH domain-containing protein 3 Lung COSM527726 
chr15:71535077 
 
THSD4 
 
Thr185Met 
 
A disintegrin and metalloproteinase 
with thrombospondin motifs-like 
protein 6 
Lung 
 
COSM555837 
 
chr7:5112796 
 
RBAK 
 
Leu227Phe 
 
RB-associated KRAB zinc finger 
protein  
pleomorphic sarcoma (RB1) 
 
Function 
Related 
 
 
chr7:124503601 
 
POT1 
 
Arg117Cys 
 
Telomere end-binding protein 
 
Blood/ 
nervous 
Gastric carcinoma, 
melanoma, glioma  
chr2:37347280 EIF2AK Ser316* Apoptosis  p53 related 
chr7:151945007 
 
 
MLL3 
 
 
Gly838Ser 
 
 
Lysine N-methyltransferase 2C 
 
 
Muscular 
 
 
myeloid/lymphoid or mixed-
lineage leukemia 
Tissue 
Related 
  
chr5:79030433 CYMA5 His1949Tyr  Cardiac  
chr2:220355477 SPEG Val3062Leu Differentiation Aortic    
chr1:161721670 DUSP12 Phe158Ser Protein-tyrosine phosphatase   
chr10:81932595 ANXA11 Phe8Leu Annexin     
 
*Stop codon 
Supplementary Table 2: Haplotype frequency study for families 1and 2. 
 
SNP Position Annotation MAF 1* 2 3 4 5 6 
rs67585224 124537476 Intron 1 0.21 A C A A A C 
rs68091803 124526331 Intron 2 0.20 T T T T T T 
rs7784168 124492038 Intron 6 0.28 C C T T T T 
rs7801661 124483222 Intron 8 0.21 T C T T T T 
rs35536751 124481185 Exon10 0.01 C C C C C C 
rs17246404 124462661 3'UTR 0.20 C T C T C T 
rs76436625 124462655 3UTR 0.12 T T T T C T 
Frequency    42.0% 21.1% 7.7% 7.7% 3.3% 2.2% 
 
* Unique haplotype found in different members of families 1 and 2. 
MAF: Minor Allele Frequency. 
Supplementary Table 3: In silico PACC score of aa annotated in the OB fold and described stacking to DNA (T1-G10) 14 for POT1 proteins 
with mutations within OB1 domain (Categorization is shown in brackets). 
 
Interaction    Postion (aa) WT p.Y89>C p.Q94>G p.G95>C p.R117>C p.R137>H OBDelta* OBDelta** 
OB fold 146 122(E)  122(E)  122(E)  122(E)  122(E)  122(E)  122(E)  97(E)  
 147 93(E)  117(E)  93(E)  93(E)  93(E)  117(E)  117(E)  93(E)  
 148 45(I) 45(I) 45(I) 45(I) 45(I) 45(I) 95(E)  45(I) 
 149 59(E)  59(E)  79(E)  59(E)  59(E)  59(E)  59(E)  59(E)  
 150 19(I) 9(B) 19(I) 9(B) 9(B) 9(B) 9(B) 9(B) 
 151 32(I) 32(I) 32(I) 32(I) 61(I) 9(B) 19(I) 49(I) 
 152 86(E)  86(E)  86(E)  86(E)  0(B)  61(I)  86(E)  86(E)  
T1; T2 62 0(B) 0(B) 0(B) 0(B) 0(B) 0(B) - - 
A3; G4 89 26(I) 16(I) 26(I) 26(I) 26(I) 26(I) - - 
G5; G6 31 0(B) 0(B) 0(B) 0(B) 0(B) 0(B) - - 
T7 271 26(I) 26(I) 26(I) 26(I) 26(I) 26(I) 66(I) 66(I) 
 161 0(B) 0(B) 0(B) 0(B) 0(B) 0(B) 0(B) 0(B) 
 245 0(B) 0(B) 0(B) 0(B) 0(B) 0(B) 0(B) 0(B) 
T8; A9 266 36(I) 0(B) 36(I) 22(I) 0(B) 0(B) 55(I) 22(I) 
G10 223 0(B) 0(B) 0(B) 0(B) 0(B) 0(B) 0(B) 0(B) 
 
*: 1-126 deletion; **: 10-141 deletion; (E): Exposed; (I): Intermediate; (B): Buried 
Highlighted in grey: Most significant changes 
Supplementary Table 4: In silico protein-protein interaction score for positions with significant acceptance in wt POT1 (threshold >20) for POT1 
proteins with mutations within OB1 domain. 
Position (aa) WT p.Y89>C p.Q94>G p.G95>C p.R117>C p.R137>H OBDelta* OBDelta** 
1 (M) 26 26 26 26 28 24 NA 19 
2 (S) 30 31 26 30 27 24 NA 10 
3 (L) 27 25 25 28 25 21 NA -23 
39 (K) 26 24 24 24 24 22 NA NA 
91 (K) 26 29 29 28 31 29 NA NA 
253 (S) 33 28 35 34 30 36 38 32 
254 (E) 28 19 24 25 31 31 21 28 
255 (N) 34 23 26 28 36 36 29 38 
341 (Q) 23 23 15 13 21 28 23 19 
363 (R) 47 48 47 48 47 49 49 42 
427 (K) 23 21 23 29 20 26 10 10 
428 (N) 23 17 20 23 17 22 10 6 
499 (H) 21 19 16 20 -24 15 18 -23 
599 (A) 28 23 17 23 24 28 23 19 
 
*: 1-126 deletion; **: 10-141 deletion; NA: Not applicable 
Highlighted in grey: Most significant changes 
 
 
 
 
Supplementary Table 5: Primers used for variant validation and further segregation and for POT1 gene and 
haplotype studies. 
 
Gene 
Position of the 
variant  Forward Reverse TºC 
Product 
size (bp) 
ACAP3 chr1:1238583 GCTGGTGAAGCTGTGCAGT GTAGGCTGTCAGCGAACCTC 57 338 
THSD4 chr15:71535077 CCCTGGCAAGTATGGCTATG ACTTGAAGCTGCAGGGTAGC 64 286 
RBAK chr7:5112796 TTCTAGCCAGCACCAGGAAG CCCAAAAGGAAACAGCACCT 64 364 
POT1 chr7:124503601 AATGATGCTCCGTCCACTTC TGGTTCGTAGGTTGTGCATC 64 351 
EIF2AK chr2:37347280 ATGTTGGCCAGACTGGTTTC CCGGAGTAGCTGGGACTACA 64 609 
MLL3 chr7:151945007 TCAGTCACTCCAAAAATTGG TGGCATTCTTCATTAACAGCA 65 260 
CYMA5 chr5:79030433 GATGTTGGGAAAGCCAGAAA GAATCTCCTTCCCCTCTGCT 59 350 
SPEG chr2:220355477 GCCACACTCCAGGGTTATTG AAGATCGTGCCCTATGCTG 64 245 
DUSP12 chr1:161721670 TGCAGGAGTCAGTCGAAGTG TCTCAGGGATTGCTGGAAGT 64 405 
ANXA11 chr10:81932595 GAGGAGGGGAGTGAGGAAAC CACCAGCAGGAGACAGTGAA 64 326 
Gene EXON Forward Reverse TºC 
Product 
size (bp) 
POT1 1 TTAGGCTGGAGATGGGTAAAA CACATGTATCTATGTGTGTGGCATA 60 589 
 2.1 CATGGATTTGCTGCTAATATGAT AATGCATTTCCACTCCAAAAA 58 246 
 2.2 AATTGTACCATTTATAAACAAAGTTC GCATCAGTGTTGTTTGGCAAT 58 451 
 3 TGCTTTAAAATATTGAAAGTCAGG CAGTGAACAATACAGAGTTCTCTTCAA 58 238 
 4 TGGTTCGTAGGTTGTGCATC GGTGCTAACTTATAATTCCCAGTA 58 400 
 5 TTTTTCAAAAGGATCATAAAACTACTC AAAAATTGCTCTAACCCATTAAG 58 398 
 6 CCACTTTCTAAATAACAAATGATCT TCGGCTTAATCGATACCTTA 58 250 
 7 TCTGGATTTTGTGGGTAGAGC AGCAAGAACTAAACTGTCAATGTT 58 199 
 8 AGCAACGCTCCATTGTTTTC TGCTCATTACTGTGCCCATC 58 175 
 9 GCCTAGCGTAATATTTTCTTAGC CGTTTGTTTTATTATGGAAAATACTCA 60 500 
 10 TCACGCTTACACCAAAATCG GCAAAAGGAGTATTCTAACAAAACA 58 300 
 11 CATTTTATTTGCACTACTTGAAGG AGCACATGACCCCAGAACTT 60 248 
 12 GCAGTAAAAAGTTATAACAAACAAGC TCTGAATTGGCCAAACAACAT 60 494 
 13 GCAGACTCATATGGTTTGATCTTTT TCCTTTTAGGAACAAAGCAGGT 60 224 
 14 TTTTGGAGTTGAGACCAGCA GGGATTGTTAAAATATTCTTGCCTAC 60 298 
 15 CAGAGTTATTTATTTTGTTTTAATGG AAACTCAGGTCAGGAAAAGA 60 250 
Gene 
Position of the 
SNP Forward Reverse TºC 
Product 
size (bp) 
POT1 rs67585224 TCCTGAGAACTGTCCTGAGAACT AAAATATTCAAATTCACTAGGATGACA 57 205 
 rs68091803 AGCCATGGGGAACAAGAATA TTTTCACGAAAAATTCTAGCTAATGA 57 586 
 rs7784168  TCTGGATTTTGTGGGTAGAGC AGCAAGAACTAAACTGTCAATGTT 58 199 
 rs7801661  GCCTAGCGTAATATTTTCTTAGC CGTTTGTTTTATTATGGAAAATACTCA 62 500 
 rs35536751 TCACGCTTACACCAAAATCG GCAAAAGGAGTATTCTAACAAAACA 58 300 
 rs17246404 
AGAATATAGACTCTTGGTTCAAAACAT CTTCTAGATTGAGGGCTTCCTG 57 150 
 rs76436625 
 
.
Supplementary Table 6: Characteristics of the antibodies used for Western blotting and FISH 
studies. 
 
Antibody 
 
Reference 
 
Clone 
 
Working Concentrations 
WB IF 
POT1* 
Novus Biologicals: NB500-
176 Rabbit Polyclonal 
1:500 1:250 
GAPDH Homemade, CNIO  Monoclonal 1:500 - 
TRF2* Cell Signaling, #2645 Rabbit Polyclonal - - 
TRF1 Homemade, CNIO Rabbit Polyclonal - 1:250 
TRF1* (TRF-78) (ab10579), ABCAM Mouse monoclonal - 1:250 
γH2AX Millipore, #05-636 Mouse Monoclonal - 1:250 
555-Alexa-
donkey Life technologies, A31572  
- 1:400 
488-Alexa-goat Life technologies, A11017  - 1:400 
FLAG F3166 SIGMA Mouse monoclonal 1:1000 - 
c-MYC (9E10) 
C-40, Santa Cruz 
Biotechnology Mouse monoclonal 
1:1000 1:500 
 
*: 4 μL of antibody were used per IP Chip reaction; WB: Western Blot; IF: Inmunofluorescence 
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and marrow hypoplasia. The disease can be hereditary or acquired and develops at any stage of 
life. A subgroup of the inherited form is caused by replicative impairment of hematopoietic stem 
and progenitor cells due to very short telomeres as a result of mutations in telomerase and other 
telomere components. Abnormal telomere shortening is also described in cases of acquired 
aplastic anemia, most likely secondary to increased turnover of bone marrow stem and progenitor 
cells. Here, we test the therapeutic efficacy of telomerase activation by using adeno-associated 
virus (AAV)9 gene therapy vectors carrying the telomerase Tert gene in 2 independent mouse 
models of aplastic anemia due to short telomeres (Trf1- and Tert-deficient mice). We find that a 
high dose of AAV9-Tert targets the bone marrow compartment, including hematopoietic stem 
cells. AAV9-Tert treatment after telomere attrition in bone marrow cells rescues aplastic anemia 
and mouse survival compared with mice treated with the empty vector. Improved survival is 
associated with a significant increase in telomere length in peripheral blood and bone marrow 
cells, as well as improved blood counts. These findings indicate that telomerase gene therapy 
represents a novel therapeutic strategy to treat aplastic anemia provoked or associated with short 
telomeres. 
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Key Points
• Telomerase gene therapy in
a mouse model of aplastic
anemia targets the bone
marrow and provides
increased and stable
telomerase expression.
• Telomerase expression leads
to telomere elongation and
subsequently to the reversal
of aplastic anemia
phenotypes.
Aplasticanemia is a fatal bonemarrowdisordercharacterizedbyperipheral pancytopenia
and marrow hypoplasia. The disease can be hereditary or acquired and develops at any
stage of life. A subgroup of the inherited form is caused by replicative impairment of
hematopoietic stem and progenitor cells due to very short telomeres as a result of
mutations in telomerase and other telomere components. Abnormal telomere shortening
is alsodescribed incasesof acquiredaplastic anemia,most likely secondary to increased
turnover of bonemarrow stem and progenitor cells. Here, we test the therapeutic efficacy
of telomerase activation by using adeno-associated virus (AAV)9 gene therapy vectors
carrying the telomeraseTertgene in 2 independentmousemodels of aplastic anemia due
to short telomeres (Trf1- and Tert-deficient mice). We find that a high dose of AAV9-Tert
targets the bone marrow compartment, including hematopoietic stem cells. AAV9-Tert
treatment after telomere attrition in bone marrow cells rescues aplastic anemia and
mouse survival compared with mice treated with the empty vector. Improved survival is
associated with a significant increase in telomere length in peripheral blood and bone
marrow cells, as well as improved blood counts. These findings indicate that telomerase
gene therapy represents a novel therapeutic strategy to treat aplastic anemia provoked or associated with short telomeres. (Blood.
2016;127(14):1770-1779)
Introduction
Aplastic anemia is a potentially life-threatening, rare, and heteroge-
neous disorder of the blood in which the bone marrow cannot produce
sufﬁcient new blood cells due to a marked reduction of immature
hematopoietic stem and progenitor cells (HSPCs).1,2 The main disease
manifestations are pancytopenia and marrow hypoplasia, which can
emerge at any stage of life but are more frequent in young individuals
(age 10-25 years) and in the elderly (.60 years).3 Aplastic anemia can
be acquired or inherited. The acquired type is often of idiopathic origin
and involves autoimmune processes but can also be triggered by
environmental factors such as exposure to radiation, toxins, and viral
infections.4 The congenital form is rarer, andmutations inmore than 30
genes involved in DNA repair, ribosome biogenesis, and telomere
maintenance pathways have been identiﬁed to date.5 A frequently
observed clinical feature of aplastic anemia is the presence of short
telomeres in subpopulations of peripheral blood cells (neutrophils in
particular; less prominent in lymphocytes),6 even in the absence of
mutations in the telomere maintenance machinery.
Telomeres, the termini of vertebrate chromosomes, are special-
ized nucleoprotein structures composed of tandem repeat sequences
(TTAGGG in vertebrates) bound by a 6-protein complex (TRF1,
TRF2, TIN2, RAP1, TPP1, and POT1) known as shelterin.7,8 Telo-
meres are essential for chromosome integrity by preventing telomere
fusions and telomere fragility. Telomere length is controlled by the
ribonucleoprotein enzyme telomerase, which can add telomeric
sequences onto telomeres de novo. Because telomeres shorten with
every cell division (a phenomenon known as the “end replication
problem”) and somatic cells do not express sufﬁcient telomerase
to compensate for this, telomeres shorten throughout life. When
telomeres reach a critically short length, their protective function is
impaired, eliciting a persistent DNA-damage response at chromo-
some ends, which leads to cellular senescence or cell death.9,10 He-
matopoietic stem cells, in contrast to most somatic cells, can activate
telomerase; however, this is insufﬁcient to prevent telomere attrition
with aging, thus eventually leading to loss of the regeneration potential
of hematopoietic stem cells.11 In line with this, recipients of bone
marrow transplants have shorter telomeres than their donors, sug-
gesting that telomerase cannot fully compensate for the increased
cell proliferation that occurs during the engraftment phase of the
transplanted bone marrow.12 Telomeres also show an accelerated
rate of shortening in patients with aplastic anemia compared with
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healthy individuals, most likely due to a higher than normal number
of cell divisions in the aplastic anemia cases.13
Accelerated telomere shortening due to defects in telomerase or
other telomere maintenance genes prematurely limits the proliferation
potential of cells, including stem cells, leading to decreased tissue
renewal capacity.9,14 Highly proliferative tissues such as the hemato-
poietic system are particularly vulnerable to defects in telomere main-
tenance genes, leading to severe disorders such as aplastic anemia.15As
an example, the telomeropathy dyskeratosis congenita (DKC) has
been linked to mutations in 11 genes that encode components of the
telomerase complex (TERT, TERC, DKC1, NOP10, and NHP2) or of
the telomere capping complex shelterin (TIN2). Other genes altered in
DKC encode for accessory proteins important for telomerase assem-
bly and trafﬁcking (CTC1, ACD7 [alias TPP1], and TCAB1) or for
telomere replication (RTEL1).16 Mutated PARN was also recently
linked to reduced messenger RNA (mRNA) levels of several key
genes in telomere maintenance.17 In all these cases, DKC is charac-
terized by very short telomeres. DKC is a multisystem syndrome
comprising diverse clinical features such as nail dystrophy, oral leu-
koplakia, abnormal skin pigmentation, and cerebellar hypoplasia.16
Themost severe complication, however, is the development of aplastic
anemia in 80% of the cases, underlining that the clinical features are
caused by excessive telomere shortening that eventually leads to the
exhaustion of the stem cell reserve.5
These ﬁndings suggest that telomerase activation could be a good
therapeutic strategy to treat those forms of aplastic anemia associated
with a limited blood-forming capacity due to the presence of very short
telomeres. We have previously developed a telomerase (Tert) gene
therapy using adeno-associated virus (AAV)9 vectors,18 which atten-
uated or reverted aging-associated telomere erosion in peripheral blood
mononuclear cells (PBMCs).18
To test the efﬁcacy of this strategy in the treatment of aplastic
anemia, we ﬁrst used amouse model of aplastic anemia generated by
us inwhichwe depleted the TRF1 shelterin protein speciﬁcally in the
bone marrow, leading to a bone marrow phenotype that recapitu-
lates the main pathological ﬁndings of human aplastic anemia
patients, including extreme telomere shortening.19,20 In particular,
partial depletion of the Trf1 gene speciﬁcally in bone marrow causes
severe telomere uncapping and provokes a persistent DNA-damage
response at telomeres, which in turn leads to a fast clearance of those
HSPCs deﬁcient for Trf1. In this context, the remaining HSPCs that
did not delete the Trf1 gene undergo additional rounds of compen-
satory proliferation to regenerate the bone marrow, leading to very
rapid telomere attrition. Thus, partial depletion of the bone marrow
stem cell and progenitor compartments by Trf1 deletion recapitulates
the compensatory hyperproliferation and short telomere phenotype
observed after bone marrow transplant or in other acquired forms of
aplastic anemia, as well as in patients due to mutations in telomere
maintenance genes. Interestingly, thismousemodel allows adjustment
of the rate of telomere shortening bymodulating the frequency of Trf1
deletion–mediated HSPC depletion, thus controlling the onset of bone
marrow aplasia and pancytopenia.19,20
As an additional model to mimic the presence of very short telo-
meres speciﬁcally in the bone marrow, we transplanted irradiated
wild-type mice with bone marrow from late (third)-generation (G3)
telomerase-deﬁcient Tert-knockout mice, which have short telo-
meres due to telomerase deﬁciency during 3 mouse generations.
Here, we tested telomerase activation by using gene therapy AAV
vectors in both mouse models of aplastic anemia produced by short
telomeres. Our results show that telomerase treatment is sufﬁcient
to attenuate telomere attrition and HSPC depletion with time, thus
signiﬁcantly preventing death by bone marrow failure.
Material and methods
Study approval
All experimental procedures with mice (Mus musculus) were approved by the
Spanish National Cancer Research Center Instituto de Salud Carlos III Ethics
Committee forResearchandAnimalWelfare.Micewere treated in accordance to
the Spanish laws and the Federation of European Laboratory Animal Science
Associations guidelines (approval ﬁle number CBA PA 87_2012).
Mice and animal procedures
Mice of pure C57/BL6 background were produced and housed at the speciﬁc-
pathogen-free animal house of the Spanish National Cancer Research Center in
Madrid, Spain.Trf1lox/loxMx1-Cre andTrf1lox/loxMx1-wtmiceweregenerated as
described previously.21 First-generation (G1) Tert2/2 mice were generated by
intercrossing Tert1/2. G3 Tert2/2mice were obtained by intercrossing G1mice
(to give second-generation [G2] mice) and subsequently intercrossing G2
mice.22 Ten-week-old Trf1lox/lox Mx1-Cre or G3 Tert2/2 mice were used as
bonemarrow donors for transplant into 8-week-old lethally irradiated (12Gy)
wild-type mice as described previously.19,23 Two million cells were trans-
planted via tail vein injection at a donor-to-recipient ratio of 1:8, and mice were
left for 30 days to allow bonemarrow reconstitution. To induce Cre expression,
mice were intraperitoneally injectedwith 15mg/g body weight of polyinosinic:
polycytidylic acid (pI:pC; Sigma-Aldrich) 3 times per week for a total of
5 weeks. After 1 week, micewere treatedwith the AAV9-Tert or AAV9-empty
vector. Vectors were administered via tail vein injection at a concentration of
3.53 1012 viral genomes per mouse.
Gene therapy vector production
Viral vectors were generated24 and puriﬁed as described previously.25 Brieﬂy,
vectors were produced through triple transfection of HEK293T. Expression
cassettes were under the control of the cytomegalovirus promoter and contained
an SV40 polyA signal for EGFP and the cytomegalovirus promoter, and a 39
untranslated region of the Tert gene as polyA signal for Tert. AAV9 particles
were puriﬁed using 2 cesium chloride gradients, dialyzed against phosphate-
buffered saline (PBS) andﬁltered.25Viral genomeparticle titerswere determined
by a quantitative real-time polymerase chain reaction (PCR) method.26
Histology
Bone marrow samples (sternum or tibia bone) were ﬁxed in 4% paraformal-
dehyde and parafﬁn embedded after decalciﬁcation. Tissue sections (5mm)were
stained with hematoxylin and eosin. Immunohistochemistry was performed
on deparafﬁnized sections. After antigen retrieval, samples were stained with
anti–enhanced green ﬂuorescent protein (EGFP) (rabbit anti-EGFP, 1:200,
ab290; Abcam). EGFP-positive cells were counted in a semiautomated way
using ImageJ software.
FACS
For sorting of HSPCs, whole bone marrow cells were extracted from the long
bones (femur and tibia) as described previously.23 Erythrocytes were lysed
for 10minutes in 10mLof erythrocyte lysis buffer (Roche), washed oncewith
10mLof PBS, and resuspended inﬂuorescence-activated cell sorting (FACS)
buffer (PBS, 2mMEDTA, 0.3% bovine serum albumin) containing Fc-block
(1:400) at a concentration of 5 to 10 3 106 cells per 100 mL. Cells were in-
cubated for 10 minutes and washed once in FACS buffer. Cells were then
resuspended in FACS buffer at 20 to 25 3 106 cells per milliliter, and the
antibody cocktail was added as follows: anti–Sca-1–PerCP-Cy5.5 (1:200), lin
cocktail-eFluor450 (1:50) (all eBioscience), and anti–c-kit–APC-H7 (1:100)
(BD Pharmingen). Cells were incubated for 30 minutes. After washing cells
twice with PBS, 2 mL of 4,6 diamidino-2-phenylindole (DAPI; 2 mg/mL)
was added and cells were sorted in a FACSAria IIU (Becton Dickinson, San
Jose, CA) into HSPCs (lin2, Sca-11, and c-kit1) and lineage-positive fractions.
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Colony-forming assay
A short-term colony-forming assay was performed by plating 1 3 104 and
23 104 freshly isolated mononucleated bone marrow cells in 35 mm dishes
containing MethoCult media (both STEMCELL Technologies) following
the manufacturer’s protocol. All experiments were performed in duplicate,
and the number of colonies was counted after 12 days of incubation at 37°C.
Blood counts
Peripheral blood was drawn from the facial vein (;50 mL) and collected
into anticoagulation tubes (EDTA). Blood counts were determined using an
Abacus Junior Vet veterinary hematology analyzer.
Quantitative real-time PCR and western blot analysis
Total RNA from whole bone marrow extracts or from bone marrow cells sorted
by FACS was isolated using QIAGEN’s RNeasy Mini Kit according to the
manufacturer. Quantitative real-time PCRwas performed using an ABI PRISM
7700 or QuantStudio 6 Flex (both Applied Biosystems). Primer sequences
for Tert and reference genes Act1 and TBP are as follows: Tert-forward
59GGATTGCCACTGGCTCCG; Tert-reverse 59TGCCTGACCTCCTCT
TGTGAC; actin-forward 59GGCACCACACCTTCTACAATG; actin-reverse
59GTGGTGGTGAAGCTGTAG; TBP-forward 59CTTCCTGCCACAATG
TCACAG; TBP-reverse 59CCTTTCTCATGCTTGCTTCTCTG.
Q-FISH telomere analysis
Quantitative FISH (Q-FISH) on parafﬁn-embedded tissue sections was
performed as described previously.27 Confocal images were acquired as
stacks every 0.5 mm for a total of 1.5 mm using a Leica SP5-MP confocal
microscope, and maximum projections were done with the Leica Application
Suite–Advanced Fluorescence software. Telomere signal intensity was quan-
tiﬁed in at least 6 images per mouse using Deﬁniens software, with a speciﬁc
script allowing for individual spot background correction.
High-throughput (HT)-Q-FISH on peripheral blood leukocytes was done
using 120 to 150 mL of blood as described previously.28 Confocal images were
captured using the Opera High-Content Screening system (Perkin Elmer).
Telomere length values were analyzed using individual telomere spots
(.10 000 telomere spots per sample). The average ﬂuorescence intensities of
each sample were converted into kilobases using L5178-R and L5178-S cells
as calibration standards, which have stable telomere lengths of 79.7 kb and
10.2 kb, respectively.29 Samples were analyzed in duplicate.
Real-time PCR–basedmeasurement of relative telomere lengthwas done on
genomicDNA isolated fromwhole bonemarrowsamples following apreviously
described protocol.30,31
Results
AAV9-Tert targets bone marrow and hematopoietic stem cells
First, we tested the ability of AAV9 vectors to transduce bone marrow
cells upon mouse IV injection. In particular, to determine the location
and percentage of transduced cells, we ﬁrst treated wild-type mice with
an AAV9-EGFP reporter virus (3.53 1012 viral genomes per mouse)
via tail vein injections.We found that 2% of the BMcells were positive
for EGFP upon immunohistochemistry with anti-EGFP antibodies in
in middle bone sections, and this increased to 10% in bone regions
adjacent to the joints, which showed the highest AAV9 transduction
(Figure 1A-B).We then injected wild-type mice with the same amount
of AAV9-Tert particles and determined Tert mRNA expression by
quantitative real-time PCR in whole bone marrow isolates at 2 weeks
and 8 months after virus injection. At 2 weeks posttreatment with the
AAV9 vectors, Tert mRNA expression was signiﬁcantly increased in
the AAV9-Tert-treated mice compared with those treated with the
AAV9-empty vector, and this increased expression was maintained up
to 8months after the initial treatment (Figure 1C-E). In agreement with
the known tropism of the AAV9 serotype, we found a stronger
induction of Tert in organs such as heart and liver, which are
preferential AAV9 targets (supplemental Figure 1, available on the
Blood Web site).32 We then studied Tert mRNA expression
speciﬁcally in the blood-forming compartments of the bone marrow.
To this end, we performed FACS of c-kit1 and Sca-11 HSPCs and
lin1 lineage-committed cells.We found a signiﬁcant increase in Tert
mRNA in HSPCs (10-fold) and lineage-committed bone marrow
cells (3.5-fold) in AAV9-Tert-treated mice compared with mice
treatedwith the empty vector (Figure 1F-G), demonstrating that bone
marrow cells, including HSPCs, are targeted by Tert gene therapy.
Of note, the higher expression in whole bonemarrow comparedwith
isolated hematopoietic cells (HPSCs and lin1 cells) could suggest
that additional bone marrow cells corresponding to the stroma (ie,
adipocytes) may also be infected. In this regard, we previously
demonstrated that adipocytes are efﬁciently targeted by AAV9.33
Moreover, the relative lower fold changes in Tert in HSPCs compared
with total bonemarrowmay alsobedue to higher levels of endogenous
Tert in HPSCs compared with whole bone marrow. As a control,
AAV9-Tert treatment of wild-type mice did not affect the relative
numbers of lineage-positive or -negative cells or the proportion of
HSPCs (supplemental Figure 2). Given the increased Tert expression
in HSPCs, we next addressed whether this affected their proliferation/
colony-formingpotential. To this end,weperformed a colony-forming
cell assay (MethoCult).We observed a signiﬁcantly increased number
of colonies in the bone marrow from AAV9-Tert-treated mice
compared with those treated with the empty vector (Figure 1H).
In summary, IV injection of AAV9 vectors administered at a high
dose can target Tert to hematopoietic cells, including HSPCs.
AAV9-Tert treatment rescues survival in a mouse model of
aplastic anemia
We next tested whether treatment with AAV9-Tert was effective in
increasing survival upon induction of lethal aplastic anemia due to
critically short telomeres. First, we used the conditional Trf1 mouse
model recently developed by us (Trf1lox/lox Mx1-Cre mice) in which
we induce partial Trf1 deletion speciﬁcally in the bone marrow.19 To
this end, we transplanted lethally irradiated wild-type mice with bone
marrow isolated from Trf1lox/lox Mx1-Cre mice, followed by admin-
istration of pI:pC to induce the expression of Cre recombinase and Trf1
deletion.19,20 Genotyping conﬁrmed that the new bone marrow solely
consisted of donor cells with excisable Trf1 (supplemental Figure 3).
Thus, Trf1lox/lox Mx1-Cre mice allow study of the effects of Trf1
depletion exclusively in the bone marrow. We previously showed
that partial Trf1 deletion in the bone marrow results in rapid death
and removal of the Trf1-deleted cells, whereas cells that fail to delete
Trf1 undergo compensatory rounds of cell division, leading to rapid
telomere shortening and replicative senescence, eventually resulting
in bone marrow failure.19,20
Here, we induced Trf1 deletion with pI:pC injections at a frequency
of 3 times per week for 5 weeks, at which point these mice started
to show signs of aplastic anemia.19,20 One week after the last pI:pC
injection, mice were treated with either the AAV9-Tert or AAV9-
empty vector (Figure 2A). Mouse survival was monitored for 100
days after treatment with the AAV9 vectors (note: beyond 100 days
after virus treatment, none of the mouse cohorts developed signs of
aplastic anemia. At 120 days post–virus administration, all mice
were euthanized for further analyses). Strikingly, AAV9-Tert treatment
signiﬁcantly increased survival: 87%ofmicewere still alive at 100 days
after virus administration in the AAV9-Tert-treated group compared
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Figure 1. High dose of AAV9 particles targets bone marrow, including HSPCs. (A) Representative anti-EGFP immunohistochemistry (IHC) images of bone marrow
corresponding to the tibia. Mice were injected with the AAV9-EGFP vector or AAV9-empty vector at a concentration of 3.5 3 1012 viral genomes (vg) per mouse. EGFP-
positive cells were mainly located toward the end of the bones. Bars represent 500 mm (left) and 50 mm (right); hematoxylin and eosin stain. (B) Percentage of EGFP-positive
cells relative to the total number of cells. Cells were separately counted in joint adjacent areas and in the middle of the bone. (C-D) Tert mRNA expression level in total bone
marrow isolated 2 weeks (C) and 8 months (D) after VI with 3.5 3 1012 viral genomes per mouse. AAV9-Tert relative to the expression of mice injected with the same amount
of AAV9-empty vector. (E) D Ct values (Tertminus Act1) of the quantitative real-time PCR shown in panel D. Quantitative real-time PCR determined relative Tert expression in
HSPCs (HSCs) sorted by FACS (F) and lineage-committed cells (G). (H) Colony-forming assay in MethoCult with whole bone marrow cells isolated from mice injected with
AAV9-Tert or AAV9-empty. For all experiments, n indicates number of mice. Data are mean 6 SEM. Statistical analysis: 2-sided Student t test; P values are shown. SEM,
standard error of the mean; VI, virus injection.
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Figure 2. AAV9-Tert treatment rescues the aplastic anemia phenotype in Trf1lox/lox mice. (A) Experimental design. Mice were lethally irradiated and transplanted the following
day with Trf1lox/lox Mx1-Cre bone marrow. After engraftment, Cre expression and Trf1 excision was induced by pI:pC injections for 5 weeks. One week later, mice were injected with AAV9-
Tert or AAV9-empty particles. (B) Kaplan-Meier survival curves showing that AAV9-Tert treatment significantly rescues mouse survival. (C) Kaplan-Meier survival curves considering only
those animals that died of aplastic anemia within 100 days after virus treatment show significant protection of AAV9-Tert treatment from deaths due to aplastic anemia. Platelet counts (D)
and hemoglobin levels (E) in mice of the AAV9-Tert-treated and AAV9-empty-treated groups showing clear signs of anemia compared with healthy mice from the same AAV9-Tert-treated
and AAV9-empty-treated groups. (F) Representative bone marrow images of healthy controls (no Cre-mediated induction of Trf1 deletion) and of mice with bone marrow aplasia.
Genotypes and AAV9 treatments are indicated. Bars represent 500 mm (left) and 20 mm (right); hematoxylin and eosin stain. (G) Quantification of bone marrow cellularity expressed as
number of nucleated cells per field. Four to 5 fields per mouse were counted. (H) Quantification of bone marrow cellularity expressed as the percentage of nuclear area (purple stain) to total
areas per field. Four to 5 fields per mouse were counted. In all graphs, n indicates number of mice. Data are mean 6 SEM. Statistical analysis: log-rank test in panels B and C; 2-sided
Student t test in panels D, E, G, and H; P values are shown. n.s., not significant.
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with only 55% of mice alive in the empty vector–treated group
(Figure 2B). In particular, whereas only 4 of 31 mice (13%) treated
with AAV9-Tert developed aplastic anemia, 16 of 36 mice (44%)
died with clear signs of aplastic anemia in the group treated with the
empty vector (Figure 2C). In both groups, aplastic anemia was
determined as the cause of death in thosemice showing a drastic drop
in platelet counts and hemoglobin levels at the time of death
(Figure 2D-E) and presenting with severe bone marrow hypoplasia
and aplasia after postmortem histopathological analysis of bone
marrow sections (Figure 2F). Interestingly, among those mice that
died of aplastic anemia, we observed a tendency to show a milder bone
marrow aplasia phenotype in the AAV9-Tert-treated group compared
with the AAV9-empty-treated group, as indicated by higher bone
marrow cellularity in the AAV9-Tert-treated group (Figure 2F).
Quantiﬁcation of the bone marrow cellularity conﬁrmed a drastic
decrease of cellularity in aplastic anemiamice comparedwith wild-type
controlmice.Of importance, the decrease in cellularitywas signiﬁcantly
attenuated in the AAV9-Tert-treated cohort compared with the AAV9-
empty-treatedgroup (Figure 2G-H).Our results suggest thatAAV9-Tert
treatment of mice with induced severe telomere shortening signiﬁcantly
reduces mortality due to aplastic anemia.
Telomerase treatment reverses telomere shortening in
peripheral blood and bone marrow cells in a mouse model of
aplastic anemia
Because aplastic anemia in our mouse model is caused by extreme
telomere shortening,19,20 we next compared the dynamics of telomere
length in mice treated with AAV9-Tert vs mice treated with the empty
vector. To this end, we performed a longitudinal study to follow
telomere length in peripheral blood (PBMCs) over time using telomere
HT-Q-FISH technology.34 To do so, we extracted blood at 4 different
time points (time point 1, 30 days after bonemarrow engraftment; time
point 2, 5 weeks after pI:pC treatment; time point 3, 2 months after
treatment with the AAV9 vectors; and time point 4, 4 months after
treatment with the AAV9 vectors) (note: longitudinal telomere mea-
surements were done on PBMCs from mice that did not develop
aplastic anemia). In agreement with previous ﬁndings, we found a
dramatic drop in telomere length of ;10 kb in all mice after
induction of Trf1 deletion with pI:pC and prior to treatment with the
gene therapy vectors (Figure 3A; compare time points 1 and 2).19,20
We observed a further drop in telomere length in those mice treated
with theAAV9-empty vectorwhen comparing time point 4with time
point 2 in this mouse cohort (Figure 3A-B). Importantly, during the
same period of time, mice treated with AAV9-Tert showed a net
increase in average telomere length of 10 kb when comparing time
point 4 with time point 2 (Figure 3A-B). Indeed, throughout the
course of the experiment, AAV9-empty-treated mice showed a total
decrease in average telomere length of 12 kb, whereas mice treated
with AAV9-Tert showed re-elongation of telomeres to a similar
telomere length as before the induction of Trf1 deletion by pI:pC
treatment (Figure 3C). These ﬁndings indicate that AAV9-Tert
treatment is sufﬁcient to stop and even revert initial telomere
shortening. To further conﬁrm whether telomeres were elongated as
the consequence of AAV9-Tert gene therapy speciﬁcally in the bone
marrow, we performed Q-FISH analysis on bone marrow cross-
sections at the end point of the experiment. In agreement with longer
telomeres in peripheral blood cells in the AAV9-Tert-treated mice,
we found that AAV9-Tert-treated mice also had signiﬁcantly longer
telomeres in the bone marrow compared with mice treated with the
empty vector (Figure 3D-F). We conﬁrmed the AAV9-Tert-mediated
telomere elongation on independent samples using a real-time PCR
assay for relative telomere length determination30,31 (supplemental
Figure 4A). Furthermore, in linewithourhypothesis that aplastic anemia
is the consequence of drastically shortened telomeres, mice treated with
the AAV9-empty vector that developed aplastic anemia had signiﬁ-
cantly shorter telomeres thanmice that were treated in the same manner
but did not develop aplastic anemia (supplemental Figure 4B).
Of note, telomere length analysis on bone marrow sections or bone
marrow DNA does not allow one to distinguish between various cell
populations. However, the observed telomere elongation in PBMCs
suggests a direct effect of AAV9-Tert on HSPCs.
Telomerase gene therapy of aplastic anemia produced by short
telomeres resulting from Tert deletion improves blood counts
and increases telomere length
To validate the therapeutic use of telomerase gene therapy in aplastic
anemiaprovokedby short telomeres,weusedan additionalmousemodel
for modeling short telomere length in the hematopoietic system (in this
case due to telomerase deﬁciency during several mouse generations):
the Tert-deﬁcient mouse model.22 To this end, we irradiated wild-type
mice and transplanted them with bone marrow from G3 Tert-knockout
mice,which have short telomeres in allmouse tissues, including the bone
marrow22 (Figure 4A). First, we conﬁrmed shorter telomeres in the G1
andG3Tert-knockout bonemarrowdonors comparedwith thewild-type
bone marrow donors by performing HT-Q-FISH analysis on PBMCs.
In particular, Tert deﬁciency leads to progressive telomere shortening,
with G3 mice having an average telomere length of ;25 kb compared
with ;40 kb in the wild-type controls (Figure 4B). One month after
transplantation of irradiated wild-type mice with G3 Tert knockout bone
marrow, mice were divided in 2 groups and treated with either AAV9-
Tert or AAV9-empty gene therapy vectors (3.5 3 1012 viral genomes
per mouse) (Figure 4A). After treatment, we monitored mice during a
follow-up period of 5 months and observed robust expression of Tert
in the bone marrow in the AAV9-Tert-treated group (supplemental
Figure 5). Importantly, in response to AAV9-Tert treatment, we
observed an increase in survival compared with the AAV9-empty-
treated group that almost reached statistical signiﬁcance (P5 .058)
(Figure 4C).Uponmouse euthanasia,Tert-treatedmicehad signiﬁcantly
increased hemoglobin levels and higher erythrocyte and platelet counts
compared with mice treated with the empty vector (Figure 4D-F). The
same trend was observed for leukocyte counts, which were higher in
AAV9-Tert-treated mice compared with the AAV9-empty group,
although the trend did not reach statistical signiﬁcance (P 5 .09)
(Figure 4G). Lastly, to analyze the mechanism by which Tert gene
therapy improved survival and blood counts in these mice, we
followed longitudinally the telomere length in PBMCs in both mouse
cohorts. To this end, we extracted blood before and 3 and 5 months
after mice were injected with the viruses and performed HT-Q-
FISH analysis. In line with the results obtained with the Trf1lox/lox
mousemodel (see “AAV9-Tert treatment rescues survival in a mouse
model of aplastic anemia”), we found thatAAV9-Tert treatment led
to a net increase in average telomere length of 5.18 kb with time,
whereas during the same period, mice treated with the AAV9-empty
vector suffered a slight telomere shortening of21.76 kb (Figure 5A-
B). These ﬁndings were also conﬁrmed by telomere Q-FISH analysis
on bone marrow sections at 5 months after virus administration. In
particular, we found significantly longer telomeres in the bonemarrow
ofTert-treatedmice comparedwithmice treatedwith the empty vector
(Figure 5C-D).
In summary, these results indicate that a single treatment with the
AAV9-Tert vector in mice with previously shortened telomeres in the
bone marrow due to telomerase deﬁciency is sufﬁcient to increase
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telomere length in the bone marrow and in blood. Telomerase gene
therapy also improved blood counts and mouse survival.
Discussion
Here, we set out to test the hypothesis of whether increased expression
of telomerase through systemic virus-based Tert delivery may delay or
prevent the emergence of aplastic anemia provoked by short telomeres.
We tested this hypothesis in 2 independent mouse models with very
short telomeres speciﬁcally in the bone marrow due to either Trf1 or
Tert deﬁciency.20,22
The rationale for this study was based on our previous ﬁnding
showing that systemic AAV9-Tert gene therapy in wild-type mice was
sufﬁcient to delay different age-related diseases and to signiﬁcantly
increase mouse life span by delaying telomere shortening with age in
different tissues.18A5-month longitudinal follow-up of thesemice also
Figure 3. AAV9-Tert treatment causes telomere elongation in blood and bone marrow. (A) Longitudinal HT-Q-FISH analysis of telomere length in peripheral blood
monocytes (Trf1lox/lox Mx1-Cre–transplanted mice; see also Figure 2A). Blood was extracted at 4 different time points (time point 1, before pI:pC treatment; time point 2, after 5
weeks of pI:pC treatment and before AAV9 injection; time point 3, 2 months after AAV9 injection; and time point 4, 4 months after AAV9 injection). Relative variation (D) of telomere
length in AAV9-Tert-treated and AAV9-empty-treated animals between time points 2 and 4 (B) and between time points 1 and 4 (C). (D) Relative telomere length in bone marrow
sections from AAV9-Tert-treated and AAV9-empty-treated mice shown as arbitrary units of fluorescence (a.u.f.). Each square and triangle represents the mean telomere length per
nucleus of an individual mouse. (E) Frequency distribution blot of telomere length showing a higher abundance of short telomeres in the AAV9-empty-treated group compared with
AAV9-Tert-treated mice (pooled data from panel D). (F) Representative images of bone marrow sections from AAV9-Tert-treated and AAV9-empty-treated mice used for Q-FISH
analysis. Cell nuclei are stained blue (DAPI) and telomeres are stained red (Cy3). White arrowheads indicate nonspecific extranuclear signals and yellow arrowheads indicate
specific telomere signals within DAPI-stained nuclei. Bars represent 20 mm (top) and 10 mm (bottom). In all graphs, n indicates number of mice. Data are mean 6 SEM. Statistical
analysis: 2-way analysis of variance in panel A; 2-sided Student t test in panels B and C; P values are shown. a.u., arbitrary units.
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revealed increased telomere length in PBMCs from mice treated with
telomerase gene therapy, suggesting that the vectorswere also targeting
the bone marrow.18 This ﬁnding is in line with recent reports showing
that AAV9 viral genome copies are readily detectable in bone marrow
isolates even 20 weeks postinjection35 and with the fact that FACS
analysis of bone marrow from neonatal mice administered AAV9–
greenﬂuorescent protein show increased amounts of greenﬂuorescent
protein–positive cells.36 Thus, Tert delivery via AAV9 may hold
potential for treating aplastic anemia triggered or associated with short
telomeres in the bone marrow, a common consequence of telomerase
mutations in the so-called telomeropathies or telomere syndromes, as
well as in some acquired cases of aplastic anemia.37-39
To demonstrate this, we ﬁrst conﬁrmed that a high dose (3.53 1012
viral genomes per mouse) of AAV9-EGFP reporter vector injected IV
was able to transduce the bone marrow, as indicated by the presence of
EGFP-positive cells. Furthermore, administration of the same amount
of AAV9-Tert particles led to robust Tert expression in whole bone
marrow isolates 2 weeks after treatment; this increased expression
was maintained at 8 months posttreatment. To rule out the possibility
that AAV9 may be targeting only bone marrow stroma cells, we
Figure 4. AAV9-Tert treatment improves blood counts in mice with short telomeres resulting from specific Tert deletion in the bone marrow. (A) Experimental
design. G3 Tert2/2 mice with short telomeres were generated by consecutive crosses of Tert-deficient mice. Bone marrow from these G3 mice was isolated and transplanted
into irradiated wild-type mice. After engraftment, mice were injected with AAV9-Tert or AAV9-empty virus particles. (B) HT-Q-FISH analysis of telomere length in PBMCs from
wild-type, G1 Tert2/2, and G3 Tert2/2 mice reveals progressive telomere shortening with consecutive mouse generations. (C) Kaplan-Meier survival curves show that AAV9-
Tert treatment improves survival of mice with very short telomeres in the bone marrow due to Tert deficiency specifically in the bone marrow (irradiated wild-type mice
transplanted with G3 Tert2/2 bone marrow). AAV9-Tert compared with AAV9-empty treatment improves erythrocyte counts (D), hemoglobin levels (E), platelet counts (F), and
leukocyte counts (G). In all graphs, n indicates number of mice. Data are mean6 SEM. Statistical analysis: log-rank test in panel A; 2-sided Student t test in panels B and E-H;
P values are shown.
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demonstrated signiﬁcantly increased Tert mRNA expression both
in isolated hematopoietic stem cells (lin2, Sca-11, c-kit1) and in
lineage-committed bone marrow cells (lin1) from mice treated with
AAV9-Tert compared with mice treated with the AVV9-empty
vector. Importantly, bone marrow cells from AAV9-Tert-treated
mice showed enhanced colony-forming abilities, suggesting that
telomerase expression may increase the stem cell reserve.
Indeed,AAV9-Tert treatmentofmicewithaplasticanemia triggered
by short telomeres resulting from marrow-speciﬁc Trf1 deletion19
signiﬁcantly rescued mortality due to aplastic anemia, concomitant
with telomere re-elongation in blood and bonemarrow cells from these
mice after telomerase treatment. We conﬁrmed these ﬁndings by
generating a secondmousemodel of aplastic anemia produced by short
telomeres, in this case due to telomerase deﬁciency. In particular, we
generatedmicewith Tert deﬁciency speciﬁcally in the bonemarrow. In
this case, the treatment of Tert gene therapy in mice with Tert-deﬁcient
bone marrow and short telomeres (irradiated wild-type mice trans-
planted with G3 Tert-knockout bone marrow) showed a moderate
improvement of survival,whichwas not as dramatic as in the caseof the
Trf1-deﬁcient bone marrow model. This result is likely due to the fact
that in contrast to the Trf1-deletion model, which shows a very severe
and rapid induction of aplastic anemia,19,20 Tert deﬁciency leads to
a variable penetrance of aplastic anemia with increasing mouse
generations.40,41 Similarly to the Trf1-deﬁcient mouse model, Tert gene
therapy of the Tert-deﬁcient bonemarrowmousemodel also resulted in
increased telomere length with time in peripheral blood cells and
signiﬁcantly improved blood counts. In both mouse models, improve-
ment of blood counts can be interpreted as the consequence of improved
stem cell reserve. This is in line with recently published data showing
that genetic Tert re-activation in ﬁfth-generation Tert2/2 mice using a
Cre-inducible system restored HSPC proliferation, concomitant with
improved erythrocyte counts and hemoglobin levels.42
In summary, we provide proof of concept for a therapeutic effect of
telomerase treatment usingAAV9gene therapyvectors in the treatment
of aplastic anemia provoked by short telomeres. A strategy based on
AAV9-Tert treatment may be beneﬁcial not only in the correction of
monogenic bone marrow disease such as in carriers of Tert mutations
(we demonstrated improved blood counts in Tert-knockout mice) but
also in other forms of aplastic anemia associated with short telomeres
and hematopoietic stem cell depletion (eg, Fanconi anemia43). Gener-
ally, due to an excellent safety proﬁle attributable to their low im-
munogenicity and the fact that they are nonintegrative, AAV vectors
have become an attractive gene therapy tool, and many clinical trials
using those vectors are already underway (see www.clinicaltrials.gov).
However, despite the fact that AAV9 vectors carrying the Tert gene are
nonintegrative and therefore unlikely to aid in the division of cancer
cells, the association of many cancers with telomerase expression
imposes speciﬁc safety concerns. In this regard, it is important to point
out that in a previous study, a longer than 1-year follow-up ofwild-type
mice treated with AAV9-Tert did not show increased cancer; in fact,
cancer onset was delayed in the same manner as other age-related
diseases.18 Nevertheless, subsequent studies should address the safety
of this strategy in long-livedmammals such as primates. If those studies
conﬁrm our proof-of-principle ﬁndings, this gene therapy approach
may also be adapted to treat hereditary forms of aplastic anemia caused
by mutations other than Tert by replacing the gene to be delivered.
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Supplementary Information 
 
Supplementary Figure 1 | AAV9-Tert mRNA expression level. Tert expression 
(qPCR) in heart and liver tissue and peripheral blood cells 2 weeks after virus injection 
with 3.5x1012 vg/mouse AAV9-Tert relative to the expression of mice injected with the 
same amount of AAV9-empty vector. 
 
Supplementary Figure 2 | AAV9-Tert treatment does not alter bone marrow 
constitution in wild-type mice. (A) Representative FACS analysis of HSCs. Single cell 
(doublet exclusion) (i) were next gated on forward and side scatter (FSC and SSC 
respectively) to eliminate debris and erythrocytes (ii). Including only viable cells on the 
basis of DAPI exclusion, lineage negative (Lin-) cells were then separated (iii). c-Kit and 
Sca1 double positive cells were then sorted to obtain purified HSCs. (iv) (B) Bar graphs 
indicating the proportions of Lin+, Lin- and HSCs cells in total bone marrow isolates 
from mice treated with AAV9-Tert or AAV9-empty as indicated. No significant 
differences were observed, P-values are depicted. Statistical analysis: Two-tailed 
student’s t-test. n = number of mice. 
 
Supplementary Figure 3 | Bone marrow genotype of transplanted mice and pI:pC 
mediated Trf1 excision. Genomic DNA from whole bone marrow cells of wild-type 
mice and mice transplanted with Trf1lox/lox Mx1-Cre bone marrow which were injected 
with pI:pC to induce Trf1 excision was isolated. The Trf1 locus was PCR amplified with 
specific primers and PCR products were run on a 1% agarose gel. Lane 1-3 shows, in 
three individual animals, that the bone marrow consist only of the transgenic, donor 
bone marrow as seen by the presence of the 1.5kb Trflox and the 0.45kb Trf1'  excision 
fragment, while the 1.4kb band indicating the TrfWT is absent in lane 1-3. In contrast only 
the 1.4kb TrfWT fragment is detected in lane 4-5 where donor bone marrow was wild-
type. 
 
Supplementary Figure 4 | Relative telomere length. (A) Relative telomere length 
determined by real time PCR (T/S method) in bone marrow genomic DNA of mice 
transplanted with G3 Tert knock-out bone marrow and treated with AAV9-Tert or AAV9-
empty as indicated. For the control genomic DNA of bone marrow from 3 wild-type mice 
was pooled. (B) Relative telomere lengths of bone marrow samples from mice treated 
with AAV9-empty virus indicate that mice with shorter telomeres are prone to develop 
aplastic anemia. Compared is the telomere length of mice that developed aplastic 
anemia (white bars) with those that did not (grey bars). Each bar represents the relative 
telomere length of one mouse. Statistical analysis: two-sided Student’s t-test, P-value is 
shown. 
 
Supplementary Figure 5 | AAV9-Tert leads to robust Tert expression in tert knock-
out bone marrow. (A) Quantitative analysis of Tert mRNA expression level expressed 
as deltaCT values in total bone marrow isolated 1 month and (B) 4 months after virus 
injection (VI) with 3.5x1012 vg/mouse AAV9-Tert relative to the expression of mice 
injected with the same amount of AAV9-empty vector. Data are mean r SEM. Statistical 
analysis: two-sided Student’s t-test, P-values are shown. n = number of mice.  
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At the moment of writing this discussion, the search “telomere length cancer” in PubMed 
rendered 2524 academic entries. In spite of 30 years of research, it is still not clear whether TL in 
surrogate tissues such as blood can be used as a biomarker to predict cancer risk susceptibility. 
The reason is simple: TL regulation is complex and although telomere shortening can contribute 
to genome instability in some type of cancers, there are several environmental and genetic factors 
that determine TL for each individual. 
The main focus of this thesis was the identification of environmental and genetic factors 
that modify TL, in order to improve TL association studies and gain a better understanding of TL 
regulation and its relation with cancer, especially in the context of FBOC. 
As a potential exogenous TL modifier, the effect of chemotherapy on TL was evaluated in 
sporadic and in familial breast cancer patients, to assess whether it could be a confounding factor 
that may bias TL results in those association studies that use TL as a biomarker of disease 
susceptibility. 
As potential genetic factors modifying TL, we evaluated the effect of two “cancer risk 
polymorphisms” in DNA glycosylases (BER pathway) in hereditary breast and ovarian cancer 
patients. We studied the role of these polymorphisms in TL regulation, telomerase activity, 
oxidative stress susceptibility, oxidative DNA damage at telomeres, and nuclear DNA damage. 
We wanted to explain the molecular mechanism behind the cancer modifier effect of these 
polymorphisms, but also to explore their involvement in TL regulation and telomere stability. 
To this end, we first designed a prospective study to include and evaluate periodically 
individuals from families harboring a familial mutation in BRCA1 or BRCA2, and from families 
without mutations in BRCA1 or BRCA2 (BRCAX). Evaluation consisted in filling out a 
questionnaire with information related to lifestyle and personal habits, as well as blood extraction 
to perform different biological studies (quantification of mRNA expression for OGG1 and NEIL2, 
TL and telomerase activity measurement and oxidative stress evaluation). 
In the first part of this Thesis, from article 1 to article 3, individuals from the familial 
breast / breast and ovarian cancer series (FBC/FBOC) also took part in the prospective study 
mentioned above. 
As a consequence of our findings exploring those “cancer risk polymorphisms” and their 
relation with genome and telomere instability in BRCA1 and BRCA2 mutation carriers, we opened 
a new line of research. We considered the possibility that OGG1 and NEIL2 might display 
synthetic lethality together with BRCA1 and BRCA2, respectively. We also considered the 
possibility that the DNA glycosylases OGG1 and NEIL2 might be candidates for being targeted 
as a treatment strategy for BRCA1- and BRCA2-derived tumors. We therefore started a 
collaboration with the Thomas Helleday laboratory (Karolinska Institutet, Stockholm) to further 
explore this hypothesis. Article 4 summarizes the results and findings in relation to this topic. 
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Finally, articles 5 and article 6 summarize the results of collaborations with other groups, 
and were included in this thesis to illustrate that cancer and disease susceptibility are not 
exclusively associated with telomere shortening. In fact, TL dysregulation due to mutations in 
genes directly associated with telomere maintenance presents different phenotypes, and both 
telomere shortening and telomere lengthening can converge in the manifestation of a disease. 
 
EXOGENOUS FACTORS THAT MODIFY TELOMERE LENGTH: 
CHEMOTHERAPY 
	
Article 1 
	
Hereditary breast and ovarian cancer presents some characteristics that are common to 
certain telomeropathies, characterized by mutations in genes related with telomere biology 
(shelterin complex or telomerase).  
Familial breast and ovarian cancer (FBOC) is predominantly associated with inherited 
mutations in two genes, BRCA1 and BRCA2, which are tumor suppressor genes responsible for 
maintaining genome stability through their involvement in homologous recombination (HR) 
double-stranded break DNA repair (Roy et al. 2012). In addition, there is evidence to suggest that 
BRCA1 is localized at telomeres and may regulate TL and stability (Blasco 2005; Badie et al. 
2010; Badie et al. 2015; Cabuy et al. 2009) and that BRCA2 protein may be involved in telomere 
replication (Badie et al. 2010). 
As described earlier for dyskeratosis congenita (DKC) (Vulliamy et al. 2004), our group 
described a mechanism of genetic anticipation in hereditary breast cancer (Martinez-Delgado et 
al. 2011) driven by telomere shortening in BRCA1 and BRCA2 mutation carriers, and a subgroup 
of BRCAX cancer cases. These results suggested that BRCA1 and BRCA2 proteins, were likely 
involved in TL maintenance, and that telomere shortening was the causal mechanism explaining 
the cancer anticipation across generations. It also opened the possibility of looking for new cancer 
susceptibility genes associated with TL maintenance that could explain other BRCAX breast 
cancer families.  
After this initial report, two independent reports using larger series of BRCA1 and BRCA2 
hereditary breast cancer patients showed different results (Killick et al. 2014; Pooley et al. 2014).  
These three reports paint three different scenarios for the roles of the BRCA1 and BRCA2 
mutations in TL regulation in relation with cancer risk development. In the first scenario,  
telomere shortening as a hallmark of genome instability may be associated with BRCA1 and 
BRCA2 mutations, and this would contribute to cancer risk development (Martinez-Delgado et al. 
2011). In the second scenario, TL is not associated either with BRCA1/BRCA2 mutations or cancer 
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risk  (Killick et al. 2014). In the third scenario, longer telomeres are associated with BRCA1 and 
BRCA2 mutations, independently of cancer status (Pooley et al. 2014). 
The three studies were done in a retrospective manner and in none of them treatment 
status, which might constitute a confounding factor, was evaluated independently as a possible 
modifier of TL. We tried to overcome this possible bias by working with two independent cohorts 
of women with breast cancer (sporadic and familial) and using two different approaches (cross-
sectional and longitudinal). In addition, we measured TL by two independent methods and 
obtained similar results. 
We used a series composed of 266 sporadic breast cancer patients, treated with 
conventional chemotherapy and with a follow-up of 5 years and detailed clinical and treatment 
records, to characterize the effect of the two major chemotherapy schedules (AC+T/T+AC and 
FEC+T/T+FEC) on TL (Table 1).  
Overall, we found that TL was shortened by the effect of the chemotherapy, although this 
effect was not permanent, and TL could be recovered after the treatment: 
Telomere shortening started at 91-180 days after the beginning of treatment and reached its 
maximum effect between 91-180 days after the end of treatment. Then, a recovery phase started, 
and it lasted for a maximum of 5 years. After this period, the original TL was recovered (Table 
S2). We detected some variations in the chemotherapy effects during the initial “telomere 
shortening phase” and during the “recovery phase”, depending on the chemotherapy combination 
(Figure 2). These variations suggest that TL is affected by conventional chemotherapies in 
different ways, depending on the mechanism of action of the specific drug involved ((hypo-) 
alkylating agents, anti-replicative molecules, spindle poisons, anti-topoisomerase I and II). The 
effects of chemotherapeutic drugs on TL and telomerase activity in cell culture experiments with 
different cell lines have been the subject of a recent review and are summarized in Table below*.  
 
 
Table* Effect of chemotherapeutic drugs on telomere length and telomerase activity in cultured 
cells (Bolzán 2016). 
DRUG TL TELOMERASE ACTIVITY CELL TYPE REFERENCE 
Cisplatin 
↓ ND Hela cells (Ishibashi & Lippard 1998) 
ND ↓ 
Human 
testicular cancer 
cells 
(Burger et al. 1997) 
ND ↓ 
Human 
endometrial 
cancer cells 
 
(Basiak et al. 2002) 
↓ ↓ 
Mouse 
spermatogonial 
cells 
 
(Liu et al. 2014) 
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↓ ↑ Human ovarian cancer cells 
(Kiyozuka et al. 
2000) 
↓ ↓ Human hepatoma cells (Zhang et al. 2002) 
ND ↓ Human ovarian cancer cells 
(Kunifuji et al. 
2002) 
ND ↓ 
Human head and 
neck squamous 
cell carcinoma 
cell lines 
(Kunifuji et al. 
2002) 
ND -- 
Human 
haematopoietic 
cancer cell lines 
(Park et al. 1998) 
Paclitaxel 
↓ -- Mouse melanoma cells 
(Asha S. Multani et 
al. 1999a) 
↓ -- 
Paclitaxel-
requiring mutant 
CHO cells 
(A S Multani et al. 
1999b) 
 
↓ ↓ Human pharynx tumor cells (Mo et al. 2003) 
-- -- Human ovarian cancer cells 
(Kiyozuka et al. 
2000) 
↓ ND Human pharynx tumor cells 
(Johnston et al. 
2003) 
Doxorubicin 
↓ ↓ Human hepatoma cells (Zhang et al. 2002) 
-- -- Human ovarian cancer cells 
(Kiyozuka et al. 
2000) 
-- ↓ Human breast tumor cells (Elmore et al. 2002) 
ND ↓ 
Human breast 
and stomach 
cancer cells 
(Park et al. 1998) 
↓ ↓ 
Human normal 
T-lymphocytes 
and fibroblasts 
(Li et al. 2012) 
ND ↓ Human ovarian cancer cells 
(Kunifuji et al. 
2002) 
ND -- 
Human 
testicular cancer 
cells 
(Burger et al. 1997) 
Cyclophosphamide ↓ ↑ Human ovarian cancer cells 
(Kiyozuka et al. 
2000) 
4OOH-CPA (**) ↓ ↓ 
Mouse 
spermatogonial 
cells 
 
(Liu et al. 2014) 
5-Fluorouracil 
(5-FU) ND -- 
Human head and 
neck squamous 
cell carcinoma 
cell lines 
(Lee et al. 2007) 
↑: increasing effect (telomere elongation); ↓: decreasing effect (telomere shortening or erosion); --: no 
effect; ND: Not determined; **:  4-hydroperoxycyclophosphamide, a preactivated analog of 
cyclophosphamide. 
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Once we confirmed that chemotherapy was a TL modifier in sporadic breast cancer 
patients, we moved to the FBC model. We used both cross-sectional and longitudinal approaches 
to test whether the BRCA genes and chemotherapy are modifiers of TL and/or telomerase activity 
in these patients. 
In the cross-sectional approach, we found similar results as in our previous study 
(Martinez-Delgado et al. 2011): familial cases presented shorter telomeres than controls. 
However, a substantial proportion of the samples were taken during or after a short time of 
chemotherapy administration. When we corrected for treatment status, we were not able to detect 
any effect of the BRCA1 and/or BRCA2 mutations on telomere shortening, neither in healthy 
carriers nor in post-treatment BRCA1/2 patients. In contrast, patients “during treatment” exhibited 
shorter TL independently of the mutational status. This suggests that the treatment is the real TL 
modifier (Figure 3b). In addition, these results partially explain the discrepancies reported in the 
literature regarding the role of the BRCA1 and BRCA2 mutations as modifiers of TL (Martinez-
Delgado et al. 2011) and point to chemotherapy as a factor that needs to be taken into 
consideration to obtain reliable results.  
Although it is not clear yet whether BRCA1 and/or BRCA2 are involved in TL 
maintenance and their relation with cancer risk, recent studies suggest that mutations in these 
genes disrupt TL homeostasis and contribute to malignant transformation and cancer risk for 
BRCA mutant carriers (Uziel et al. 2016; Thorvaldsdottir et al, 2017).  
To summarize, our study focused on the effect of cancer treatment on TL in both familial 
and sporadic breast cancer cases. We cannot rule out that BRCA1 and BRCA2 might be minor 
modifiers of TL, but it appears from our results that the treatment is the true cause of telomere 
shortening. The rates of telomere shortening and recovery may vary depending on the treatment. 
These results stress the need to perform prospective and retrospective TL association studies, 
considering the variability found as a consequence of the treatment status for cancer patients 
(untreated, during treatment and post treatment), to avoid reverse causation bias.  
 
ENDOGENOUS FACTORS THAT MODIFY TL: “CANCER RISK 
POLYMORPHISMS” IN DNA GLYCOSYLASES OF THE BER PATHWAY 
 
At the age of 70, cumulative cancer risk for BRCA1 and BRCA2 mutation carriers ranges 
from 43% to 88% for breast cancer development, and from 11% to 59% for ovarian cancer 
(Antoniou et al. 2003; Milne et al. 2008). This high variability is the consequence of other genetic 
and/or environmental factors that can modify cancer risk. 
Regarding genetic factors, Single Nucleotide Polymorphisms (SNPs) located in the 
OGG1 and NEIL2 genes were identified as cancer risk modifiers for BRCA1 and BRCA2 mutation 
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carriers, respectively (Osorio et al. 2014). Although the molecular mechanism underlying the 
cancer risk association is still unknown, both SNPs were in transcriptional regulatory regions of 
genes encoding DNA glycosylase enzymes involved in the BER DNA repair pathway. 
Oxidative DNA damage is repaired by the BER pathway, in which DNA glycosylases 
play an important role by recognizing and excising the oxidized bases in the DNA, at the very 
first step of the pathway (Dianov & Hübscher 2013). Later steps are also dependent on DNA 
glycosylases to finish the repair process. Oxidative DNA damage is especially challenging at 
telomere regions, because telomeres are prone to oxidation and because the complex structure of 
the telomeres makes access of the DNA repair machinery to telomeres difficult (Wallace 2014). 
Oxidative DNA damage at telomeres leads to telomere shortening, and proper BER performance 
is crucial to maintain TL homeostasis.  
Hence, we tried to explain the molecular bases underlying their association with cancer 
in the context of BRCA1 and BRCA2 deficiency, taking into consideration that they could be TL 
modifiers given the role that these enzymes play in oxidative DNA damage repair, especially at 
the telomere region. 
 
Article 2 
 
The first SNP, rs2304277, was reported to be a modifier of ovarian cancer risk for BRCA1 
mutation carriers (Osorio et al. 2014). This SNP is located 1.8Kb downstream of the 3´UTR 
region of the DNA glycosylase OGG1 (BER). Polymorphisms that create potential illegitimate 
microRNA target sites (Clop et al. 2006; Brewster et al. 2012) may be involved in altering normal 
OGG1 mRNA or protein levels. Indeed, by using the segRNA2.0 web server to identify functional 
RNA motifs, we found a new miRNA interaction region for miRNA-23a created by the SNP (not 
included as a result of this thesis). Interestingly, this miRNA is highly expressed in ovarian cancer 
(Vaksman et al. 2011). 
We decided to explore the role of this SNP in transcriptional regulation using two sets of 
samples. The first set consisted of 223 blood samples from controls and FBOC patients with a 
heterogeneous BRCA mutational status (BRCA1, BRCA2 and BRCAX), and the second was a 
panel of 23 lymphoblastoid cell lines (LCLs) derived from BRCA1 mutation carriers and non-
carrier controls.  
We confirmed in both sample sets (FBOC series and LCLs) a significantly lower 
expression of OGG1 mRNA transcripts associated with the SNP, independently of BRCA 
mutational status (Figure 1a & Figure 1b). We extended the analysis by consulting the Gtex eQTL 
database (http://www.gtexportal.org) for the effect of the SNP on OGG1 mRNA levels in different 
tissues, and we found significant down-regulation in ovary tissue (p=0.023) where this SNP was 
initially found to contribute to cancer risk (Supplementary Table S4).  
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These results suggest that this cancer risk variant is likely associated with transcriptional 
down-regulation of OGG1 mRNA, which could lead to higher genome/telomere instability due 
to a defective 8-oxoG repair capacity.  
Given the role of the BER pathway and in particular the OGG1 enzyme in telomere repair 
(Wang et al. 2010; Lu & Liu 2010), we explored the impact of this SNP on some features related 
to telomere biology that are considered as hallmarks of genome instability, such as telomere 
shortening or the percentage of critically short telomeres. Using linear regression analysis, we 
found that the SNP may be a TL modifier for BRCA1 and BRCA2 mutation carriers (p=0.013). 
Carriers of BRCA1/2 mutations and the OGG1 SNP presented a significantly shorter TL 
compared to both controls (p=0.009) and mutation carriers not harboring the SNP (p=0.003) 
(Figure 2a), likely due to accelerated telomere shortening during life (Figure 2c). These results 
were experimentally validated in our LCL set by measuring TL after 55 passages. We found 
significantly faster telomere shortening in the group of samples harboring a BRCA1 mutation 
together with the SNP (p=0.033) (Figure 3a). Our results point to a synergistic effect of the SNP 
and the BRCA1 mutation on telomere shortening. This may be due to the accumulation of 
oxidative lesions at the telomeric region (Ahmed et al. 2008; Coluzzi et al. 2014) triggered by a 
defective BER performance (Wang et al. 2010) due to this SNP and its effect on OGG1 
transcriptional down-regulation. 
Using the LCL panel, we compared the percentage of damaged cells and nuclear γH2AX 
signal intensity among different genotypes under basal conditions (first passage and no 
irradiation). We found that LCLs harboring the SNP presented significantly higher γH2AX signal 
intensity at the nucleus (p=0.010) (Figure 4b), suggesting that this SNP contributes to DNA 
damage. These results are similar to others reported in the literature establishing an association 
between SNPs in OGG1 at the same gene region and an increased DNA damage/genome 
instability due to  impaired BER performance (Krupa et al. 2011; Berger et al. 2013; Cardin et 
al. 2012; Yuan et al. 2012; Moritz et al. 2014). 
In summary, we found that the OGG1 SNP itself contributes to increased nuclear DNA 
damage, probably due to a defective BER performance triggered by OGG1 transcriptional down-
regulation. Additionally, our results suggest a synergistic effect between BRCA1 or BRCA2 
mutations and SNP rs2304277 on telomere shortening and telomere instability. 
These results suggest a possible synthetic lethal interaction between OGG1 from the BER 
pathway and BRCA1 from the HR DNA repair pathways, although further studies are needed to 
confirm this hypothesis. 
 
 
 
178 
	
Article 3 
 
The original study of Osorio et al reported that SNP rs1466785 located in the NEIL2 gene 
was a breast cancer risk modifier for BRCA2 mutation carriers (Osorio et al. 2014). Imputation 
using “1000 Genomes” data showed that there were several SNPs in strong linkage disequilibrium 
(LD) with rs1466785 (Osorio et al. 2014). Of these, we considered rs804271 to be the best 
candidate, given that it showed the most significant associations and that there were 
epidemiological and functional data supporting its putative role in cancer (Osorio et al. 2014), 
although the molecular mechanism underlying this association is unknown. This SNP is located 
at the promoter region of the NEIL2 gene, within a previously described transcriptional regulatory 
region (Kinslow et al. 2010). Indeed, 18 proteins are predicted to interact with that region, and 3 
motifs, which are binding regions for transcription factors (E2F, Sin3Ak-20 and YY1), are 
predicted to be altered in the presence of this polymorphism (http://archive.broadinstitute.org).  
Previous characterization of the NEIL2 gene promoter region showed that NEIL2 
transcription is influenced by certain SNPs located upstream of the transcription start site 
(Kinslow et al. 2008). The results presented in this report support these findings and suggest that 
rs804271 is associated with constitutive transcriptional activation of NEIL2.  
First, we checked the effect of rs804271 on NEIL2 mRNA levels in different tissues using 
the Gtex eQTL database (http://www.gtexportal. org), and we found a significant up-regulation 
associated with the presence of the SNP in several tissues including breast, ovary and blood 
(p<0.0001) (Supplementary Table S3). 
Next, we validated these results in our FBOC series and we found significantly increased 
NEIL2 mRNA levels in individuals harboring the SNP (p=0.003), suggesting that it is associated 
with transcriptional activation of the NEIL2 gene (Supplementary Table S4). 
Consistent with the fact that NEIL2 is an important enzyme of the BER pathway, it was 
recently reported to be the gene most frequently displaying loss of copy number (Chae YK et al 
2016). In addition, it appears to be significantly down-regulated in several tumors (Hildrestrand 
et al. 2009). Taking these facts into consideration, it seems unlikely that NEIL2 transcriptional 
activation is the causal explanation for the cancer modifier effect of this polymorphism in BRCA2 
mutation carriers.  
As an alternative hypothesis, it is possible that this SNP reduces the activity of the NEIL2 
enzyme, leading to an accumulation of oxidative lesions and to a NEIL2 transcriptional activation 
by a positive feedback mechanism.  
Since NEIL2 is involved in oxidative DNA damage repair at the telomeres (Zhou et al. 
2015; Chakraborty et al. 2015) and since these regions are very susceptible to being oxidized, we 
evaluated telomere oxidation levels to assess the constitutive oxidative DNA repair capacity 
among the different FBOC genotypes. Strikingly, we found that BRCA2 mutation carriers 
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presented significantly higher levels of oxidation at the telomeres (p<0.0001); those levels were 
mainly explained by the subgroup of patients harboring the NEIL2 SNP (Figure 1a & Figure 1b), 
which suggests that oxidative DNA repair is compromised when the rs804271 is present together 
with a BRCA2 mutation. These results were unrelated to oxidative stress susceptibility 
(Supplementary Table S7).  
In support of a functional role of this polymorphism in the performance of the NEIL2 
enzyme, it was previously reported in the literature that polymorphism rs804271 (previously 
ss74800505) was associated with significantly increased mutagen-induced genetic damage 
(Kinslow et al. 2008). 
A functional effect on transcription was initially expected, since this SNP is in the 
promoter region of NEIL2. However, our results suggest that this polymorphism is also associated 
with a reduced enzymatic activity exclusively in BRCA2 mutation carriers that leads to an 
accumulation of oxidative DNA damage, which can be detected at the telomere region. This 
scenario could be the molecular mechanism explaining the cancer modifier effect of this SNP in 
BRCA2 mutation carriers.  
Regarding the role of this SNP in BRCA1 mutation carriers, we found it to be significantly 
associated with higher MDA levels in plasma (Supplementary Table 6). This result correlated 
with a higher telomere instability reflected by reduced TL (β=-0.54; p= 0.007), accumulation of 
short telomeres (β=0.45; p= 0.024) and lower telomerase activity levels (β=-0.57; p= 0.035) 
(Supplementary Table S8). In relation with these results, a large number of studies have 
demonstrated that the BRCA1 protein is also involved in the response to oxidative stress through 
its interaction with NFR2, a key player that regulates antioxidant signaling response and cell 
proliferation (Gorrini et al. 2013; Marks 2013). Since oxidative stress correlates with telomere 
shortening (Richter & Zglinicki 2007), it was not surprising to find this telomere phenotype in 
BRCA1 mutation carriers, although the SNP is not associated with cancer risk for this group. 
Altogether, our results suggest that rs804271, located in the promoter region of the gene 
NEIL2, has a functional effect on NEIL2 mRNA transcriptional activation although it is unlikely 
to be related to the cancer risk modifier effect of the SNP in BRCA2 mutation carriers. In addition, 
we found that the SNP is associated with short TL, accumulation of short telomeres and lower 
telomerase activity in BRCA1 mutation carriers, likely due to a higher oxidative stress 
susceptibility for this group. Finally, we found that the SNP in BRCA2 mutation carriers may 
reduce NEIL2 enzyme activity leading to a significant accumulation of oxidative DNA damage 
that can be detected at the telomere region. This suggests that the effect of this SNP on cancer 
risk for BRCA2 mutation carriers could be driven by its effect on enzymatic activity.    
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BER DNA GLYCOSYLASES AS POTENTIAL TARGETS FOR TREATING 
BRCA1/ BRCA2-DERIVED TUMORS  
	
Article 4 
 
As was shown in articles 2 and 3, common genetic variations in OGG1 and NEIL2 can 
contribute to cancer risk for BRCA1 and BRCA2 mutation carriers, likely through a synthetic lethal 
interaction between both genetic events. 
These results not only imply that DNA glycosylases play an important role in telomere 
maintenance and genome stability in BRCA1 and BRCA2 mutation carriers, but also that OGG1 
and NEIL2 could be targets for the development of molecules inhibiting enzyme activity in 
BRCA1- and BRCA2-derived tumors, to promote synthetic lethality as an anticancer strategy 
against these types of tumors.  
Following this hypothesis, we tested a set of novel molecules that effectively inhibit 
OGG1 enzyme activity “in vitro” (data not shown) in a breast cancer cell line (MDA-MB-231) 
with functional BRCA1 protein, and in the same cell line with BRCA1 inactivated through shRNA 
constructs (MDA-MB-231shBRCA1) (Supplementary Figure1). 
We observed that in this specific model the entire set of molecules tested sensitized 
preferentially MDA-MB-231shBRCA1 after 5 days of treatment compared to MDA-MB-231 with 
functional BRCA1 protein (Figure1 and Table1). In addition, we confirmed this result in a 
commercial BRCA1-deficient breast cancer cell line (MDA-MB-436). In contrast, the pancreatic 
BRCA2-deficient cancer cell line PL45 was not sensitized at all by OGG1 inhibitors (figure2).  
To explain the sensitization observed in BRCA1-deficient cells after pharmacological inhibition 
of OGG1, we evaluated oxidative DNA damage accumulation and its conversion into DSBs in 
both MDA-MB-231 and MDA-MB-231shBRCA1 cells. 
To study the accumulation of oxidative DNA damage, we modified a previously 
described protocol to detect oxidative lesions (8-oxoG) at the telomere region (O’Callaghan et al. 
2011). We used this method to quantify the effectiveness of the OGG1 inhibitor molecule TH5487 
in cultured cells.  
After 24 hours of exposure to TH5487, we observed higher levels of oxidative damage at 
the telomere in both MDA-MB-231 and MDA-MB-231shBRCA1 cells, suggesting that cells 
cannot effectively repair endogenous oxidative DNA damage generated during cell culture. As a 
result, we found a significant accumulation of these lesions at the telomere (Figure2).  
Accumulation of oxidative lesions was significantly higher in MDA-MB-231shBRCA1 
cells than in MDA-MB-231 breast cancer cells, which suggests a role for BRCA1 in the repair of 
oxidative lesions at the telomere region. In relation with this, BRCA1 contributes to the repair of 
the 8-oxoG oxidative damage in human cells (Le Page et al. 2000) protecting against oxidative 
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DNA damage being converted into double-strand breaks during DNA replication (Fridlich et al. 
2015). Hence, it is likely that BRCA1 is involved in oxidative DNA damage repair at telomeres, 
since there is evidence that the BRCA1 protein interacts with the telomere (Acharya et al. 2014; 
Badie et al. 2015). 
Finally, we could confirm by immunofluorescence (IF) that after 5 days of TH5487 
exposure, MDA-MB-231 cells presented an induction of the γH2AX nuclear signal and foci 
formation (Figure 4). This may suggest that inhibition of OGG1 first leads to an accumulation of 
oxidative damage, which later is converted into DSBs, contributing to a higher genome instability.  
Considering that DSBs are the most dangerous perturbation for DNA, and because 
BRCA1 is an essential protein in the HR DNA repair pathway for DSBs, we believe that this 
could be the mechanistic explanation of the effects observed on proliferation in MDA-MB-
231shBRCA1 cells when exposed to the OGG1 inhibitor (TH5487). 
In summary, in the present report we described how in cells with the same genetic 
background, inactivation of BRCA1 makes cells very sensitive to OGG1 inhibitors. This effect on 
proliferation correlates with an accumulation of oxidative damage and nuclear γH2AX induction. 
This evidence, together with previous evidence (Osorio et al. 2014) points to a synthetic lethal 
interaction between OGG1 and BRCA1.   
 
TL MODIFICATION CAUSED BY OTHER GENETIC EVENTS 
 
Defects in genes involved in telomere maintenance (shelterin complex or telomerase) 
result in a wide spectrum of overlapping symptoms (Kirwan & Dokal 2008), which converge in 
disruption of TL regulation and end protection, and finally in disease manifestation.  
In article 5 and article 6, two examples of TL dysregulation caused by defects in genes 
from the shelterin or telomerase complex are shown. In these examples, disease manifestation is 
not exclusively associated with telomere shortening. TL equilibrium is maintained by both 
telomerase and the shelterin complex, and aberrant telomere elongation or shortening can 
converge in disease manifestation. 
 
Article 5 
 
We found a novel damaging missense variant (p.R117C) in the POT1 gene in TP53-
negative Li-Fraumeni-like families with cardiac angiosarcoma and other tumors. Mutations in 
POT1 were recently associated with familial melanoma (Shi et al. 2014; Robles-Espinoza et al. 
2014),  glioma (Bainbridge et al. 2015), and mutated POT1 was shown to be a driver for chronic 
lymphocytic leukemia (Ramsay et al. 2013). This suggests a new role of POT1 not only as 
telomere protector, but also as one of the main proteins responsible for the development of 
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different familial cancer types when mutated. In silico studies showed that the p.R117C 
substitution putatively disrupts the interaction between oligonucleotide/oligosaccharide-binding 
(OB) folds 1 and 2 (Figure 2d) and affects the site for binding to TPP1 (Supplementary Table 4), 
which might result in the loss of capability of the POT1R117C protein to interact with ssDNA and 
to be recruited to telomeres. POT1 has been shown to be important to prevent telomerase access 
to telomeres by sequestering the DNA terminus (Baumann & Price 2010; Loayza & De Lange 
2003). Indeed, telomere lengthening was observed in mutation carriers likely due to unlimited 
telomerase recruitment and action on telomeres.  
In addition, disruption of POT1 function was associated with increased DNA damage at 
telomeres and telomere fragility (Ramsay et al. 2013).  
Therefore, it is tempting to speculate that telomere elongation induced by this mutation 
in POT1 may constitute the underlying molecular mechanism favoring tumor formation. 
 
Article 6 
 
Telomerase activation may be a good therapeutic strategy to treat those forms of aplastic 
anemia that are associated with short telomeres. Indeed, we previously developed a telomerase 
(Tert) gene therapy using adeno-associated virus (AAV) 9 vectors, which attenuated or reverted 
aging-associated telomere erosion in peripheral blood mononuclear cells (PBMCs; Bernardes de 
Jesus et al. 2012). To test the efficacy of this strategy for the treatment of aplastic anemia, we first 
used a mouse model of aplastic anemia generated by us in which we depleted the TRF1 shelterin 
protein specifically in the bone marrow, leading to a bone marrow phenotype that recapitulates 
the main pathological findings in human aplastic anemia patients, including extreme telomere 
shortening (Beier et al. 2012; Bär et al. 2015).  
Administration of a high dose of AAV9-Tert particles led to robust Tert expression in 
whole bone marrow isolates 2 weeks after treatment. AAV9-Tert treatment of mice with aplastic 
anemia triggered by short telomeres rescued mortality concomitant with telomere re-elongation 
in blood and bone marrow cells.  
These findings were confirmed in a second mouse model of aplastic anemia produced by 
short telomeres, in this case due to telomerase deficiency (Herrera et al. 1999a; Herrera et al. 
1999b). In this case, Tert gene therapy of the Tert-deficient bone marrow mouse model also 
resulted in increased telomere length, improved blood counts and, albeit moderately, survival. 
 
GENERAL DISCUSSION 
 
Telomere association studies are subject to reverse causality,	which	refers to a direction 
of cause-and-effect contrary to a common presumption, especially in case-control and 
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retrospective studies. This is one of the reasons for the lack of consensus when TL is used as a 
predictor for cancer risk. 
Hence, it is important to redefine TL association studies: large sample size, long follow-
up with periodical TL measurements, homogeneous ethnicity of the studied population and 
identification and correction of exogenous factors that can modify and bias TL association studies, 
such as chemotherapy. All these improvements need to be implemented across laboratories to 
minimize reverse causality and to clarify which is the relation between TL and cancer/disease 
susceptibility. 
Reverse causality and possible bias due to exogenous and endogenous factors that can 
modify TL may be avoided by using a Mendelian randomization approach. Because genotype–
phenotype associations are not vulnerable to biases by the environment, Mendelian randomization 
is an attractive approach for estimating relationships between TL and cancer risk. It consists in 
testing the association between TL-associated SNPs and the relative risk for cancer/disease 
susceptibility.  
Until now, not many TL-associated SNPs have been described. For this reason, it is 
important to identify new TL-associated genetic variants to improve this type studies. We believe 
genetic variants in DNA glycosylases could be TL-associated SNPs in a specific genetic context: 
for example, rs2304277 in BRCA1 and BRCA2 mutation carriers, and rs804271 in BRCA1 
mutation carriers are both associated with short TL. 
Interestingly, rs2304277 also modifies cancer risk for BRCA1 mutation carriers, and 
rs804271 modifies the risk for BRCA2 mutation carriers. Again, telomere shortening is associated 
with cancer risk in the context of hereditary breast and ovarian cancer, although in this case this 
is true for a specific group of BRCA1 and BRCA2 mutation carriers, namely those who harbor a 
specific “cancer modifier” SNP in OGG1 and NEIL2, respectively.  
It is possible that these SNPs affect two or more seemingly unrelated traits, such as cancer 
risk or TL in an independent manner. However, it is also possible that their effect 
(telomere/genome instability) directly modifies cancer risk for BRCA1 and BRCA2 mutation 
carriers and TL in a specific genetic context (BRCA1/BRCA2). 
Indeed, our results suggest the existence of a synthetic lethal interaction between OGG1 
and BRCA1, with oxidative DNA accumulation, especially at telomeres, as the potential driver of 
the anti-proliferative effect observed in BRCA1-deficient breast cancer cells after drug inhibition 
of OGG1. Hence, the combination of both genetic events (cancer-causing SNPs in DNA 
glycosylases and BRCA1 and BRCA2 mutations) may be related to both cancer risk and telomere 
shortening, since oxidative DNA damage is associated with telomere shortening.   
The most recent results of TL association studies indicate a complex relationship between 
TL and cancer risk, rather than a simple linear relationship. Short telomeres may be associated 
with an increased risk for some cancer types (gastrointestinal tumor and head and neck cancer) 
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(Zhu et al. 2016) while longer telomeres confer risk for other types such as glioma, ovarian cancer, 
and lung adenocarcinoma (Haycock et al 2017). This variability across cancer types may reflect 
different carcinogenic mechanisms in specific cancer types (Zhu et al. 2016). As illustrated in this 
thesis (articles 5 and 6), telomere lengthening or shortening can converge in disease manifestation 
due to impairment of two different telomere-related genes affecting two different molecular 
mechanisms of telomere maintenance (shelterin and telomerase). 
To conclude, further insights into telomere biology are needed. It seems likely that the 
sole focus on LTL, rather than on other features of telomere maintenance and stability, is overly 
simplistic. Similarly, the assumption that LTL is reflected in disease-relevant tissue needs further 
investigation, and consideration should be given to measuring LTL at more than one time point. 
It is important to take into consideration that TL in relation with cancer is not linear, but rather 
dynamic. Hence, we should break with the dogma in which telomere shortening and disease 
susceptibility are an unbreakable marriage. In addition, any diagnostic, prognostic, or therapeutic 
application based on TL should be regarded with caution. 
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CONCLUSIONS/CONCLUSIONES 
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1. Conventional chemotherapeutic agents included in breast cancer treatment exert a transient 
telomere shortening effect. One year after completion of cancer treatment TL is restored to normal 
values. Chemotherapy is a confounding factor in TL association studies, and must be corrected 
for to obtain reliable results. 
 
2. We found that rs2304277, located at the 3´UTR of the OGG1 DNA glycosylase gene from the 
BER pathway, is associated with a constitutive transcriptional downregulation of OGG1 that leads 
to both genome and telomere instability in patients harboring deleterious mutations in the BRCA1 
or BRCA2 genes. This could be the molecular mechanism by which rs2304277 contributes to 
cancer risk susceptibility for BRCA1 mutation carriers. 
 
3. We found that rs804271, located in the promoter region of the NEIL2 gene from the BER 
pathway, may reduce NEIL2 enzyme activity leading to a significant accumulation of oxidative 
DNA damage at telomeres in BRCA2 mutation carriers. This could be the molecular mechanism 
by which rs804271 contributes to cancer risk susceptibility for BRCA2 mutation carriers. In 
addition, we found that the SNP is associated with short TL, accumulation of short telomeres and 
lower telomerase activity in BRCA1 mutation carriers, likely due to a higher oxidative stress 
susceptibility for this group.  
 
4. In cells with the same genetic background, inactivation of BRCA1 make cells very sensitive to 
OGG1 inhibitors. This effect on proliferation correlates with an accumulation of oxidative 
damage and nuclear γH2AX induction, suggesting the existence of a synthetic lethal interaction 
between OGG1 from the BER pathway and BRCA1 from the HR pathway. 
 
5. Telomere length dysregulation caused by defects in genes from the shelterin or telomerase 
complex can converge in disease manifestation through (or in parallel with) telomere elongation 
or shortening. This fact underscores the complexity of TL maintenance, which appears to depend 
on several endogenous and exogenous factors. 
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1. El tratamiento con agentes quimioterapéuticos en el cáncer de mama tiene un efecto secundario 
relacionado con el acortamiento telomerico. Este acortamiento es transitorio, y la longitud 
telomerica se recupera pasado un año desde la finalización del último ciclo de la quimioterapia. 
La quimioterapia es un agente modificador de la longitud telomérica y, en aquellos estudios de 
asociación en los que la longitud telomérica se utiliza como un biomarcador para predecir el riesgo 
a desarrollar ciertas enfermedades, es importante que se identifique la quimioterapia como un 
factor de confusión que ha de ser corregido con el fin de obtener resultados fiables. 
 
2. Hemos identificado que el polimorfismo rs2304277 localizado en la región 3´UTR del gen 
OGG1, el cual está involucrado en la vía de reparación del ADN por escisión de base (BER), está 
asociado a unos niveles más bajos de transcrito. Esto se correlaciona con unos mayores niveles 
de inestabilidad genética y telomérica para los pacientes portadores de mutaciones en los genes 
de alta susceptibilidad al desarrollo de cáncer de mama y ovario hereditarios BRCA1 y BRCA2. 
Este podría ser el mecanismo por el cual este polimorfismo está asociado a un mayor riesgo de 
desarrollar cáncer en individuos portadores de mutación en BRCA1. 
 
3. Hemos encontrado que el polimorfismo rs804271, situado en la región promotora del gen 
NEIL2 de la vía de reparación del ADN por escisión de base (BER), puede reducir la actividad de 
la enzima NEIL2 conduciendo a una acumulación significativa de daño oxidativo del ADN en 
telómeros para los portadores de mutación BRCA2. Este podría ser el mecanismo molecular por 
el cual el rs804271 contribuiría a una mayor susceptibilidad al desarrollo de cáncer en portadores 
de mutaciones en BRCA2. Además, hemos encontrado que este SNP se asocia con una menor 
longitud telomérica, una acumulación de telómeros cortos y una menor actividad de la telomerasa 
para los portadores de mutación BRCA1, probablemente debido a una mayor susceptibilidad al 
estrés oxidativo para este grupo. 
 
4. Un estudio preliminar en el que se ha inhibido farmacológicamente la enzima OGG1 en líneas 
tumorales de mama con inactivación en BRCA1, sugiere que podría existir una relación de 
letalidad sintética entre OGG1, de la vía de reparación del ADN por escisión de base (BER) y 
BRCA1, de la vía de la recombinación homóloga (HR). 
 
5. La desregulación en la homeostasis de la longitud telomérica causada por defectos en los genes 
del complejo protector de las shelterinas o en la telomerasa pueden dar lugar a la manifestación 
de enfermedad/cáncer mediante la elongación o el acortamiento de los telómeros. Este hecho 
remarca la complejidad en la relación existente entre la longitud telomérica y el riesgo a 
desarrollar enfermedad/cáncer, el cual parece depender de varios factores endógenos y exógenos. 
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